Chimeric receptors and methods of use thereof
Patent Information
- Application Number
- JP2023530945
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-08-10
- Filing Date
- 2021-11-24
- Publication Date
- 2024-12-04
- Estimated Expiration
- Not applicable · inactive patent
Abstract
Description
[Technical Field]
[0001] Cross-reference of related applications This application claims the interests and priority of U.S. Provisional Application No. 63 / 231,626 filed on 10 August 2021 and U.S. Provisional Application No. 63 / 117,861 filed on 24 November 2020, each of which is incorporated herein by reference in whole for all purposes.
[0002] Sequence List This application includes a sequence listing filed via EFS-Web, which is incorporated herein by reference in its entirety. The ASCII copy thereof, created in XX month, 20XX, is named XXXXXUS_sequencelisting.txt and has a size of X,XXX,XXX bytes.
[0003] Field of Invention This application relates to solid tumor antigen targets for chimeric receptors and chimeric inhibitory receptors, and to methods of using them, for example, for the treatment of cancer. [Background technology]
[0004] background Immunotherapies, such as chimeric antigen receptor (CAR) adoptive cell therapy used to redirect the specificity and function of immune-responsive cells (e.g., T cells, natural killer (NK) cells), have shown efficacy in patients with malignancies, and many prior studies have focused on hematological malignancies (Pule et al., Nat. Med. (14):1264-1270 (2008) (Non-Patent Literature 1), Maude et al., N Engl J Med. (371):1507-17 (2014) (Non-Patent Literature 2), Brentjens et al., Sci Transl Med. (5):177ra38 (2013) (Non-Patent Literature 3)). For example, CAR T cells have been shown to induce complete remission in patients with CD19-expressing malignancies that have developed drug resistance and tumor progression due to chemotherapy.
[0005] Unlike T cells, natural killer (NK) cells can eliminate abnormal cells such as cancer cells without priming. NK cell activity is determined by the balance of external signals from inhibitory and activating NK cell receptors. Inhibitory receptors such as killer immunoglobulin receptors (KIR) interact with major histocompatibility complex (MHC) class I antigens and protect normal cells from NK cell activity (see US2018 / 0057795A1 (Patent Document 1)).
[0006] One challenge in developing CAR therapies for solid tumors is the lack of suitable targets. The ability to identify appropriate CAR targets is important for effectively targeting and treating tumors without damaging normal cells that express the same target antigen. Therefore, there remains a need for CAR-NK cell-based tumor therapies that target tumor cells without targeting normal cells or tissues.
Prior Art Documents
Patent Documents
[0007]
Patent Document 1
Non-Patent Documents
[0008]
Non-Patent Document 1
Non-Patent Document 2
Non-Patent Document 3
Summary of the Invention
[0009] Summary In one aspect, provided herein is an isolated cell that (a) An inhibitory chimeric receptor comprising an extracellular antigen-binding domain that binds to an antigen, wherein the antigen is selected from the group consisting of VSIG2, CPM, ITM2C, SLC26A2, SLC4A4, GPA33, PLA2G2A, ABCA8, ATP1A2, CHP2, and SLC26A3, (b) Isolated cells comprising a chimeric receptor having one or more extracellular antigen-binding domains, wherein one or more extracellular antigen-binding domains bind to one or more additional antigens selected from the group consisting of CEA, CEACAM1, CEACAM5, and CEACAM6.
[0010] In some embodiments, the antigen-binding domain of an inhibitory chimeric receptor comprises one or more single-chain variable fragments (scFv), each of which optionally comprises a heavy-chain variable domain (VH) and a light-chain variable domain (VL), each of which optionally separates VH and VL by a peptide linker, each of which optionally comprises the amino acid sequence of SEQ ID NO: 39 or SEQ ID NO: 77, and / or optionally comprises the structure VH-L-VL or VL-L-VH, where VH is the heavy-chain variable domain, L is the peptide linker, and VL is the light-chain variable domain.
[0011] In some embodiments, the inhibitory chimeric receptor includes a transmembrane domain, and the transmembrane domain is selected from the group consisting of a CD8 transmembrane domain, a CD28 transmembrane domain, a CD25 transmembrane domain, a CD7 transmembrane domain, a CD3 zeta chain transmembrane domain, a CD4 transmembrane domain, a 4-1BB transmembrane domain, an OX40 transmembrane domain, an ICOS transmembrane domain, a CTLA-4 transmembrane domain, a LAX transmembrane domain, a LAT transmembrane domain, a PD-1 transmembrane domain, a LAG-3 transmembrane domain, a TIM3 transmembrane domain, a KIR3DS1 transmembrane domain, a KIR3DL1 transmembrane domain, an NKG2D transmembrane domain, an NKG2A transmembrane domain, a TIGIT transmembrane domain, a 2B4 transmembrane domain, and a BTLA transmembrane domain.
[0012] In some embodiments, the inhibitory chimeric receptor includes a spacer region between the antigen-binding domain and the transmembrane domain, and optionally, the spacer region has an amino acid sequence selected from the group consisting of SEQ ID NOs: 49-58: and / or
[0013] In some embodiments, the inhibitory chimeric receptor comprises one or more intracellular inhibitory domains selected from the group consisting of PD-1, CTLA4, TIGIT, LAIR1, GRB-2, Dok-1, Dok-2, SLAP, LAG3, HAVR, BTLA, LIR1, NKG2A, KIR3DL1, GITR, PD-L1, CSK, SHP-1, PTEN, CD45, CD148, PTP-MEG1, PTP-PEST, c-CBL, CBL-b, PTPN22, LAR, PTPH1, SHIP-1, RasGAP, CD94, and CD161.
[0014] In some embodiments, the chimeric receptor is a CAR. In some embodiments, the CAR comprises one or more intracellular signaling domains, one or more intracellular signaling domains selected from the group consisting of a CD3 zeta chain intracellular signaling domain, a CD3 epsilon chain intracellular signaling domain, a CD97 intracellular signaling domain, a CD11a-CD18 intracellular signaling domain, a CD2 intracellular signaling domain, an ICOS intracellular signaling domain, a CD27 intracellular signaling domain, a CD154 intracellular signaling domain, a CD8 intracellular signaling domain, an OX40 intracellular signaling domain, a 4-1BB intracellular signaling domain, a CD28 intracellular signaling domain, a ZAP40 intracellular signaling domain, a CD30 intracellular signaling domain, a GITR intracellular signaling domain, a HVEM intracellular signaling domain, a DAP10 intracellular signaling domain, a DAP12 intracellular signaling domain, a MyD88 intracellular signaling domain, a 2B4 intracellular signaling domain, an NKp46 intracellular signaling domain, an NKp30 intracellular signaling domain, an NKp44 intracellular signaling domain, an NKG2D intracellular signaling domain, a CD226 intracellular signaling domain, and a CD160 intracellular signaling domain. In some embodiments, the CAR includes a transmembrane domain, and the transmembrane domain is selected from the group consisting of a CD8 transmembrane domain, a CD28 transmembrane domain, a CD25 transmembrane domain, a CD7 transmembrane domain, a CD3 zeta chain transmembrane domain, a CD4 transmembrane domain, a 4-1BB transmembrane domain, an OX40 transmembrane domain, an ICOS transmembrane domain, a CTLA-4 transmembrane domain, a LAX transmembrane domain, a LAT transmembrane domain, a PD-1 transmembrane domain, a LAG-3 transmembrane domain, a TIM3 transmembrane domain, a KIR3DS1 transmembrane domain, a KIR3DL1 transmembrane domain, an NKG2D transmembrane domain, an NKG2A transmembrane domain, a TIGIT transmembrane domain, a 2B4 transmembrane domain, and a BTLA transmembrane domain.
[0015] In some embodiments, the CAR includes a spacer region between the antigen-binding domain and the transmembrane domain, and the spacer region has an amino acid sequence selected from the group consisting of SEQ ID NOs: 49-58.
[0016] In some embodiments, the inhibitory chimeric receptor and / or the antigen-binding domain of the chimeric receptor comprises one or more single-chain variable fragments (scFv), each of which optionally comprises a heavy-chain variable domain (VH) and a light-chain variable domain (VL), each optionally separated by a peptide linker, and optionally comprising the amino acid sequence of SEQ ID NO: 39 or SEQ ID NO: 77.
[0017] In some embodiments, each of one or more scFv comprises the structure VH-L-VL or VL-L-VH, where VH is a heavy chain variable domain, L is a peptide linker, and VL is a light chain variable domain.
[0018] In some embodiments, one or more additional antigens are CECAM1, and optionally, the antigen-binding domain that binds to CEACAM1 comprises a heavy chain variable domain (VH) containing the amino acid sequence of SEQ ID NO: 1 and a light chain variable domain (VL) containing the amino acid sequence of SEQ ID NO: 2.
[0019] In some embodiments, one or more additional antigens are CECAM5, and the antigen-binding domain that binds to CEACAM5 is optional. (i) VH containing the amino acid sequence of SEQ ID NO: 3 and VL containing the amino acid sequence of SEQ ID NO: 4, (ii) VH containing the amino acid sequence of SEQ ID NO: 9 and VL containing the amino acid sequence of SEQ ID NO: 10, (iii) VH containing the amino acid sequence of SEQ ID NO: 11 and VL containing the amino acid sequence of SEQ ID NO: 12, (iv) VH containing the amino acid sequence of SEQ ID NO: 13 and VL containing the amino acid sequence of SEQ ID NO: 14, (v) VH containing the amino acid sequence of SEQ ID NO: 78 and VL containing the amino acid sequence of SEQ ID NO: 79, (vi) A heavy chain variable domain (VH) and a light chain variable domain (VL) selected from the group consisting of VH containing the amino acid sequence of SEQ ID NO: 15 and VL containing the amino acid sequence of SEQ ID NO: 16.
[0020] In some embodiments, the antigen-binding domain that binds to CEACAM5 is (i) HC containing the amino acid sequence of SEQ ID NO: 5 and LC containing the amino acid sequence of SEQ ID NO: 6, (ii) A heavy chain (HC) and a light chain (LC) selected from the group consisting of an HC containing the amino acid sequence of SEQ ID NO: 7 and an LC containing the amino acid sequence of SEQ ID NO: 8, or (c) One or more additional antigens are CECAM6, and optionally, the antigen-binding domain that binds to CECAM6 comprises a heavy chain variable domain (VH) containing the amino acid sequence of SEQ ID NO: 17 and a light chain variable domain (VL) containing the amino acid sequence of SEQ ID NO: 18.
[0021] In some embodiments, the cells are immune-responsive cells. In some embodiments, the binding of an inhibitory chimeric receptor to an antigen can inhibit immune-responsive cells, and / or the binding of the chimeric receptor to one or more additional antigens can activate immune-responsive cells.
[0022] In some embodiments, the chimeric receptor binds to one or more additional antigens with low binding affinity.
[0023] In some embodiments, the chimeric receptor binds to one or more additional antigens at a binding affinity lower than that of the inhibitory chimeric receptor.
[0024] In some embodiments, inhibitory chimeric receptors bind to antigens with low binding activity.
[0025] In some embodiments, the chimeric receptor is expressed by recombination, and optionally, the chimeric receptor is expressed from a locus selected from the vector or the cell's genome.
[0026] In some embodiments, the cells are selected from the group consisting of T cells, natural killer (NK) cells, cytotoxic T lymphocytes (CTLs), regulatory T cells, natural killer T (NKT) cells, myeloid cells, macrophages, human embryonic stem cells (ESCs), ESC-derived cells, pluripotent stem cells, and induced pluripotent stem cells (iPSCs), as well as iPSC-derived cells. In some embodiments, the cells are autologous or allogeneic.
[0027] In some embodiments, what is provided herein are isolated nucleic acids encoding inhibitory chimeric receptors provided herein.
[0028] In some embodiments, what is provided herein is a vector comprising nucleic acids provided herein.
[0029] In some embodiments, what is provided herein are gene-modified cells comprising nucleic acids or vectors provided herein.
[0030] In some embodiments, provided herein are pharmaceutical compositions comprising an effective amount of isolated cells, isolated nucleic acids, or vectors provided herein, and a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, or a combination thereof.
[0031] In some embodiments, what is provided herein is a method for administering treatment to a subject that requires treatment, the method comprising administering an effective amount of isolated cells provided herein, isolated nucleic acids provided herein, vectors provided herein, or pharmaceutical compositions provided herein to the subject.
[0032] In some embodiments, what is provided herein is a method for stimulating a cellular immune response against tumor cells in a subject, the method comprising administering an effective amount of the isolated cells, isolated nucleic acids, vectors, or pharmaceutical compositions provided herein to a subject having a tumor.
[0033] In some embodiments, what is provided herein is a method for providing antitumor immunity in a subject, the method comprising administering an effective amount of isolated cells, isolated nucleic acids, vectors, or pharmaceutical compositions provided herein to a subject in need thereof.
[0034] In some embodiments, the methods provided herein are methods for reducing tumor load in a subject, comprising administering to the subject an effective amount of isolated cells provided herein, isolated nucleic acids provided herein, vectors provided herein, or pharmaceutical compositions provided herein. In some embodiments, the methods reduce the number of tumor cells, the methods reduce the tumor size, the methods reduce the tumor volume, and / or the methods eradicate the tumor in the subject.
[0035] In some embodiments, what is provided herein is a method for treating a subject having a tumor, the method comprising administering an effective amount of isolated cells provided herein, isolated nucleic acids provided herein, vectors provided herein, or pharmaceutical compositions provided herein.
[0036] In some embodiments, provided herein are methods for treating or preventing cancer in a subject, wherein the cancer is selected from the group consisting of colorectal cancer, pancreatic cancer, lung adenocarcinoma, and gastric cancer, and the method comprises administering an effective amount of isolated cells provided herein, isolated nucleic acids provided herein, vectors provided herein, or pharmaceutical compositions provided herein to the subject.
[0037] In some embodiments, the method increases progression-free survival in the subjects, and / or the method increases survival in the subjects.
[0038] In some embodiments, provided herein are kits for treating and / or preventing colorectal cancer, pancreatic cancer, lung adenocarcinoma, and / or gastric cancer, comprising isolated cells provided herein, isolated nucleic acids provided herein, vectors provided herein, or pharmaceutical compositions provided herein. In some embodiments, the kit further includes written instructions for using the isolated cells or pharmaceutical composition for treating and / or preventing colorectal cancer, pancreatic cancer, lung adenocarcinoma, and / or gastric cancer in a subject, or the kit further includes instructions for using nucleic acids or vectors for producing one or more antigen-specific cells for treating and / or preventing colorectal cancer, pancreatic cancer, lung adenocarcinoma, and / or gastric cancer in a subject.
[0039] In some embodiments, provided herein are inhibitory chimeric receptors comprising an extracellular antigen-binding domain that binds to an antigen selected from the group consisting of VSIG2, CPM, ITM2C, SLC26A2, SLC4A4, GPA33, PLA2G2A, ABCA8, ATP1A2, CHP2, and SLC26A3.
[0040] In some embodiments, the antigen is VSIG2. In some embodiments, the antigen is CPM. In some embodiments, the antigen is ITM2C. In some embodiments, the antigen is SLC26A2. In some embodiments, the antigen is SLC4A4. In some embodiments, the antigen is GPA33. In some embodiments, the antigen is PLA2G2A. In some embodiments, the antigen is ABCA8. In some embodiments, the antigen is ATP1A2. In some embodiments, the antigen is CHP2. In some embodiments, the antigen is SLC26A3.
[0041] In some embodiments, when expressed on cells, inhibitory chimeric receptors inhibit one or more cellular activities.
[0042] In some embodiments, the antigen is either not expressed on tumor cells, or it is expressed on tumor cells at a lower level than it is expressed on non-tumor cells.
[0043] In some embodiments, the antigen is expressed on non-tumor cells, or the antigen is expressed on non-tumor cells at a higher level than it is expressed on the corresponding tumor cells.
[0044] In some embodiments, the antigen is expressed on non-tumor cells derived from tissues selected from the group consisting of the lungs, pancreas, gastrointestinal tract, colon, brain, nervous tissue, endocrine system, bone, bone marrow, immune system, muscle, liver, gallbladder, kidney, bladder, male genitalia, female genitalia, fat, soft tissue, and skin.
[0045] In some embodiments, the inhibitory chimeric receptor comprises one or more intracellular inhibitory domains selected from the group consisting of PD-1, CTLA4, TIGIT, LAIR1, GRB-2, Dok-1, Dok-2, SLAP, LAG3, HAVR, BTLA, LIR1, NKG2A, KIR3DL1, GITR, PD-L1, CSK, SHP-1, PTEN, CD45, CD148, PTP-MEG1, PTP-PEST, c-CBL, CBL-b, PTPN22, LAR, PTPH1, SHIP-1, RasGAP, CD94, and CD161.
[0046] In some embodiments, the antigen-binding domain includes one or more antibodies, antigen-binding fragments of antibodies, F(ab) fragments, F(ab') fragments, single-chain variable fragments (scFv), or single-domain antibodies (sdAb).
[0047] In some embodiments, the antigen-binding domain comprises one or more single-chain variable fragments (scFv). In some embodiments, each of the one or more scFv comprises a heavy-chain variable domain (VH) and a light-chain variable domain (VL). In some embodiments, VH and VL are separated by a peptide linker. In some embodiments, the peptide linker comprises the amino acid sequence of SEQ ID NO: 39 or SEQ ID NO: 77. In some embodiments, each of the one or more scFv comprises the structure VH-L-VL or VL-L-VH, where VH is the heavy-chain variable domain, L is the peptide linker, and VL is the light-chain variable domain.
[0048] In another embodiment, provided herein are isolated cells comprising an inhibitory chimeric receptor of any one of the embodiments described above. In some embodiments, the inhibitory chimeric receptor is expressed by recombination. In some embodiments, the inhibitory chimeric receptor is expressed from a vector or a locus selected from the cell's genome. In some embodiments, the cell further comprises a chimeric receptor comprising one or more extracellular antigen-binding domains, the one or more extracellular antigen-binding domains binding to one or more antigens selected from the group consisting of CEA, CEACAM1, CEACAM5, and CEACAM6.
[0049] In another embodiment, provided herein are isolated cells, (a) An inhibitory chimeric receptor comprising an extracellular antigen-binding domain that binds to an antigen, wherein the antigen is selected from the group consisting of VSIG2, CPM, ITM2C, SLC26A2, SLC4A4, GPA33, PLA2G2A, ABCA8, ATP1A2, CHP2, and SLC26A3, (b) Isolated cells comprising a chimeric receptor having one or more extracellular antigen-binding domains, wherein one or more extracellular antigen-binding domains bind to one or more additional antigens selected from the group consisting of CEA, CEACAM1, CEACAM5, and CEACAM6.
[0050] In some embodiments, the chimeric receptor is a chimeric T cell receptor or a chimeric antigen receptor (CAR). In some embodiments, the CAR comprises one or more intracellular signaling domains, and one or more intracellular signaling domains are selected from the group consisting of a CD3 zeta chain intracellular signaling domain, a CD3 epsilon chain intracellular signaling domain, a CD97 intracellular signaling domain, a CD11a-CD18 intracellular signaling domain, a CD2 intracellular signaling domain, an ICOS intracellular signaling domain, a CD27 intracellular signaling domain, a CD154 intracellular signaling domain, a CD8 intracellular signaling domain, an OX40 intracellular signaling domain, a 4-1BB intracellular signaling domain, a CD28 intracellular signaling domain, a ZAP40 intracellular signaling domain, a CD30 intracellular signaling domain, a GITR intracellular signaling domain, a HVEM intracellular signaling domain, a DAP10 intracellular signaling domain, a DAP12 intracellular signaling domain, a MyD88 intracellular signaling domain, a 2B4 intracellular signaling domain, an NKp46 intracellular signaling domain, an NKp30 intracellular signaling domain, an NKp44 intracellular signaling domain, an NKG2D intracellular signaling domain, a CD226 intracellular signaling domain, and a CD160 intracellular signaling domain.
[0051] In some embodiments, the CAR includes a transmembrane domain, and the transmembrane domain is selected from the group consisting of the CD8 transmembrane domain, CD28 transmembrane domain, CD25 transmembrane domain, CD7 transmembrane domain, CD3 zeta chain transmembrane domain, CD4 transmembrane domain, 4-1BB transmembrane domain, OX40 transmembrane domain, ICOS transmembrane domain, CTLA-4 transmembrane domain, LAX transmembrane domain, LAT transmembrane domain, PD-1 transmembrane domain, LAG-3 transmembrane domain, TIM3 transmembrane domain, KIR3DS1 transmembrane domain, KIR3DL1 transmembrane domain, NKG2D transmembrane domain, NKG2A transmembrane domain, TIGIT transmembrane domain, 2B4 transmembrane domain, and BTLA transmembrane domain.
[0052] In some embodiments, the CAR includes a spacer region between the antigen-binding domain and the transmembrane domain, and the spacer region has an amino acid sequence selected from the group consisting of SEQ ID NOs: 49 to 58.
[0053] In some embodiments, the inhibitory chimeric receptor and / or the antigen-binding domain of the chimeric receptor comprises one or more antibodies, antigen-binding fragments of antibodies, F(ab) fragments, F(ab') fragments, single-chain variable fragments (scFv), or single-domain antibodies (sdAb).
[0054] In some embodiments, the inhibitory chimeric receptor and / or the antigen-binding domain of the chimeric receptor comprises one or more single-chain variable fragments (scFv). In some embodiments, each of the one or more scFv comprises a heavy-chain variable domain (VH) and a light-chain variable domain (VL). In some embodiments, VH and VL are separated by a peptide linker. In some embodiments, the peptide linker comprises the amino acid sequence of SEQ ID NO: 39 or SEQ ID NO: 77. In some embodiments, each of the one or more scFv comprises the structure VH-L-VL or VL-L-VH, where VH is the heavy-chain variable domain, L is the peptide linker, and VL is the light-chain variable domain.
[0055] In some embodiments, the cells are immune-responsive cells. In some embodiments, binding of an inhibitory chimeric receptor to an antigen can inhibit the immune-responsive cells. In some embodiments, binding of the chimeric receptor to one or more additional antigens can activate the immune-responsive cells.
[0056] In some embodiments, the chimeric receptor binds to one or more additional antigens with low binding affinity.
[0057] In some embodiments, the chimeric receptor binds to one or more additional antigens at a binding affinity lower than that of the inhibitory chimeric receptor. In some embodiments, the inhibitory chimeric receptor binds to the antigen with low binding activity.
[0058] In some embodiments, the chimeric receptor is expressed by recombination. In some embodiments, the chimeric receptor is expressed from a locus selected from a vector or the cell's genome.
[0059] In some embodiments, the cells are selected from the group consisting of T cells, natural killer (NK) cells, cytotoxic T lymphocytes (CTLs), regulatory T cells, natural killer T (NKT) cells, myeloid cells, macrophages, human embryonic stem cells (ESCs), ESC-derived cells, pluripotent stem cells, and induced pluripotent stem cells (iPSCs), as well as iPSC-derived cells.
[0060] In some embodiments, the cells are autologous. In some embodiments, the cells are allogeneic.
[0061] In another embodiment, provided herein are isolated nucleic acids encoding any one of the above-described inhibitory chimeric receptors.
[0062] In another embodiment, provided herein is a vector comprising the nucleic acid of the above embodiment.
[0063] In another embodiment, provided herein are gene-modified cells comprising nucleic acids or vectors as described above.
[0064] In another embodiment, provided herein is a method for administering treatment to an object requiring treatment, wherein the method comprises administering isolated cells from any one of the embodiments described above.
[0065] In another embodiment, provided herein is a method for stimulating a cellular immune response against tumor cells in a subject, wherein the method comprises administering isolated cells of any one of the above embodiments to a subject having a tumor.
[0066] In another embodiment, provided herein is a method for providing antitumor immunity in a subject, the method comprising administering isolated cells of any one of the above embodiments to a subject requiring it.
[0067] In another embodiment, provided herein is a method for reducing tumor mass in a subject, comprising administering isolated cells of any one of the embodiments described above to the subject. In some embodiments, the method reduces the number of tumor cells. In some embodiments, the method reduces the tumor size. In some embodiments, the method reduces the tumor volume. In some embodiments, the method eradicates the tumor in the subject.
[0068] In another embodiment, provided herein is a method for treating a subject having a tumor, the method comprising administering isolated cells from any one of the embodiments described above.
[0069] In another embodiment, provided herein is a method for treating or preventing colorectal cancer in a subject, comprising administering isolated cells of any one of the embodiments described above to the subject.
[0070] In another embodiment, provided herein is a method for treating or preventing pancreatic cancer in a subject, comprising administering isolated cells of any one of the embodiments described above to the subject.
[0071] In another embodiment, provided herein is a method for treating or preventing lung adenocarcinoma in a subject, comprising administering isolated cells of any one of the embodiments described above to the subject.
[0072] In another embodiment, provided herein is a method for treating or preventing gastric cancer in a subject, comprising administering isolated cells of any one of the embodiments described above to the subject.
[0073] In some embodiments of the above-described portion, isolated cells are administered in an effective dose. In some embodiments of the above-described portion, the method increases progression-free survival in the subject. In some embodiments of the above-described portion, the method increases survival in the subject.
[0074] In another embodiment, provided herein are pharmaceutical compositions comprising an effective amount of isolated cells from any one of the above embodiments, and a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, or a combination thereof. In some embodiments, the pharmaceutical compositions are for the treatment and / or prevention of colorectal cancer, pancreatic cancer, lung adenocarcinoma, and / or gastric cancer.
[0075] In another embodiment, provided herein are kits for treating and / or preventing colorectal cancer, pancreatic cancer, lung adenocarcinoma, and / or gastric cancer, comprising isolated cells of any one of the embodiments described above, or a pharmaceutical composition of the embodiments described above. In some embodiments, the kit further includes written instructions for using the isolated cells to treat and / or prevent colorectal cancer, pancreatic cancer, lung adenocarcinoma, and / or gastric cancer in a subject.
[0076] In another embodiment, provided herein are kits for treating and / or preventing colorectal cancer, pancreatic cancer, lung adenocarcinoma, and / or gastric cancer, comprising the isolated nucleic acids or vectors of the above embodiments. In some embodiments, the kit further includes instructions for using nucleic acids to produce one or more antigen-specific cells for treating and / or preventing colorectal cancer, pancreatic cancer, lung adenocarcinoma, and / or gastric cancer in a subject. [Brief explanation of the drawing]
[0077] This patent or application document includes at least one drawing made in color. Copies of this patent or patent application publication including the color drawing are available from the Patent Office upon request and payment of the necessary fees.
[0078] These and other features, aspects, and advantages of this disclosure will be better understood in relation to the following description and accompanying drawings.
[0079] [Figure 1] This diagram shows the CEA family members, their structure, and their functions. [Figure 2] This shows the gene expression of CEACAM5 and CEACAM6 in colorectal cancer (CRC) and normal tissue. [Figure 3A] This shows the gene expression of CEACAM5 in colorectal cancer (CRC) and normal tissue. [Figure 3B] This shows the gene expression of CEACAM6 in colorectal cancer (CRC) and normal tissue. [Figure 4] This shows the protein expression of CEACAM1, CEACAM5, and CEACAM6 in patient samples in tissue microarrays containing both cancer and normal tissue samples. [Figure 5] This paper presents flow cytometry-based analysis of CEACAM1, CEACAM5, and CEACAM6 expression in a panel of human colon cancer cell lines obtained from ATCC. [Figure 6A]This paper presents an analysis of NOT targets using bulk RNA-seq gene expression data from ABCA8. [Figure 6B] This paper presents an analysis of NOT targets using bulk RNA-seq gene expression data for ATP1A2. [Figure 7A] The analysis of the single-cell RNA-seq dataset GSE144735 after dimensionality reduction and clustering is shown, with different cell types annotated and color-coded. [Figure 7B] The expression of ABCA8 in normal tissue is shown (Figure 7A), and its expression in stromal cells is emphasized. [Figure 8] This shows the gene expression of VSIG2 in colorectal cancer (CRC) and normal tissue. [Figure 9A] This report presents gene expression analysis of VSIG2, showing its expression in normal and tumor tissue epithelial cells in the single-cell RNA-seq dataset GSE144735. [Figure 9B] This paper presents gene expression analysis for VSIG2, showing overall gene expression in normal and tumor tissues from the single-cell RNA-seq dataset GSE132465. [Figure 10A] This shows a comparative gene expression analysis of VSIG2 and CEACAM5. [Figure 10B] The comparative gene expression analysis of VSIG2 and CEACAM5, presented as relative proportions within each population, is shown. [Figure 10C] This shows a comparative gene expression analysis of VSIG2 and CEACAM5 in normal gastrointestinal tissue (ileum, colon, and rectum). [Figure 10D] This shows a comparative analysis of VSIG2 and CEACAM5 gene expression in normal lung epithelial tissue. [Figure 10E] This shows a comparative analysis of VSIG2 and CEACAM5 gene expression in normal kidney and liver tissue. [Figure 11] This shows an expression analysis of the potential NOT target VSIG2 across a range of normal and cancerous colonic subtypes (datasets: GSE81861, GSE144735, GSE132465). [Figure 12A] This shows VSIG2 expression in healthy lung epithelial cells (EGAS00001004344). [Figure 12B] We will compare the expression levels of VSIG2, CEACAM5, and CEACAM6 in healthy lung epithelial cells. [Figure 13A] This image shows tissue microarrays (TMAs) of gastrointestinal tumors and healthy gastrointestinal tissue stained for VSIG2. [Figure 13B] This is a typical healthy tissue sample of TMA stained with VSIG2. [Figure 13C] This is a typical healthy tissue sample of TMA stained with VSIG2. [Figure 14A] Multiplex IHC analysis of healthy tissue stained with VSIG2 (pink) and CEACAM5 (white) is shown. The nuclei are stained with DAPI (blue). [Figure 14B] Multiplex IHC analysis of healthy tissue stained with VSIG2 (pink) and CEACAM5 (white) is shown. The nuclei are stained with DAPI (blue). [Figure 15] This image shows the localization analysis of VSIG2 (pink) and CEACAM5 (white) in grade 3, stage IIB colon cancer. The nuclei are stained with DAPI (blue). [Figure 16A] This paper presents gene expression analyses of VSIG2 and CEACAM5 in stromal cells and immune cells from colon cancer samples from two cohorts. [Figure 16B] This paper presents gene expression analyses of VSIG2 and CEACAM5 in stromal cells and immune cells from colon cancer samples from two cohorts. [Figure 16C] This paper presents gene expression analyses of VSIG2 and CEACAM5 in stromal cells and immune cells from colon cancer samples from two cohorts. [Figure 17A] This shows gene expression analysis of CPM in colon cancer and normal tissue (datasets: GSE81861, GSE144735, GSE132465). [Figure 17B]This shows the comparative expression of CPM, CEACAM5, and CEACAM6 in normal lung tissue (dataset EGAS00001004344). [Figure 17C] This shows the comparative expression of CPM, CEACAM5, and CEACAM6 in healthy lung cells (dataset EGAS00001004344). [Figure 18] This shows an analysis of the expression of the potential NOT target GPA33. Figure 18A shows GPA33 expression across a range of normal and CRC cell subtypes (datasets: GSE81861, GSE144735, GSE132465). Figure 18B shows an analysis of GPA33 gene expression in normal lung tissue (dataset EGAS00001004344). [Figure 19] This shows an analysis of the expression of the potential NOT target PLA2G2A. Figure 19A shows PLA2G2A expression across a range of normal and CRC cell subtypes (datasets: GSE81861, GSE144735, GSE132465). Figure 19B shows an analysis of PLA2G2A gene expression in normal lung tissue (dataset EGAS00001004344). [Figure 20] This shows the expression analysis of the potential NOT target ITM2C. Figure 20A shows ITM2C expression across a range of normal and CRC cell subtypes (datasets: GSE81861, GSE144735, GSE132465). Figure 20B shows the ITM2C gene expression analysis in normal lung tissue. [Figure 21] This shows an analysis of the expression of the potential NOT target CHP2. Figure 21A shows CHP2 expression across a range of normal and CRC cell subtypes (datasets: GSE81861, GSE144735, GSE132465). Figure 21B shows the CHP2 gene expression analysis in normal lung tissue. [Figure 22] This shows the expression analysis of the potential NOT target SLC26A2. Figure 22A shows SLC26A2 expression across a range of normal and CRC cell subtypes (datasets: GSE81861, GSE144735, GSE132465). Figure 22B shows the SLC26A2 gene expression analysis in normal lung tissue. [Figure 23] This shows the expression analysis of the potential NOT target SLC4A4. Figure 23A shows SLC4A4 expression across a range of normal and CRC cell subtypes (datasets: GSE81861, GSE144735, GSE132465). Figure 23B shows the SLC4A4 gene expression analysis in normal lung tissue. [Figure 24] This shows the expression analysis of the potential NOT target SLC26A3. Figure 24A shows SLC26A3 expression across a range of normal and CRC cell subtypes (datasets: GSE81861, GSE144735, GSE132465). Figure 24B shows the SLC26A3 gene expression analysis in normal lung tissue. [Figure 25] Figures 25A and 25B show the LDH activity of parental untransduced LS174t cells (Figure 25A) and mKATE-expressing target cells (Figure 25B) after co-culturing with CEA aCAR transduced T cells from the first donor ("T cell donor 1"). [Figure 26] Figures 26A and 26B show the LDH activity of parental untransduced LS174t cells (Figure 26A) and mKATE-expressing target cells (Figure 26B) after co-culturing with CEA aCAR transduced T cells from a second donor ("T cell donor 2"). [Figure 27] Figures 27A-27F show cytokine activity (IL-2, Figure 27A; IFN-gamma, Figure 27B; TNF-alpha, Figure 27C; caspase-3, Figure 27D; perforin, Figure 27E; and granzyme B, Figure 27F) of CEA aCAR transduced T cells after co-culture with target cells. [Figure 28] This shows the killing activity of CEA aCAR-transduced NK cells transduced with the first set of CEA aCAR, as determined by a flow assay. [Figure 29] This shows the killing activity of CEA aCAR-transduced NK cells transduced with a second set of CEA aCAR, as determined by a flow assay. [Figure 30]This shows the killing activity of NK cells transduced with two different CEA aCARs at various effector cell-to-target (E:T) ratios, as determined by flow assays. [Figure 31] Figures 31A-31C show the activation of surface markers (NKp46, Figure 31A; CD16, Figure 31B; and CD107a, Figure 31C) in target cells and cultured CEA aCAR-transduced NK cells. [Figure 32] This assay demonstrates the killing activity of transduced CEA aCAR NK cells using a real-time fluorescence assay. [Figure 33] Figures 33A and 33B show the magnification changes in tumor bioluminescence after treatment of mice with NK cells expressing CEA aCAR (Figure 33A) and representative tumor images 16 days after treatment (Figure 33B). [Figure 34] This shows the killing activity of NK cells transduced with various CEA aCAR constructs, as determined by real-time fluorescence assays. [Figure 35] This shows the killing activity of NK cells transduced with various CEA aCAR constructs, as determined by real-time fluorescence assays. [Figure 36] Representative images taken two days after NK cell treatment are shown for mice that were intraperitoneally inoculated with target cells of colorectal cancer cell lines and treated with NK cells transduced with various CEA aCAR constructs. [Figure 37] Representative images taken 13 days after NK cell treatment are shown for mice that were intraperitoneally inoculated with target cells of a colorectal cancer cell line and treated with NK cells transduced with a CEA aCAR construct. [Figure 38]Figures 38A–38D show the expression levels of various CEA-CAR lentivirus and retroviral constructs on transduced NK cells (3 days post-transduction). Figures 38A, 38B, and 38C provide flow cytometry histograms showing expression levels (38A, for lentivirus constructs 3 days post-transduction; 38B, for retroviral constructs 3 days post-transduction; and 38C, for retroviral constructs 11 days post-transduction). The dotted line represents the negative threshold (based on expression in non-transduced "virus-free" NK cells). Figure 38D shows the time course of expression from retroviral constructs, with the left panel showing the time course of expression percentage and the right panel showing the time course of mean fluorescence intensity (MFI). [Figure 39] Figures 39A-39C show CEA CAR expression from various retroviral transduction systems pseudotyped with baboon endogenous viral envelope (BaEv). Figure 39A shows expression from the first retroviral skeleton ("Skeleton 1"). Figure 39B shows expression from the first retroviral vector skeleton ("Skeleton 1") and with an alternative nucleotide sequence ("New Codon Optimization"). Figure 39C shows expression from the second retroviral skeleton ("Skeleton 2"). [Figure 40] Figures 40A and 40B show the transduction efficiency (Figure 40A) and CAR expression (Figure 40B) for CEA CARs with various CAR structures. [Figure 41] Figures 41A–41B show the killing of CEA CAR NK cells (derived from two different donors, Donor 7, Figure 41A, and Donor 13, Figure 41B) at a 1:1 effector cell-to-target cell ratio. [Figure 42] Figures 42A–42B show the killing of CEA CAR NK cells (derived from two different donors, Donor 7, Figure 42A, and Donor 13, Figure 42B) at an effector cell to target cell ratio of 1:2. [Figure 43] This shows CEA CAR expression by NK cells for various CAR structures. [Figure 44]This shows NK cell activation measured by granzyme B and interferon gamma in CEA CAR NK cells co-cultured with target cells (colorectal cancer cell line Ls174t). [Figure 45] Figures 45A and 45B show the multiplicative change in tumor volume calculated on day 5 after treatment with NK cells (Figure 45A), and representative images measured by bioluminescence imaging of tumor-bearing mice treated with CEA CAR NK cells (Figure 45B). [Figure 46] This shows the tumor response rate in mice in the study. [Figure 47] Figures 47A and 47B show the CAR expression levels of NK cells expressing CEA aCAR and off-target iCAR (Figure 47A), and NK cells expressing CEA aCAR and inhibitory CARs specific to the model safety antigen HER2 (Figure 47B). [Figure 48] This shows the NK cell expression levels of inhibitory CARs (specific to the safety antigen VSIG2) and activated anti-CEA CARs. [Figure 49] This demonstrates the killing of HER2+Ls174t cells co-cultured with NK cells expressing off-target iCARs and CEA aCARs, or HER2 iCARs and CEA aCARs. [Figure 50] Figures 50A-50B show the phosphorylation levels of NK cell activation markers in NK cells expressing aCAR / iCAR combinations after co-culture with target cells expressing safety antigens. [Figure 51] This shows the percentage reduction in target cells, measured via flow cytometry, after overnight co-culture with NK cells expressing aCAR / iCAR combination or aCAR alone. [Modes for carrying out the invention]
[0080] Detailed explanation The practices described herein, unless otherwise indicated, employ conventional methods of molecular biology, chemistry, biochemistry, virology, and immunology within the scope of the art. Such methods are fully described in the literature, e.g., Hepatitis C Viruses: Genomes and Molecular Biology (SLTan ed., Taylor & Francis, 2006); Fundamental Virology, 3 rd Edition,vol.I & II(BNFields and DMKnipe,eds.);Handbook of Experimental Immunology,Vols.I-IV(DMWeir and CCBlackwell eds.,Blackwell Scientific Publications);ALLehninger,Biochemistry(Worth Publishers,Inc.,current addition);Sambrook,et al.,Molecular Cloning:A Laboratory Manual(3rd Edition, 2001); Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.).
[0081] definition Unless otherwise defined, all terms, notations, and other scientific terms used herein are intended to have meanings generally understood by those skilled in the art. In some cases, terms having generally understood meanings are defined herein for clarity and / or immediate reference, and the inclusion of such definitions herein should not necessarily be interpreted as representing a difference from what is generally understood in the art. The techniques and procedures described or referenced herein are generally well known and commonly used by those skilled in the art, for example, using conventional methodologies such as the widely used molecular cloning methodology described in Sambrook et al., Molecular Cloning: A Laboratory Manual 4th ed. (2012), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. Procedures involving the use of commercially available kits and reagents, where necessary, are generally carried out according to the protocols and conditions defined by the manufacturers, unless otherwise stated.
[0082] As used herein, the singular forms "a," "an," and "the" include multiple referents unless the context explicitly indicates otherwise. Terms such as "includes" and "etc." are intended to convey inclusion without limitation unless otherwise indicated.
[0083] As used herein, the term “including” also specifically includes embodiments that “consist of” and “essentially consist of” the listed elements, unless otherwise indicated.
[0084] The term "approximately" indicates and encompasses both the value and the range above and below that value. In certain embodiments, the term "approximately" indicates a specified value ± 10%, ± 5%, or ± 1%. In certain embodiments, where applicable, the term "approximately" indicates a specified value ± one standard deviation of that value.
[0085] As used herein, the term “activating immune-responsive cells” refers to the induction of signaling or changes in protein expression in cells that result in the initiation of an immune response. For example, when CD3 chains cluster in response to ligand binding and immune receptor tyrosine system inhibitory motifs (ITAMs), a signaling cascade is produced. In certain embodiments, when an endogenous TCR or exogenous CAR binds to an antigen, immunological synapse formation occurs, involving the clustering of many molecules in the vicinity of the bound receptor (e.g., CD4 or CD8, CD3γ / δ / ε / ζ, etc.). This clustering of membrane-bound signaling molecules allows the ITAM motif contained within the CD3 chain to be phosphorylated. This phosphorylation then initiates a T cell activation pathway, ultimately activating transcription factors such as NF-κB and AP-1. These transcription factors induce overall T cell gene expression by increasing IL-2 production for proliferation and inducing the expression of key regulatory T cell proteins, in order to initiate a T cell-mediated immune response.
[0086] As used herein, the terms “stimulate” or “stimulate immune response” refer to generating a signal that elicits an immune response by one or more cell types or cell populations. Immunostimulatory activity may include pro-inflammatory activity. In various embodiments, the immune response may occur after the activation of immune cells (e.g., T cells or NK cells) or, non-limitingly, simultaneously via receptors containing CD28, CD137(4-1BB), OX40, CD40, and ICOS, and their corresponding ligands, including B7-1, B7-2, OX-40L, and 4-1BBL. Such polypeptides may be present in the tumor microenvironment and may activate an immune response against tumor cells. In various embodiments, promoting, stimulating, or having ligands stimulate receptors of pro-inflammatory polypeptides and / or their ligands may enhance the immune response of immune-responsive cells. While not bound by any particular theory, receiving multiple stimulating signals (e.g., co-stimulation) is crucial for carrying out robust and long-lasting cell-mediated immune responses, such as T-cell-mediated immune responses, in which T cells may be inhibited and unresponsive to antigens (also called "T-cell anergy") in the absence of co-stimulating signals. Without receiving these stimulating signals, T cells are quickly inhibited and become unresponsive to antigens. The various effects of co-stimulating signals are not fully understood, especially when combined with each other, but these co-stimuli generally result in increased gene expression to generate long-lived, proliferative, and anti-apoptotic resistant cells, such as T cells or NK cells, that respond strongly to antigens, for example, in mediating the complete and / or sustained elimination of target cells expressing congenital antigens.
[0087] As used herein, the terms “chimeric antigen receptor” or, alternatively, “CAR” refer to a recombinant polypeptide construct comprising at least an extracellular antigen-binding domain, a transmembrane domain, and a cytoplasmic signaling domain (also referred to herein as an “intracellular signaling domain”) which includes a functional signaling domain.
[0088] As used herein, the terms “activated CAR” or “aCAR” refer to a CAR construct / structure that has the ability to induce changes in signaling or protein expression in activated CAR-expressing cells that initiate, activate, stimulate, or increase an immune response upon binding to a congeneral aCAR ligand.
[0089] As used herein, the terms “inhibitory CAR” or “iCAR” refer to a CAR construct / structure that, upon binding to a homologous iCAR ligand, can induce alterations in signaling or protein expression in inhibitory CAR-expressing cells that prevent, attenuate, inhibit, reduce, decrease, suppress, or repress an immune response, including co-stimulatory signals or reduced activation of immune-responsive cells that have received or are receiving one or more stimulating signals.
[0090] As used herein, the term “enzyme inhibitory domain” refers to a protein domain that inhibits an intracellular signaling cascade, such as the innate T cell activation cascade. In some embodiments, the enzyme inhibitory domain of the chimeric inhibitory receptor of this disclosure includes at least a portion of an extracellular domain, a transmembrane domain, and / or an intracellular domain. In some embodiments, the enzyme inhibitory domain includes at least a portion of an enzyme. In some embodiments, the enzyme is selected from CSK, SHP-1, PTEN, CD45, CD148, PTP-MEG1, PTP-PEST, c-CBL, CBL-b, PTPN22, LAR, PTPH1, SHIP-1, and RasGAP (see, for example, Stanford et al., Regulation of TCR signaling by tyrosine phosphatases: from immune homeostasis to autoimmunity, Immunology, 2012 Sep;137(1):1-19). In some embodiments, the portion of the enzyme includes an enzyme domain, an enzyme fragment, or a variant thereof. In some embodiments, a portion of the enzyme is the catalytic domain of the enzyme. In some embodiments, the enzyme domain, enzyme fragment, or variant thereof is selected to maximize efficacy and minimize basal inhibition.
[0091] As used herein, the term “intracellular signaling domain” refers to a functional portion of a protein that acts by transmitting information within a cell to modulate cellular activity via a defined signaling pathway, either by generating a second messenger or by acting as an effector in response to such a messenger.
[0092] As used herein, the terms “extracellular antigen-binding domain” or “antigen-binding domain” (ABD) refer to a polypeptide sequence or polypeptide complex that specifically recognizes or binds to a given antigen or epitope, such as, for example, a polypeptide sequence or polypeptide complex portion of a chimeric protein described herein that provides VSIG2-specific binding. An ABD (or antibody, antigen-binding fragment, and / or a chimeric protein containing them) is said to “recognize” an epitope (or more generally, an antigen) to which the ABD specifically binds, and the epitope is said to be the “recognition specificity” or “binding specificity” of the ABD. An ABD is said to bind to its specific antigen or epitope with a particular affinity. As described herein, “affinity” refers to the strength of the non-covalent intermolecular force interaction between one molecule and another. Affinity, i.e., the strength of the interaction, is measured by the dissociation equilibrium constant (K). D It can be expressed as, K D A lower value indicates stronger intermolecular interactions. (K of antibody construct) D The values are measured by methods well known in the art, including, but not limited to, biolayer interferometry (e.g., Octet / FORTEBIO®), surface plasmon resonance (SPR) technology (e.g., Biacore®), and cell binding assays (e.g., flow cytometry). Specific binding evaluated by affinity may refer to binding molecules that have affinity between ABD and its homologous antigen or epitope, and K D The value is 10 -6 M, 10 -7 M, 10 -8 M, 10-9 M, or 10 -10 It is less than M. Specific binding can also include the recognition and binding of a biological molecule of interest (e.g., a polypeptide), while not specifically recognizing or binding other molecules in a sample, e.g., a biological sample that naturally contains a polypeptide of the present disclosure. In certain embodiments, specifically binding means that the binding is in a manner such that it can be substituted or compete with a second preparation of the same or a similar epitope, antigen, or antigenic determinant, and refers to the binding of an epitope or antigen or antigenic determinant of an ABD, antibody, or antigen-binding fragment.
[0093] The ABD can be an antibody. As used herein, the term "antibody" refers to a protein or polypeptide sequence derived from an immunoglobulin molecule that specifically binds to an antigen. An antibody can be polyclonal or monoclonal, multichain or single-chain, or intact immunoglobulin, and can be derived from a natural or recombinant source. An antibody can be a tetramer of an immunoglobulin molecule.
[0094] The ABD can be an antigen-binding fragment of an antibody. As used herein, the term "antigen-binding fragment" refers to at least one part of an intact antibody, or a recombinant variant thereof, that is sufficient to confer recognition and specific binding to a target such as an antigen or epitope. Examples of antigen-binding fragments include Fab, Fab’, F(ab’)2, Fv, scFv, linear antibodies, single-domain antibodies such as sdAb (VL or VH), camelid V HExamples include, but are not limited to, multispecific antibodies formed from antigen-binding fragments, such as a bivalent fragment containing an H domain and two Fab fragments linked by disulfide crosslinking in the hinge region, and isolated CDRs or other epitope-binding fragments of antibodies. Antigen-binding fragments can also be incorporated into single-domain antibodies, maxibodies, minibodies, nanobodies, intrabodies, diabodies, triabodies, tetrabodies, v-NARs, and bis-scFvs (see, e.g., Hollinger and Hudson, Nature Biotechnology 23:1126-1 136, 2005). Antigen-binding fragments can also be transplanted onto scaffolds based on polypeptides such as fibronectin type III (Fn3) (see U.S. Patent No. 6,703,199 describing fibronectin polypeptide minibodies).
[0095] The number of ABDs in a binding molecule, such as a chimeric protein, as described herein defines the “valence” of the binding molecule. A binding molecule with a single ABD is said to be “monovalent.” A binding molecule with multiple ABDs is said to be “polyvalent.” A polyvalent binding molecule with two ABDs is “divalent.” A polyvalent binding molecule with three ABDs is “trivalent.” A polyvalent binding molecule with four ABDs is “tetravalent.” In various polyvalent embodiments, all of the multiple ABDs have the same recognition specificity and can be called a “monospecific polyvalent” binding molecule. In other polyvalent embodiments, at least two of the multiple ABDs have different recognition specificities. Such a binding molecule is polyvalent and “multispecific.” In a polyvalent embodiment where the ABDs collectively have two recognition specificities, the binding molecule is “dualspecific.” In a polyvalent embodiment where the ABDs collectively have three recognition specificities, the binding molecule is “triplespecific.” In a polyvalent embodiment where ABD possesses multiple recognition specificities for different epitopes present on the same antigen, the binding molecule is a "multiple paratope." In a polyvalent embodiment where ABD recognizes two epitopes on the same antigen, it is a "double paratope."
[0096] In various polyvalent embodiments, polyvalent binding molecules improve the binding activity of the binding molecule to a particular target. Where used herein, “binding activity” refers to the overall strength of the interaction between two or more molecules, e.g., polyvalent binding molecules to a particular target, and binding activity is the cumulative strength of the interaction provided by the affinity of multiple ABDs. Binding activity can be measured by the same method used to determine affinity, as described above. In certain embodiments, the binding activity of a binding molecule to a particular target is such that the interaction is a specific binding interaction, and the binding activity between the two molecules is such that 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, or 10 -10 Less than M K D It has a value. In certain embodiments, the binding activity of the binding molecule to a particular target is such that the interaction is a specific binding interaction. D A value is present, and one or more affinity values of individual ABDs are considered to specifically bind to their respective antigens or epitopes. D It does not have a value. In certain embodiments, binding activity is the cumulative strength of the interaction resulting from the affinity of multiple ABDs to a shared specific target or distinct antigen on a complex, such as distinct antigens found on individual cells. In certain embodiments, binding activity is the cumulative strength of the interaction resulting from the affinity of multiple ABDs to distinct epitopes on shared individual antigens.
[0097] As used herein, the terms “single-chain variable fragment” or “scFv” refer to a fusion protein comprising at least one antigen-binding fragment containing a light-chain variable region and at least one antigen-binding fragment containing a heavy-chain variable region, wherein the light-chain and heavy-chain variable regions are linked via a short, mobile polypeptide linker, and the scFv can be expressed as a single-chain polypeptide, and the scFv retains the specificity of the intact antibody from which it is derived. As used herein, unless otherwise specified, an scFv may have VL and VH variable regions in either order with respect to the N-terminus and C-terminus of the polypeptide, for example, and the scFv may comprise a VL-linker-VH or a VH-linker-VL.
[0098] As used herein, “variable region” refers to a variable region resulting from recombination after V, J, and / or D segment recombination in an immunoglobulin gene in a B cell or a T cell receptor (TCR) gene in a T cell. In immunoglobulin genes, variable regions are typically defined by the antibody chain from which they are induced; for example, VH refers to the variable region of the antibody heavy chain, and VL refers to the variable region of the antibody light chain. Selective VH and VL can bind together to form an antigen-binding domain that confers antigen specificity and binding affinity.
[0099] As used herein, the terms “complementarity-determining region” or “CDR” refer to sequences within the antibody variable regions VH and VL that confer antigen specificity and binding affinity. For example, generally, each heavy chain variable region has three CDRs (e.g., HCDR1, HCDR2, and HCDR3), and each light chain variable region has three CDRs (LCDR1, LCDR2, and LCDR3). The precise amino acid sequence boundaries of a given CDR can be determined using one of several well-known schemes, including those described by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (“Kabat” numbering scheme), Al-Lazikani et al. (1997) JMB 273, 927-948 (“Chothia” numbering scheme), or a combination thereof. Under the Kabat numbering scheme, in some embodiments, the CDR amino acid residues of the heavy chain variable domain (VH) are numbered 31-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3), and the CDR amino acid residues of the light chain variable domain (VL) are numbered 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3). Under the Chothia numbering scheme, in some embodiments, the CDR amino acids of VH are numbered 26-32 (HCDR1), 52-56 (HCDR2), and 95-102 (HCDR3), and the CDR amino acid residues of VL are numbered 26-32 (LCDR1), 50-52 (LCDR2), and 91-96 (LCDR3). In the combined Kabat and Chothia numbering scheme, in some embodiments, a CDR corresponds to an amino acid residue that is part of a Kabat CDR, a Chothia CDR, or both.For example, in some embodiments, the CDR corresponds to amino acid residues 26-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3) of VH, e.g., mammalian VH, e.g., human VH, and amino acid residues 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3) of VL, e.g., mammalian VL, e.g., human VL. In various embodiments, the CDR is a mammalian sequence including, but not limited to, mouse, rat, hamster, rabbit, camel, donkey, goat, and human sequences. In preferred embodiments, the CDR is a human sequence. In various embodiments, the CDR is a naturally occurring sequence.
[0100] As used herein, the term “framework region” or “FR” typically refers to a generally conserved sequence within the antibody variable regions VH and VL, which functions as a scaffold for scattered CDRs in the FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 arrangement (N-terminus to C-terminus). In various embodiments, FR is a mammalian sequence, non-limitingly including mouse, rat, hamster, rabbit, camel, donkey, goat, and human sequences. In certain embodiments, FR is a human sequence. In various embodiments, FR is a naturally occurring sequence. In various embodiments, FR is a synthetic sequence, non-limitingly including a reasonably designed sequence.
[0101] As used herein, the term “antibody heavy chain” refers to the larger of two types of polypeptide chains present in antibody molecules in their naturally occurring three-dimensional structure, which typically determine the class to which the antibody belongs.
[0102] As used herein, the term “antibody light chain” refers to the smaller of two types of polypeptide chains present in antibody molecules in their naturally occurring three-dimensional structures. Kappa (κ) and lambda (λ) light chains refer to the two main antibody light chain isotypes.
[0103] As used herein, the term “recombinant antibody” refers to an antibody produced using recombinant DNA technology, such as an antibody expressed by a bacteriophage or yeast expression system. The term should also be interpreted as meaning an antibody produced by the synthesis of a DNA molecule encoding the antibody, in which the DNA molecule expresses an antibody protein, or an amino acid sequence that identifies the antibody, and the DNA or amino acid sequence is obtained using recombinant DNA or amino acid sequence technologies that are available and well known in the art.
[0104] As used herein, the terms “antigen” or “Ag” refer to a molecule that elicits an immune response. This immune response may involve antibody production, activation of cells with specific immunological capabilities, or both. Those skilled in the art will understand that virtually any macromolecule, including proteins or peptides, can function as an antigen.
[0105] As used herein, the terms “antitumor effect” or “antitumor activity” refer to a biological effect that can be manifested by a variety of means, including, but not limited to, a reduction in tumor volume, a reduction in the number of tumor cells, a reduction in the number of metastases, an increase in lifespan, a decrease in tumor cell proliferation, a decrease in tumor cell survival rate, or an improvement in various physiological symptoms associated with a cancerous condition. The “antitumor effect” can also be manifested by the ability of the peptides, polynucleotides, cells, and antibodies of this disclosure to prevent tumor development in the first place, such as through prophylactic therapy or treatment.
[0106] As used herein, the term “autologous” refers to any substance derived from the same subject that is later reintroduced into the subject.
[0107] As used herein, the term “homogeneous” refers to any substance originating from different animals of the same species as the subject into which the substance is introduced. Two or more subjects are said to be homogeneous if their genes at one or more loci are not identical. In some embodiments, homogeneous substances from individuals of the same species may be sufficiently genetically different to interact antigenically at certain genes, such as MHC alleles. In some embodiments, homogeneous substances from individuals of the same species may be sufficiently genetically identical to not interact antigenically at certain genes, such as MHC alleles.
[0108] The isolated nucleic acid molecules of this disclosure include any nucleic acid molecules encoding a polypeptide or fragment thereof of this disclosure. Such nucleic acid molecules do not need to be 100% homologous or identical to the endogenous nucleic acid sequence, but typically exhibit substantial identity. Nucleic acids having “substantial identity” or “substantial homology” to the endogenous sequence can typically hybridize with at least one strand of a double-stranded nucleic acid molecule. As used herein, “hybridization” refers to pairing to form a double-stranded molecule with a complementary polynucleotide sequence (e.g., a gene described herein) or a portion thereof, under conditions of varying strictness. For example, the strict salt concentrations may typically be about 750 mM NaCl and less than 75 mM trisodium citrate, about 500 mM NaCl and less than 50 mM trisodium citrate, or about 250 mM NaCl and less than 25 mM trisodium citrate. Low-tight hybridization can be obtained in the absence of organic solvents, such as formamide, while high-tight hybridization can be obtained in the presence of at least about 35% or at least about 50% formamide. Tight temperature conditions typically include temperatures of at least about 30°C, at least about 37°C, or at least about 42°C. Various additional parameters, such as hybridization time, the concentration of surfactants, such as sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. By combining these various conditions as needed, various levels of tightness can be achieved.
[0109] "Substantially identical" or "substantially homologous" means that a polypeptide or nucleic acid molecule exhibits at least 50% homology or identity with a reference amino acid sequence (e.g., any one of the amino acid sequences described herein) or nucleic acid sequence (e.g., any one of the nucleic acid sequences described herein). Preferably, such sequence is at least about 60%, about 80%, about 85%, about 90%, about 95%, about 99%, or about 100% homologous or identical with the sequence used for comparison at the amino acid level or at the nucleic acid level. Sequence identity is typically measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, BLAST, BESTFIT, GAP, or PILEUP / PRETTYBOX program). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and / or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine, valine, isoleucine, leucine, aspartic acid, glutamic acid, asparagine, glutamine, serine, threonine, lysine, arginine, and phenylalanine and tyrosine. An exemplary method for measuring the degree of identity may involve using the BLAST program, where probability scores from e-3 to e-100 indicate closely related sequences.
[0110] As used herein, the term “coding” refers to the inherent properties of a particular sequence of nucleotides in a polynucleotide, such as a gene, cDNA, or mRNA, and the biological properties derived therefrom, that serve as a template for the synthesis of other polymers and macromolecules in a biological process having either a specific sequence of nucleotides (e.g., rRNA, tRNA, and mRNA) or a specific sequence of amino acids. Thus, a gene, cDNA, or RNA codes for a protein if the transcription and translation of the mRNA corresponding to that gene produces a protein in a cell or other biological system. Both the coding strand, where the nucleotide sequence is identical to the mRNA sequence and is usually provided in a sequence listing, and the non-coding strand, used as a template for the transcription of a gene or cDNA, may be said to code for a protein or other product of that gene or cDNA. Unless otherwise indicated, “nucleotide sequence coding an amino acid sequence” includes all nucleotide sequences that are degenerate versions of each other and code for the same amino acid sequence. The phrase “nucleotide sequence coding a protein or RNA” may also include introns to the extent that a nucleotide sequence coding a protein may include introns in some versions.
[0111] As used herein, the term “ligand” refers to a molecule that binds to a receptor. Specifically, a ligand binds to a receptor on another cell, enabling intercellular recognition and / or interaction.
[0112] The terms “effective dose” and “therapeutic dose” are used interchangeably herein and refer to the amount of a compound, formulation, substance, or composition described herein that is effective in achieving a particular biological outcome. In some embodiments, the “effective dose” or “therapeutic dose” is an amount sufficient to block, improve, or inhibit the continued proliferation, growth, or metastasis of a disease or disorder of interest, such as a bone marrow disorder.
[0113] As used herein, the term “immunely responsive cell” refers to a cell that functions in an immune response (e.g., an immune effector response), its precursor, or its offspring. Examples of immune effector cells include, but are not limited to, alpha / beta T cells, gamma / delta T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells, and bone marrow-derived phagocytic cells.
[0114] As used herein, the terms “immune effector response” or “immune effector function” refer to the function or response of an immune-responsive cell, for example, that enhances or promotes the immune attack of a target cell. For example, an immune effector function or response may refer to the properties of a T cell or NK cell that promote the death or inhibition of growth or proliferation of a target cell. In the case of T cells, primary stimulation and co-stimulation are examples of immune effector functions or responses.
[0115] As used herein, the terms “mobile polypeptide linker” or “linker” refer to a peptide linker consisting of amino acids, such as glycine and / or serine residues, used alone or in combination to link variable heavy chain and variable light chain regions together. In one embodiment, the mobile polypeptide linker is a Gly / Ser linker with the amino acid sequence (Gly-Gly-Gly-Gly-Ser) n Or (Gly-Gly-Gly-Ser) n The linker includes a (Gly4Ser) or (Gly4Ser)3, where n is a positive integer greater than 1. For example, n=1, n=2, n=3, n=4, n=5, n=6, n=7, n=8, n=9, or n=10. In some embodiments, the mobile polypeptide linker includes, but is not limited to, Gly4Ser or (Gly4Ser)3. In other embodiments, the linker includes multiple iterations of (Gly2Ser), (GlySer), or (Gly3Ser). In some embodiments, the mobile polypeptide linker includes a Whitlow linker (e.g., GTSTGSGKPGSGEGSTKG [SEQ ID NO: 42]). For example, the linker described in WO2012 / 138475 is also within the scope of this disclosure.
[0116] As used herein, the terms “treat,” “treatment,” and “treating” refer to the reduction or mitigation of the progression, severity, and / or duration of a proliferative disorder (e.g., cancer), or the mitigation of one or more symptoms (preferably one or more identifiable symptoms) of a proliferative disorder resulting from the administration of one or more therapies (e.g., one or more therapeutic agents such as CARs of this disclosure). In some embodiments, reduction or improvement refers to the improvement of at least one measurable physical parameter of the proliferative disorder, such as tumor growth, which is not necessarily identifiable by the patient. In other embodiments, the terms “treat,” “treatment,” and “treating” refer to the inhibition of the progression of a proliferative disorder, physically, for example, by stabilization of an identifiable symptom; physiologically, for example, by stabilization of a physical parameter; or both. In some embodiments, reduction or improvement includes reduction or stabilization of tumor size or cancer cell number.
[0117] As used herein, the term “subject” is intended to include living organisms (e.g., mammals, humans) from which an immune response may be induced.
[0118] Other Interpretation Rules The ranges listed herein are understood to be all abbreviations of values within a range that include the listed endpoints. For example, the range 1 to 50 is understood to include any number, combination of numbers, or subranges of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50.
[0119] Unless otherwise specified, references to compounds having one or more stereocenters refer to each stereoisomer and all combinations of those stereoisomers.
[0120] Solid tumor antigen Certain aspects of this disclosure relate to chimeric receptors and cells such as immune-responsive cells genetically modified to express one or more such chimeric receptors that bind to an antigen of interest, as well as methods of using such receptors and cells to treat and / or prevent solid malignancies, such as lung cancer, pancreatic cancer, gastrointestinal cancer, colon cancer, brain cancer, nerve tissue cancer, endocrine tumors, bone cancer, bone marrow cancer, immune system cancer, muscle cancer, liver cancer, gallbladder cancer, kidney cancer, bladder cancer, male reproductive organ cancer, female reproductive organ cancer, adipose cancer, soft tissue cancer, skin cancer, and other medical conditions requiring an antigen-specific immune response. Malignant cells have developed a set of mechanisms to protect themselves from immune recognition and elimination. This disclosure provides immunogenicity within the tumor microenvironment for treating such malignant cells.
[0121] Certain aspects of this disclosure relate to chimeric receptors that specifically bind to one or more antigens expressed on bone marrow cells useful for the treatment of solid malignancies, and to immune-responsive cells genetically modified to express such chimeric receptors. Solid tumors are clonal diseases caused by genetic and epigenetic changes that disrupt important processes such as cell proliferation and differentiation. Solid malignancies can be chronic or acute.
[0122] In certain embodiments, this disclosure relates to solid tumor antigens and combinations of solid tumor antigens suitable for use in chimeric receptors (e.g., chimeric TCRs or CARs) to increase efficacy in the treatment of solid tumors and / or reduce extratumor toxicity. In certain embodiments, the solid tumor antigen is a member of the CEA family. In certain embodiments, the solid tumor antigen is a member of the CEA family selected from the group consisting of CEA, CEACAM1, CEACAM5, and CEACAM6. As used herein, “CEA” refers to a family of highly relevant proteins (CD66 proteins) including, but not limited to, CEACAM1 (CD66a), CEACAM5 (CD66e), and CEACAM6 (CD66c). In certain embodiments, the antibody or antigen-binding fragment that binds to CEA binds to one or more CD66 proteins.
[0123] Table 1 provides CEA family antigens suitable for use with chimeric receptors as described in the methods and compositions presented herein.
[0124] [Table 1]
[0125] In some embodiments, the solid tumor antigen is the CEACAM1 antigen. CEACAM1 is also known in the art as BGP, BGP1, BGPI, or CD66a. In some embodiments, the solid tumor antigen is the CEACAM5 antigen. CEACAM5 was previously known in the art as CEA. Currently, CEACAM5 is also known as meconium antigen 100, carcinoembryonic antigen, or CD66e. In some embodiments, the solid tumor antigen is the CEACAM6 antigen. CEACAM6 is also known in the art as CEAL, NCA, normal cross-reactive antigen, nonspecific cross-reactive antigen, or CD66c.
[0126] Chimeric receptor Certain aspects of this disclosure relate to chimeric receptors that bind to an antigen of interest and nucleic acids encoding such chimeric receptors.
[0127] Antibody and antigen-binding fragments In some embodiments, the chimeric receptor comprises one or more antigen-binding domains capable of binding to solid tumor antigens, such as CEA family member antigens (listed in Table 1). The antigen-binding domain of the chimeric receptor may include an antibody sequence or antigen-binding fragment thereof of a representative anti-CEA antibody provided in Table 2.
[0128] [Table 2] TIFF2023552724000004.tif243170TIFF2023552724000005.tif205170
[0129] Certain aspects of this disclosure relate to chimeric receptors (e.g., CARs or chimeric TCRs) comprising an extracellular antigen-binding domain that binds to one or more antigens of this disclosure. In some embodiments, the antigen-binding domain is derived from an antibody or an antigen-binding fragment thereof. In some embodiments, the antigen-binding domain comprises a CDR sequence of an antibody or an antigen-binding fragment thereof, as shown in Table 2. CDR sequences and known systems for defining them, such as Kabat, are discussed in detail above.
[0130] Preferred antibodies of this disclosure include natural or synthetic antibodies, full-length or fragment thereof, monoclonal or polyclonal antibodies that bind sufficiently strongly and specifically to solid tumor antigens, such as CEA, CEACAM1, CEACAM5, or CEACAM6. In some embodiments, the antibody may be up to about 10 -6 M, maximum about 10 -7 M, maximum about 10 -8 M, maximum about 10 -9 M, maximum about 10 -10 M, maximum about 10 -11 M, or up to approximately 10 -12 M's K D It may have.
[0131] In some embodiments, antibodies and their derivatives that may be used include, but are not limited to, polyclonal antibodies, monoclonal antibodies, chimeric antibodies, human antibodies, humanized antibodies, primate-transplanted (CDR) antibodies, venated antibodies, single-chain antibodies, phage-producing antibodies (e.g., from phage display libraries), and functional binding fragments of antibodies. For example, antibody fragments, or some thereof, that can bind to solid tumor antigens include, but are not limited to, Fv, Fab, Fab', and F(ab')2 fragments. Such fragments may be produced by enzymatic cleavage or by recombinant techniques. For example, but are not limited to papain or pepsin cleavage, papain or pepsin cleavage can produce Fab or F(ab')2 fragments, respectively. Other proteases with the required substrate specificity may also be used to produce Fab or F(ab')2 fragments. Antibodies may also be produced in various cleavage forms using antibody genes in which one or more stop codons are introduced upstream of the native stop site. For example, a chimeric gene encoding the F(ab')2 double-stranded region can be designed to include DNA sequences encoding the CH, domain, and hinge region of the heavy chain.
[0132] Methods for producing antibodies that target specific antigens are generally known in the art. Synthesized and manipulated antibodies are described, for example, in US4816567, EP0125023Bl, US4816397, EP0120694Bl, WO86 / 01533, EP0194276Bl, US5225539, EP0239400Bl, EP0451216Bl, EP0519596Al, and US4946778.
[0133] In some embodiments, commercially available antibodies may be used to bind to solid tumor antigens. The CDRs of commercially available antibodies are readily accessible to those skilled in the art using conventional sequencing techniques. Furthermore, those skilled in the art can construct nucleic acids encoding scFv and chimeric receptors (e.g., CAR and TCR) based on the CDRs of such commercially available antibodies.
[0134] In some embodiments, the chimeric receptor includes an antigen-binding domain that specifically binds to CEA.
[0135] In some embodiments, the chimeric receptor includes an antigen-binding domain that specifically binds to CEACAM1. In some embodiments, the CEACAM1-specific antigen-binding domain is derived from an anti-CEACAM1 antibody, such as an MRG1 antibody or its antigen-binding fragment. In certain embodiments, the CEACAM1-specific antigen-binding domain includes a heavy-chain variable domain (VH) having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) the same amino acid sequence as SEQ ID NO: 1, and a light-chain variable domain (VL) having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) the same amino acid sequence as SEQ ID NO: 2. In certain embodiments, the second antigen-binding site comprises heavy chain CDR1, CDR2, and CDR3, and light chain CDR1, CDR2, and CDR3, respectively, of the VH and VL sequences of SEQ ID NOs: 1 and 2, as determined under Kabat, Chothia, MacCallum, or any other CDR determination method known in the art. The antigen-binding domain may be an scFv comprising a light chain variable domain (VL) and a heavy chain variable domain (VH). In some embodiments, the chimeric receptor may have a multispecific antigen-binding domain. For example, the chimeric receptor may be specific to CEACAM1 and one or more additional antigens. In some embodiments, the chimeric receptor may be specific to CEACAM1 and CEACAM5. In some embodiments, the chimeric receptor may be specific to CEACAM1 and CEACAM6. In some embodiments, the chimeric receptor may be specific to CEACAM5 and CEACAM6.
[0136] In some embodiments, the chimeric receptor includes an antigen-binding domain that specifically binds to CEACAM5. In some embodiments, the CEACAM5-specific antigen-binding domain is derived from an anti-CEACAM5 antibody, e.g., rabetsizimab (i.e., hMN14) or its antigen-binding fragment. In certain embodiments, the CEACAM5-specific antigen-binding domain includes a heavy-chain variable domain (VH) having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) the same amino acid sequence as SEQ ID NO: 3, and a light-chain variable domain (VL) having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) the same amino acid sequence as SEQ ID NO: 4. In certain embodiments, the second antigen-binding site comprises heavy chain CDR1, CDR2, and CDR3, and light chain CDR1, CDR2, and CDR3, respectively, of the VH and VL sequences of SEQ ID NOs: 3 and 4, as determined under Kabat, Chothia, MacCallum, or any other CDR determination method known in the art. The antigen-binding domain may be an scFv comprising a light chain variable domain (VL) and a heavy chain variable domain (VH). In some embodiments, the chimeric receptor may have a multispecific antigen-binding domain. For example, the chimeric receptor may be specific to CEACAM5 and one or more additional antigens.
[0137] In some embodiments, the CEACAM5-specific antigen-binding domain is derived from an anti-CEACAM5 antibody, such as cibisatamab or its antigen-binding fragment. In certain embodiments, the CEACAM5-specific antigen-binding domain includes a heavy chain (VH) having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) the same amino acid sequence as SEQ ID NO: 5, and a light chain (VL) having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) the same amino acid sequence as SEQ ID NO: 6. In certain embodiments, the second antigen-binding site includes the heavy chain variable domain (VH) and the light chain variable domain (VL) of the HC and LC sequences of SEQ ID NOs. 5 and 6, respectively. In certain embodiments, the second antigen-binding site comprises heavy chain CDR1, CDR2, and CDR3, and light chain CDR1, CDR2, and CDR3, respectively, of the HC and LC sequences of SEQ ID NOs. 5 and 6, as determined under Kabat, Chothia, MacCallum, or any other CDR determination method known in the Art. The antigen-binding domain may be an scFv containing a light chain variable domain and a heavy chain variable domain. In some embodiments, the chimeric receptor may have a multispecific antigen-binding domain. For example, the chimeric receptor may be specific to CEACAM5 and one or more additional antigens.
[0138] In some embodiments, the CEACAM5-specific antigen-binding domain is derived from an anti-CEACAM5 antibody, such as tusamitamab or its antigen-binding fragment. In certain embodiments, the CEACAM5-specific antigen-binding domain includes a heavy chain (VH) having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) the same amino acid sequence as SEQ ID NO: 7, and a light chain (VL) having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) the same amino acid sequence as SEQ ID NO: 8. In certain embodiments, the second antigen-binding site includes the heavy chain variable domain (VH) and the light chain variable domain (VL) of the HC and LC sequences of SEQ ID NOs: 7 and 8, respectively. In certain embodiments, the second antigen-binding site comprises heavy chain CDR1, CDR2, and CDR3, and light chain CDR1, CDR2, and CDR3, respectively, of the HC and LC sequences of SEQ ID NOs. 7 and 8, as determined under Kabat, Chothia, MacCallum, or any other CDR determination method known in the art. The antigen-binding domain may be an scFv containing a light chain variable domain and a heavy chain variable domain. In some embodiments, the chimeric receptor may have a multispecific antigen-binding domain. For example, the chimeric receptor may be specific to CEACAM5 and one or more additional antigens.
[0139] In some embodiments, the CEACAM5-specific antigen-binding domain is derived from an anti-CEACAM5 antibody, e.g., BW431 / 26 or its antigen-binding fragment. In certain embodiments, the CEACAM5-specific antigen-binding domain includes a heavy chain variable domain (VH) having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) the same amino acid sequence as SEQ ID NO: 9, and a light chain variable domain (VL) having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) the same amino acid sequence as SEQ ID NO: 10. In certain embodiments, the second antigen-binding site comprises heavy chain CDR1, CDR2, and CDR3, and light chain CDR1, CDR2, and CDR3, respectively, of the VH and VL sequences of SEQ ID NOs: 9 and 10, as determined under Kabat, Chothia, MacCallum, or any other CDR determination method known in the art. The antigen-binding domain may be an scFv comprising a light chain variable domain (VL) and a heavy chain variable domain (VH). In some embodiments, the chimeric receptor may have a multispecific antigen-binding domain. For example, the chimeric receptor may be specific to CEACAM5 and one or more additional antigens.
[0140] In some embodiments, the CEACAM5-specific antigen-binding domain is derived from an anti-CEACAM5 antibody, e.g., A5B7 or its antigen-binding fragment. In certain embodiments, the CEACAM5-specific antigen-binding domain includes a heavy chain variable domain (VH) having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) the same amino acid sequence as SEQ ID NO: 11, and a light chain variable domain (VL) having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) the same amino acid sequence as SEQ ID NO: 12. In certain embodiments, the second antigen-binding site comprises heavy chain CDR1, CDR2, and CDR3, and light chain CDR1, CDR2, and CDR3, respectively, of the VH and VL sequences of SEQ ID NOs: 11 and 12, as determined under Kabat, Chothia, MacCallum, or any other CDR determination method known in the art. The antigen-binding domain may be an scFv comprising a light chain variable domain (VL) and a heavy chain variable domain (VH). In some embodiments, the chimeric receptor may have a multispecific antigen-binding domain. For example, the chimeric receptor may be specific to CEACAM5 and one or more additional antigens.
[0141] In some embodiments, the CEACAM5-specific antigen-binding domain is derived from an anti-CEACAM5 antibody, such as MFE23 or its antigen-binding fragment. In certain embodiments, the CEACAM5-specific antigen-binding domain includes a heavy chain variable domain (VH) having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) the same amino acid sequence as SEQ ID NO: 13, and a light chain variable domain (VL) having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) the same amino acid sequence as SEQ ID NO: 14. In certain embodiments, the second antigen-binding site comprises heavy chain CDR1, CDR2, and CDR3, and light chain CDR1, CDR2, and CDR3, respectively, of the VH and VL sequences of SEQ ID NOs. 13 and 14, as determined under Kabat, Chothia, MacCallum, or any other CDR determination method known in the art. The antigen-binding domain may be an scFv comprising a light chain variable domain (VL) and a heavy chain variable domain (VH). In some embodiments, the chimeric receptor may have a multispecific antigen-binding domain. For example, the chimeric receptor may be specific to CEACAM5 and one or more additional antigens.
[0142] In some embodiments, the CEACAM5-specific antigen-binding domain is derived from an anti-CEACAM5 antibody, such as hMFE23 or its antigen-binding fragment. In certain embodiments, the CEACAM5-specific antigen-binding domain includes a heavy chain variable domain (VH) having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) the same amino acid sequence as SEQ ID NO: 78, and a light chain variable domain (VL) having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) the same amino acid sequence as SEQ ID NO: 79. In certain embodiments, the second antigen-binding site comprises heavy chain CDR1, CDR2, and CDR3, and light chain CDR1, CDR2, and CDR3, respectively, of the VH and VL sequences of SEQ ID NOs. 78 and 79, as determined under Kabat, Chothia, MacCallum, or any other CDR determination method known in the Art. The antigen-binding domain may be an scFv comprising a light chain variable domain (VL) and a heavy chain variable domain (VH). In some embodiments, the chimeric receptor may have a multispecific antigen-binding domain. For example, the chimeric receptor may be specific to CEACAM5 and one or more additional antigens.
[0143] In some embodiments, the CEACAM5-specific antigen-binding domain is derived from an anti-CEACAM5 antibody that can specifically bind to glycosylated CEACAM5. In some embodiments, the glycosylated CEACAM5-specific antigen-binding domain is derived from an anti-glycosylated CEACAM5 antibody, such as FM4 (also referred to herein as "MG7") or its antigen-binding fragment. In certain embodiments, the CEACAM5-specific antigen-binding domain includes a heavy chain variable domain (VH) having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) the same amino acid sequence as SEQ ID NO: 15, and a light chain variable domain (VL) having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) the same amino acid sequence as SEQ ID NO: 16. In certain embodiments, the second antigen-binding site comprises heavy chain CDR1, CDR2, and CDR3, and light chain CDR1, CDR2, and CDR3, respectively, of the VH and VL sequences of SEQ ID NOs. 15 and 16, as determined under Kabat, Chothia, MacCallum, or any other CDR determination method known in the art. The antigen-binding domain may be an scFv comprising a light chain variable domain (VL) and a heavy chain variable domain (VH). In some embodiments, the chimeric receptor may have a multispecific antigen-binding domain. For example, the chimeric receptor may be specific to CEACAM5 and one or more additional antigens.
[0144] In some embodiments, the chimeric receptor includes an antigen-binding domain that specifically binds to CEACAM6. In some embodiments, the CEACAM6-specific antigen-binding domain is derived from an anti-CEACAM6 antibody, e.g., tinuririmab or an antigen-binding fragment thereof. In certain embodiments, the CEACAM6-specific antigen-binding domain includes a heavy chain (VH) having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) the same amino acid sequence as SEQ ID NO: 17, and a light chain (VL) having at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) the same amino acid sequence as SEQ ID NO: 18. In certain embodiments, the second antigen-binding site comprises the heavy chain variable domain (VH) and light chain variable domain (VL) of the HC and LC sequences of SEQ ID NOs. In certain embodiments, the second antigen-binding site comprises the heavy chain CDR1, CDR2, and CDR3 and light chain CDR1, CDR2, and CDR3 of the HC and LC sequences of SEQ ID NOs. 17 and 18, respectively, as determined under Kabat, Chothia, MacCallum, or any other CDR determination method known in the Art. The antigen-binding domain may be an scFv comprising the light chain variable domain and the heavy chain variable domain. In some embodiments, the chimeric receptor may have a multispecific antigen-binding domain. For example, the chimeric receptor may be specific to CEACAM6 and one or more additional antigens.
[0145] T cell receptor (TCR) Certain embodiments of this disclosure relate to chimeric receptors that specifically bind to antigens expressed on solid tumor cells. In some embodiments, the chimeric receptor is a chimeric T cell receptor (TCR). The TCR of this disclosure is a disulfide-bonded heterodimer protein comprising two variable chains expressed as part of a complex with an invariant CD3 chain molecule. The TCR is found on the surface of T cells and plays a role in recognizing antigens as peptides bound to major histocompatibility complex (MHC) molecules. In certain embodiments, the TCR of this disclosure comprises an alpha chain encoded by TRA and a beta chain encoded by TRB. In certain embodiments, the TCR comprises a gamma chain and a delta chain (encoded by TRG and TRD, respectively).
[0146] Each chain of the TCR consists of two extracellular domains: a variable (V) region and a constant (C) region. The constant region is proximal to the cell membrane, followed by a transmembrane region and a short cytoplasmic tail. The variable region binds to peptide / MHC complexes. Each variable region has three complementarity-determining regions (CDRs).
[0147] In certain embodiments, the TCR can form receptor complexes with three dimeric signaling modules: CD3δ / ε, CD3γ / ε, and CD247ζ / ζ or CD247ζ / η. When the TCR complex is bound to its antigen and MHC (peptide / MHC), the T cells expressing the TCR complex are activated.
[0148] In some embodiments, the TCRs of this disclosure are recombinant TCRs. In certain embodiments, the TCRs are non-naturally derived TCRs. In certain embodiments, the TCRs differ from naturally derived TCRs by at least one amino acid residue. In some embodiments, the TCRs differ from naturally derived TCRs by at least two amino acid residues, at least three amino acid residues, at least four amino acid residues, at least five amino acid residues, at least six amino acid residues, at least seven amino acid residues, at least eight amino acid residues, at least nine amino acid residues, at least ten amino acid residues, at least eleven amino acid residues, at least twelve amino acid residues, at least thirteen amino acid residues, at least fourteen amino acid residues, at least fifteen amino acid residues, at least twenty amino acid residues, at least twenty-five amino acid residues, at least thirty amino acid residues, at least forty amino acid residues, at least fifty amino acid residues, at least sixty amino acid residues, at least seventy amino acid residues, at least eighty amino acid residues, at least ninety amino acid residues, at least one hundred amino acid residues, or more amino acid residues. In certain embodiments, the TCR is a naturally occurring TCR modified by at least one amino acid residue. In some embodiments, the TCR is a naturally occurring TCR modified by at least two amino acid residues, at least three amino acid residues, at least four amino acid residues, at least five amino acid residues, at least six amino acid residues, at least seven amino acid residues, at least eight amino acid residues, at least nine amino acid residues, at least ten amino acid residues, at least eleven amino acid residues, at least twelve amino acid residues, at least thirteen amino acid residues, at least fourteen amino acid residues, at least fifteen amino acid residues, at least twenty amino acid residues, at least twenty-five amino acid residues, at least thirty amino acid residues, at least forty amino acid residues, at least fifty amino acid residues, at least sixty amino acid residues, at least seventy amino acid residues, at least eighty amino acid residues, at least ninety amino acid residues, at least one hundred amino acid residues, or more amino acid residues.
[0149] Chimera TCR In some embodiments, the TCR of the Disclosure includes one or more antigen-binding domains that can be transplanted onto one or more constant domains of the TCR chain, e.g., the TCR alpha chain or the TCR beta chain, in order to create a chimeric TCR that specifically binds to the target antigen of the Disclosure (e.g., a solid tumor antigen). While not wishing to be bound by theory, it is thought that chimeric TCRs can signal through the TCR complex upon antigen binding. For example, an antibody or antibody fragment (e.g., scFv) can be transplanted onto at least a portion of the constant domains of the TCR chain, such as the TCR alpha chain and / or TCR beta chain, e.g., the extracellular constant domain, the transmembrane domain, and the cytoplasmic domain. As another example, a CDR of an antibody or antibody fragment can be transplanted onto the TCR alpha chain and / or beta chain to create a chimeric TCR that specifically binds to the antigen of the Disclosure (e.g., a solid tumor antigen). Such chimeric TCRs can be created by methods well known in the art (e.g., Willemsen RA et al., Gene Therapy). See 2000;7:1369-1377;Zhang T et al., Cancer Gene Ther 2004 11:487-496; and Aggen et al., Gene Ther. 2012 Apr;19(4):365-74).
[0150] Chimeric antigen receptor (CAR) Certain aspects of this disclosure relate to chimeric receptors that specifically bind to antigens expressed on solid tumors, such as tumors of the lung, pancreas, gastrointestinal tract, colon, brain, nervous tissue, endocrine system, bone, bone marrow, immune system, muscle, liver, gallbladder, kidney, bladder, male genitalia, female genitalia, fat, soft tissue, or skin. In some embodiments, the chimeric receptor is a chimeric antigen receptor (CAR). In some embodiments, the CAR (or an immune-responsive cell genetically engineered to contain one or more CARs, see below) specifically binds to a CEA family member tumor antigen, such as one of the CEA antigens in Table 1. In some embodiments, the CAR (or an immune-responsive cell genetically engineered to contain one or more CARs) may include an antibody sequence of a representative anti-CEA antibody provided in Table 2 or an antigen-binding fragment thereof. In some embodiments, the CAR (or an immune-responsive cell genetically engineered to contain one or more CARs) may include an scFv derived from an antibody capable of binding to a solid tumor antigen, such as a representative anti-CEA scFv provided in Table 3.
[0151] In some embodiments, CARs are manipulative receptors that transfer or confer desired specificity to immune effector cells. In certain embodiments, CARs can be used to transfer antibody specificity to immune-responsive cells such as T cells. In some embodiments, the CARs of this disclosure include an extracellular antigen-binding domain (e.g., scFv) fused to a transmembrane domain, which is fused to one or more intracellular signaling domains.
[0152] In some embodiments, binding of a chimeric antigen receptor to its homologous ligand is sufficient to induce activation of immune-responsive cells. In some embodiments, binding of a chimeric antigen receptor to its homologous ligand is sufficient to induce stimulation of immune-responsive cells. In some embodiments, activation of immune-responsive cells results in the death of target cells. In some embodiments, activation of immune-responsive cells results in the expression and / or secretion of cytokines or chemokines by the immune-responsive cells. In some embodiments, stimulation of immune-responsive cells results in the expression and / or secretion of cytokines or chemokines by the immune-responsive cells. In some embodiments, stimulation of immune-responsive cells induces differentiation of immune-responsive cells. In some embodiments, stimulation of immune-responsive cells results in the proliferation of immune-responsive cells.
[0153] The CARs of this disclosure may be first-generation, second-generation, or third-generation CARs. "First-generation" CARs generally contain a single intracellular signaling domain derived from the T cell receptor chain. "First-generation" CARs generally have an intracellular signaling domain from the CD3-zeta (CD3ζ) chain, which is the primary signaling factor from the endogenous TCR. "First-generation" CARs provide de novo antigen recognition and, independently of HLA-mediated antigen presentation, transmit signals to CD4 via the CD3ζ chain signaling domain within a single fusion molecule. + and CD8 + It induces activation of both T cells. Second-generation CARs provide additional signaling to T cells by adding a second intracellular signaling domain from one of various co-stimulatory molecules (e.g., CD28, 4-1BB, ICOS, OX40) to the cytoplasmic tail of the CAR. Second-generation CARs provide both co-stimulation (e.g., CD28 or 4-1BB) and activation (CD3ζ). Preclinical studies have shown that second-generation CARs can enhance the antitumor activity of immune-responsive cells such as T cells. Third-generation CARs have multiple intracellular co-stimulatory signaling domains (e.g., CD28 and 4-1BB) and an intracellular activation signaling domain (CD3ζ).
[0154] In some embodiments, the extracellular antigen-binding domain of the CAR disclosed herein binds to one or more antigens expressed on cells such as solid tumor cells, and approximately 2 × 10⁻⁶ antigens. -7M Below, about 1x10 -7 M or less, about 9x10 -8 M or less, about 1x10 -8 M or less, about 9x10 -9 M or less, about 5x10 -9 M or less, about 4x10 -9 M or less, about 3x10 -9 M or less, about 2x10 -9 M or less, or approximately 1x10 -9 Dissociation constants (K) less than or equal to M D ) are joined together. In some embodiments, K D It is approximately 2 x 10 -7 M ~ approx. 1×10 -9 It is within the range of M.
[0155] The binding of the extracellular antigen-binding domain of the CARs of this disclosure can be determined, for example, by enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), FACS analysis, bioassay (e.g., growth inhibition), or Western blot assay. Each of these assays generally detects the presence of a particular protein-antibody complex of interest by using the complex of interest and a specific labeling reagent (e.g., antibody or scFv). For example, scFv may be radiolabeled and used in RIA assays. Radioisotopes can be detected by means such as the use of a γ counter or scintillation counter, or by autoradiography. In certain embodiments, the extracellular antigen-binding domain of the CAR is labeled with a fluorescent marker. Non-exclusive examples of fluorescent markers include green fluorescent protein (GFP), blue fluorescent protein (e.g., EBFP, EBFP2, Azurite, and mKalamal), cyan fluorescent protein (e.g., ECFP, Cerulean, and CyPet), and yellow fluorescent protein (e.g., YFP, Citrine, Venus, and YPet).
[0156] In some embodiments, the CAR of this disclosure comprises an extracellular antigen-binding domain that binds to one or more antigens expressed on solid tumor cells (e.g., lung, pancreas, gastrointestinal tract, colon, brain, nervous tissue, endocrine, bone, bone marrow, immune system, muscle, liver, gallbladder, kidney, bladder, male genitalia, female genitalia, fat, soft tissue, or skin), a transmembrane domain, and one or more intracellular signaling domains. In some embodiments, the extracellular antigen-binding domain comprises scFv. In some embodiments, the extracellular antigen-binding domain comprises a Fab fragment which may be crosslinked. In certain embodiments, the extracellular binding domain is an F(ab)2 fragment. 。
[0157] Extracellular antigen-binding domain In some embodiments, the extracellular antigen-binding domain of the CAR of this disclosure specifically binds to one or more antigens expressed on solid tumor cells, such as those of the lung, pancreas, gastrointestinal tract, colon, brain, nervous tissue, endocrine system, bone, bone marrow, immune system, muscle, liver, gallbladder, kidney, bladder, male genitalia, female genitalia, fat, soft tissue, or skin cells. In certain embodiments, the extracellular antigen-binding domain binds to one or more antigens (solid tumor antigens) expressed on solid tumor cells. In some embodiments, the one or more solid tumor antigens are human polypeptides.
[0158] The antigen-binding domains of this disclosure include single-domain antibodies (sdAbs), such as a heavy chain variable domain (VH), a light chain variable domain (VL), and a variable domain (V) of a camel-derived nanobody. HThe CAR may include, but is not limited to, monoclonal antibodies, polyclonal antibodies, recombinant antibodies, bispecific antibodies, complex antibodies, human antibodies, humanized antibodies, and functional fragments thereof, as well as any domain that functions as an antigen-binding domain and binds to an alternative scaffold known in the art, such as recombinant fibronectin domains, T cell receptors (TCRs), recombinant TCRs with enhanced affinity, or fragments thereof, e.g., single-stranded TCRs. In some cases, it is beneficial that the antigen-binding domain originates from the same species in which the CAR is ultimately used. For example, for use in humans, it may be beneficial that the antigen-binding domain of the CAR contains human or humanized residues for the antigen-binding domain of the antibody or antibody fragment.
[0159] In some embodiments, the extracellular antigen-binding domain includes an antibody. In certain embodiments, the antibody is a human antibody. In certain embodiments, the antibody is a humanized antibody. In certain embodiments, the antibody is a chimeric antibody. In some embodiments, the extracellular antigen-binding domain includes an antigen-binding fragment of the antibody.
[0160] In some embodiments, the extracellular antigen-binding domain includes the F(ab) fragment. In certain embodiments, the extracellular antigen-binding domain includes the F(ab') fragment.
[0161] In some embodiments, the extracellular antigen-binding domain includes scFv.
[0162] Various scFvs derived from antibodies capable of binding to solid tumor antigens are provided in Table 3. In some embodiments, the extracellular antigen-binding domain includes the scFvs provided in Table 3.
[0163] [Table 3]
[0164] In some embodiments, the extracellular antigen-binding domain comprises two single-chain variable fragments (scFv). In some embodiments, each of the two scFvs binds to a distinct epitope on the same antigen. In some embodiments, the extracellular antigen-binding domain comprises a first scFv and a second scFv. In some embodiments, the first scFv and the second scFv bind to distinct epitopes on the same antigen. In certain embodiments, the scFv is a human scFv. In certain embodiments, the scFv is a humanized scFv. In certain embodiments, the scFv is a chimeric scFv. In certain embodiments, the scFv comprises a heavy-chain variable domain (VH) and a light-chain variable domain (VL). In certain embodiments, VH and VL are separated by a peptide linker. In some embodiments, the peptide linker comprises the amino acid sequence shown in Table 4.
[0165] [Table 4]
[0166] In certain embodiments, the peptide linker is encoded by a nucleic acid containing the sequence GGCGGAGGCGGATCAGGTGGCGGAGGAAGTGGCGGCGGAGGATCT (SEQ ID NO: 44).
[0167] In certain embodiments, scFv comprises the structure VH-L-VL or VL-L-VH, where VH is a heavy chain variable domain, L is a peptide linker, and VL is a light chain variable domain.
[0168] In some embodiments, each of one or more scFvs comprises the structure VH-L-VL or VL-L-VH, where VH is the heavy chain variable domain, L is the peptide linker, and VL is the light chain variable domain. When two or more scFvs are linked together, each scFv can be linked to the next scFv to which a peptide is linked. In some embodiments, each of one or more scFvs is separated by a peptide linker. In some embodiments, the peptide linker separating each scFv comprises the amino acid sequence shown in Table 4.
[0169] In some embodiments, the peptide linker includes the amino acid sequence of SEQ ID NO: 27. In some embodiments, the peptide linker includes the amino acid sequence of SEQ ID NO: 28. In some embodiments, the peptide linker includes the amino acid sequence of SEQ ID NO: 29. In some embodiments, the peptide linker includes the amino acid sequence of SEQ ID NO: 30. In some embodiments, the peptide linker includes the amino acid sequence of SEQ ID NO: 31. In some embodiments, the peptide linker includes the amino acid sequence of SEQ ID NO: 32. In some embodiments, the peptide linker includes the amino acid sequence of SEQ ID NO: 33. In some embodiments, the peptide linker includes the amino acid sequence of SEQ ID NO: 34. In some embodiments, the peptide linker includes the amino acid sequence of SEQ ID NO: 35. In some embodiments, the peptide linker includes the amino acid sequence of SEQ ID NO: 36. In some embodiments, the peptide linker includes the amino acid sequence of SEQ ID NO: 37. In some embodiments, the peptide linker includes the amino acid sequence of SEQ ID NO: 38. In some embodiments, the peptide linker includes the amino acid sequence of SEQ ID NO: 39. In some embodiments, the peptide linker includes the amino acid sequence of SEQ ID NO: 40. In some embodiments, the peptide linker includes the amino acid sequence of SEQ ID NO: 41. In some embodiments, the peptide linker includes the amino acid sequence of SEQ ID NO: 42. In some embodiments, the peptide linker includes the amino acid sequence of SEQ ID NO: 43.
[0170] In some embodiments, the cell comprises a first chimeric receptor and a second chimeric receptor. The antigen-binding domains of the first and second chimeric receptors may be suitable antigen-binding domains described herein or known in the art. For example, the first or second antigen-binding domain may be one or more antibodies, antigen-binding fragments of antibodies, F(ab) fragments, F(ab') fragments, single-chain variable fragments (scFv), or single-domain antibodies (sdAb). In some embodiments, the antigen-binding domains of the first and / or second chimeric receptors comprise two single-chain variable fragments (scFv). In some embodiments, each of the two scFv binds to a distinct epitope on the same antigen.
[0171] In some embodiments, the extracellular antigen-binding domain includes a single-domain antibody (sdAb). In certain embodiments, the sdAb is a humanized sdAb. In certain embodiments, the sdAb is a chimeric sdAb.
[0172] In some embodiments, the CAR of this disclosure may comprise two or more antigen-binding domains, three or more antigen-binding domains, four or more antigen-binding domains, five or more antigen-binding domains, six or more antigen-binding domains, seven or more antigen-binding domains, eight or more antigen-binding domains, nine or more antigen-binding domains, or ten or more antigen-binding domains. In some embodiments, each of the two or more antigen-binding domains binds to the same antigen. In some embodiments, each of the two or more antigen-binding domains binds to a different epitope of the same antigen. In some embodiments, each of the two or more antigen-binding domains binds to a different antigen. In some embodiments, the two or more antigen-binding domains provide the CAR with logical gating, such as OR logical gating.
[0173] In some embodiments, the CAR comprises two antigen-binding domains. In some embodiments, the two antigen-binding domains are linked to each other via a mobile linker. In some embodiments, each of the two antigen-binding domains may be independently selected from an antibody, an antigen-binding fragment of an antibody, scFv, sdAb, recombinant fibronectin domain, T cell receptor (TCR), a recombinant TCR with enhanced affinity, and a single-chain TCR. In some embodiments, the CAR comprising two antigen-binding domains is a bispecific CAR or a tandem CAR (tanCAR).
[0174] In certain embodiments, a bispecific CAR or tanCAR includes an antigen-binding domain containing a bispecific antibody or antibody fragment (e.g., scFv). In some embodiments, within each antibody or antibody fragment (e.g., scFv) of a bispecific antibody molecule, VH may be upstream or downstream of VL. In some embodiments, the upstream antibody or antibody fragment (e.g., scFv) is positioned upstream of its VL (VL1) with its VH (VH1), and the downstream antibody or antibody fragment (e.g., scFv) is positioned upstream of its VH (VH2) with its VL (VL2), resulting in the overall bispecific antibody molecule having the configuration VH1-VL1-VL2-VH2. In other embodiments, an upstream antibody or antibody fragment (e.g., scFv) is positioned upstream of its VH(VH1) with its VL(VL1), and a downstream antibody or antibody fragment (e.g., scFv) is positioned upstream of its VL(VL2) with its VH(VH2), so that the overall bispecific antibody molecule has the configuration VL1VH1-VH2-VL2. In some embodiments, a linker is positioned between two antibodies or antibody fragments (e.g., scFv), for example, between VL1 and VL2 when the construct is positioned as VH1-VL1-VL2-VH2, or between VH1 and VH2 when the construct is positioned as VL1-VH1-VH2-VL2. The linker may be a linker as described herein, for example, a (Gly4-Ser)n linker, where n is 1, 2, 3, 4, 5, or 6. In general, the linker between two scFvs must be long enough to avoid mismatching between the domains of the two scFvs. In some embodiments, the linker is located between the VL and VH of the first scFv. In some embodiments, the linker is located between the VL and VH of the second scFv. In a construct having multiple linkers, any two or more linkers may be the same or different. Thus, in some embodiments, a bispecific CAR or tanCAR includes VL, VH and may further include one or more linkers in the arrangements described herein.
[0175] In some embodiments, the bivalent receptor includes CEA CAR and CEACAM1 CAR. In some embodiments, the bivalent receptor includes CEA CAR and CEACAM5 CAR. In some embodiments, the bivalent receptor includes CEA CAR and CEACAM6 CAR. In some embodiments, the bivalent receptor includes CEACAM1 CAR and CEACAM5 CAR. In some embodiments, the bivalent receptor includes CEACAM1 CAR and CEACAM6 CAR. In some embodiments, the bivalent receptor includes CEACAM5 CAR and CEACAM6 CAR.
[0176] In some embodiments, the bivalent receptor includes CEA CAR and VSIG2 CAR. In some embodiments, the bivalent receptor includes CEA CAR and CPM CAR. In some embodiments, the bivalent receptor includes CEA CAR and ITM2C CAR. In some embodiments, the bivalent receptor includes CEA CAR and SLC26A2 CAR. In some embodiments, the bivalent receptor includes CEA CAR and SLC4A4 CAR. In some embodiments, the bivalent receptor includes CEA CAR and GPA33 CAR. In some embodiments, the bivalent receptor includes CEA CAR and PLA2G2A CAR. In some embodiments, the bivalent receptor includes CEA CAR and ABCA8 CAR. In some embodiments, the bivalent receptor includes CEA CAR and ATP1A2 CAR. In some embodiments, the bivalent receptor includes CEA CAR and CHP2 CAR. In some embodiments, the bivalent receptor includes CEA CAR and SLC26A3 CAR.
[0177] In some embodiments, the bivalent receptor includes CEACAM1 CAR and VSIG2 CAR. In some embodiments, the bivalent receptor includes CEACAM1 CAR and CPM CAR. In some embodiments, the bivalent receptor includes CEACAM1 CAR and ITM2C CAR. In some embodiments, the bivalent receptor includes CEACAM1 CAR and SLC26A2 CAR. In some embodiments, the bivalent receptor includes CEACAM1 CAR and SLC4A4 CAR. In some embodiments, the bivalent receptor includes CEACAM1 CAR and GPA33 CAR. In some embodiments, the bivalent receptor includes CEACAM1 CAR and PLA2G2A CAR. In some embodiments, the bivalent receptor includes CEACAM1 CAR and ABCA8 CAR. In some embodiments, the bivalent receptor includes CEACAM1 CAR and ATP1A2 CAR. In some embodiments, the bivalent receptor includes CEACAM1 CAR and CHP2 CAR. In some embodiments, the bivalent receptor includes CEACAM1 CAR and SLC26A3 CAR.
[0178] In some embodiments, the bivalent receptor includes CEACAM5 CAR and VSIG2 CAR. In some embodiments, the bivalent receptor includes CEACAM5 CAR and CPM CAR. In some embodiments, the bivalent receptor includes CEACAM5 CAR and ITM2C CAR. In some embodiments, the bivalent chimeric antigen receptor includes CEACAM5 CAR and SLC26A2 CAR. In some embodiments, the bivalent receptor includes CEACAM5 CAR and SLC4A4 CAR. In some embodiments, the bivalent receptor includes CEACAM5 CAR and GPA33 CAR. In some embodiments, the bivalent receptor includes CEACAM5 CAR and PLA2G2A CAR. In some embodiments, the bivalent receptor includes CEACAM5 CAR and ABCA8 CAR. In some embodiments, the bivalent receptor includes CEACAM5 CAR and ATP1A2 CAR. In some embodiments, the bivalent receptor includes CEACAM5 CAR and CHP2 CAR. In some embodiments, the bivalent receptor includes CEACAM5 CAR and SLC26A3 CAR.
[0179] In some embodiments, the bivalent receptor includes CEACAM6 CAR and VSIG2 CAR. In some embodiments, the bivalent receptor includes CEACAM6 CAR and CPM CAR. In some embodiments, the bivalent receptor includes CEACAM6 CAR and ITM2C CAR. In some embodiments, the bivalent receptor includes CEACAM6 CAR and SLC26A2 CAR. In some embodiments, the bivalent receptor includes CEACAM6 CAR and SLC4A4 CAR. In some embodiments, the bivalent receptor includes CEACAM6 CAR and GPA33 CAR. In some embodiments, the bivalent receptor includes CEACAM6 CAR and PLA2G2A CAR. In some embodiments, the bivalent receptor includes CEACAM6 CAR and ABCA8 CAR. In some embodiments, the bivalent receptor includes CEACAM6 CAR and ATP1A2 CAR. In some embodiments, the bivalent receptor includes CEACAM6 CAR and CHP2 CAR. In some embodiments, the bivalent receptor comprises CEACAM6 CAR and CHP2 CAR. In some embodiments, the bivalent receptor comprises CEACAM6 CAR and SLC26A3 CAR.
[0180] In some embodiments, the bivalent chimeric receptor comprises a CAR having an antigen-binding domain that targets any of the antigens provided in Table 1. In some embodiments, the bivalent chimeric receptor comprises a CAR having an antigen-binding domain derived from an antibody provided in Table 2. In some embodiments, the bivalent chimeric receptor comprises a CAR having an antigen-binding domain containing an scFv provided in Table 2. In some embodiments, the bivalent chimeric receptor comprises a CAR having two or more antigen-binding domains that target any of the antigen pairs provided in Table 5. In some embodiments, the bivalent chimeric antigen receptor comprises a CAR having any combination of two or more antigen-binding domains described herein.
[0181] In some embodiments, the chimeric receptor includes a bisistronic chimeric antigen receptor system, for example, a chimeric antigen receptor system comprising an activating CAR and an inhibitory CAR. In some embodiments, the bisistronic chimeric antigen receptor system includes a CAR having an antigen-binding domain that targets any antigen provided in Table 1, and an inhibitory CAR having an antigen-binding domain that targets any antigen provided in Table 8, for example. In some embodiments, the bisistronic chimeric antigen receptor system includes a CAR having an antigen-binding domain derived from an antibody provided in Table 2, and an inhibitory CAR having an antigen-binding domain that targets any antigen provided in Table 7, for example. In some embodiments, the bisistronic chimeric antigen receptor system includes a CAR having two or more antigen-binding domains that target any antigen pair provided in Table 5, where at least one antigen-binding domain is an activating CAR and at least one antigen-binding domain is an inhibitory CAR. In some embodiments, the bisistronic chimeric antigen receptor system comprises a CAR having any combination of two or more antigen-binding domains described herein, wherein at least one antigen-binding domain is an activating CAR and at least one antigen-binding domain is an inhibitory CAR.
[0182] transmembrane domain In some embodiments, the transmembrane domain of the CARs of this disclosure comprises a hydrophobic alpha-helix spanning at least a portion of the cell membrane. It has been shown that different transmembrane domains can result in different receptor stabilizations. After antigen recognition, the receptors cluster, and the signal is transmitted to the cell. In some embodiments, the transmembrane domain of the CARs of this disclosure may comprise the transmembrane domains of CD8 polypeptide, CD28 polypeptide, CD25 polypeptide, CD7 polypeptide, CD3-zeta polypeptide, CD4 polypeptide, 4-1BB polypeptide, OX40 polypeptide, ICOS polypeptide, CTLA-4 polypeptide, LAX polypeptide, LAT polypeptide, PD-1 polypeptide, LAG-3 polypeptide, TIM3 polypeptide, KIR3DS1 polypeptide, KIR3DL1 polypeptide, NKG2D polypeptide, NKG2A polypeptide, TIGIT polypeptide, 2B4 polypeptide, BTLA polypeptide, LIR-1 (LILRB1) polypeptide, or synthetic peptides, or any combination thereof.
[0183] In some embodiments, the transmembrane domain is derived from a CD8 polypeptide. Any suitable CD8 polypeptide may be used. Exemplary CD8 polypeptides include, but are not limited to, NCBI reference numbers NP_001139345 and AAA92533.1. In some embodiments, the transmembrane domain is derived from a CD28 polypeptide. Any suitable CD28 polypeptide may be used. Exemplary CD28 polypeptides include, but are not limited to, NCBI reference numbers NP_006130.1 and NP_031668.3. In some embodiments, the transmembrane domain is derived from a CD3-zeta polypeptide. Any suitable CD3-zeta polypeptide may be used. Exemplary CD3-zeta polypeptides include, but are not limited to, NCBI reference numbers NP_932170.1 and NP_001106862.1. In some embodiments, the transmembrane domain is derived from a CD4 polypeptide. Any suitable CD4 polypeptide may be used. Exemplary CD4 polypeptides include, but are not limited to, NCBI reference numbers NP_000607.1 and NP_038516.1. In some embodiments, the transmembrane domain is derived from a 4-1BB polypeptide. Any suitable 4-1BB polypeptide can be used. Exemplary 4-1BB polypeptides include, but are not limited to, NCBI reference numbers NP_001552.2 and NP_001070977.1. In some embodiments, the transmembrane domain is derived from an OX40 polypeptide. Any suitable OX40 polypeptide can be used. Exemplary OX40 polypeptides include, but are not limited to, NCBI reference numbers NP_003318.1 and NP_035789.1. In some embodiments, the transmembrane domain is derived from an ICOS polypeptide. Any suitable ICOS polypeptide can be used. Exemplary ICOS polypeptides include, but are not limited to, NCBI reference numbers NP_036224 and NP_059508. In some embodiments, the transmembrane domain is derived from a CTLA-4 polypeptide. Any suitable CTLA-4 polypeptide may be used.Exemplary CTLA-4 polypeptides include, but are not limited to, NCBI reference numbers NP_005205.2 and NP_033973.2. In some embodiments, the transmembrane domain is derived from a PD-1 polypeptide. Any suitable PD-1 polypeptide may be used. Exemplary PD-1 polypeptides include, but are not limited to, NCBI reference numbers NP_005009 and NP_032824. In some embodiments, the transmembrane domain is derived from a LAG-3 polypeptide. Any suitable LAG-3 polypeptide may be used. Exemplary LAG-3 polypeptides include, but are not limited to, NCBI reference numbers NP_002277.4 and NP_032505.1. In some embodiments, the transmembrane domain is derived from a 2B4 polypeptide. Any suitable 2B4 polypeptide may be used. Exemplary 2B4 polypeptides include, but are not limited to, NCBI reference numbers NP_057466.1 and NP_061199.2. In some embodiments, the transmembrane domain is derived from a BTLA polypeptide. Any suitable BTLA polypeptide may be used. Examples of BTLA polypeptides include, but are not limited to, NCBI reference numbers NP_861445.4 and NP_001032808.2. Any suitable LIR-1 (LILRB1) polypeptide may be used. Examples of LIR-1 (LILRB1) polypeptides include, but are not limited to, NCBI reference numbers NP_001075106.2 and NP_001075107.2.
[0184] In some embodiments, the transmembrane domains are NCBI reference numbers NP_001139345, AAA92533.1, NP_006130.1, NP_031668.3, NP_932170.1, NP_001106862.1, NP_000607.1, NP_038516.1, NP_001552.2, NP_001070977.1, NP_003318.1, NP_035789.1, NP_036224, NP_059508, NP_005205.2, NP_033973.2, NP_0050 The polypeptide comprises an amino acid sequence or fragment thereof that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homologous to the sequence of 09, NP_032824, NP_002277.4, NP_032505.1, NP_057466.1, NP_061199.2, NP_861445.4, or NP_001032808.2. In some embodiments, homology can be determined using standard software such as BLAST or FASTA. In some embodiments, the polypeptide may contain one conservative amino acid substitution, up to two conservative amino acid substitutions, or up to three conservative amino acid substitutions.In some embodiments, the polypeptide has an amino acid length of at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, or at least 240, with NCBI reference numbers NP_001139345, AAA92533.1, NP_006130.1, NP_0 It may have an amino acid sequence that is a contiguous portion of 31668.3, NP_932170.1, NP_001106862.1, NP_000607.1, NP_038516.1, NP_001552.2, NP_001070977.1, NP_003318.1, NP_035789.1, NP_036224, NP_059508, NP_005205.2, NP_033973.2, NP_005009, NP_032824, NP_002277.4, NP_032505.1, NP_057466.1, NP_061199.2, NP_861445.4, or NP_001032808.2.
[0185] Further examples of suitable polypeptides from which the transmembrane domain may be derived include T cell receptor, CD27, CD3 epsilon, CD45, CD5, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, CD2, CD27, LFA-1 (CD11a, CD18), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, IL2R beta, IL2R gamma, IL7R, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD10 3. This includes, but is not limited to, the transmembrane regions of the alpha, beta, or zeta strands of ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG / Cbp, NKG2D, and NG2C. In some embodiments, the transmembrane domain may include any of the amino acid sequences listed in Table 5, or an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any of the amino acid sequences listed in Table 5.
[0186] [Table 5]
[0187] Spacer area In some embodiments, the CARs of this disclosure may also include a spacer region linking the extracellular antigen-binding domain to the transmembrane domain. The spacer region may be flexible enough to allow the antigen-binding domain to be oriented in different directions to facilitate antigen recognition. In some embodiments, the spacer region may be a hinge derived from a human protein. For example, the spacer (also referred to herein as “hinge”) may be a human Ig (immunoglobulin) hinge, including, but not limited to, an IgG4 hinge, an IgG2 hinge, a CD8a hinge, or an IgD hinge. In some embodiments, the spacer region may include an IgG4 hinge, an IgG2 hinge, an IgD hinge, a CD28 hinge, a KIR2DS2 hinge, an LNGFR hinge, or a PDGFR-beta extracellular linker. In some embodiments, the spacer region is localized between the antigen-binding domain and the transmembrane domain. In some embodiments, the spacer region may include any of the amino acid sequences listed in Table 6, or an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any of the amino acid sequences listed in Table 6. In some embodiments, the nucleic acid encoding any of the spacer regions of this disclosure may include any of the nucleic acid sequences listed in Table 7, or a nucleic acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any of the nucleic acid sequences listed in Table 7.
[0188] [Table 6]
[0189] [Table 7]
[0190] In some embodiments, the spacer region includes the sequence shown in sequence number 49. In some embodiments, the spacer region includes the sequence shown in sequence number 50. In some embodiments, the spacer region includes the sequence shown in sequence number 51. In some embodiments, the spacer region includes the sequence shown in sequence number 52. In some embodiments, the spacer region includes the sequence shown in sequence number 53. In some embodiments, the spacer region includes the sequence shown in sequence number 54. In some embodiments, the spacer region includes the sequence shown in sequence number 55. In some embodiments, the spacer region includes the sequence shown in sequence number 56. In some embodiments, the spacer region includes the sequence shown in sequence number 57. In some embodiments, the spacer region includes the sequence shown in sequence number 58.
[0191] In some embodiments, the CAR of the present disclosure may further include a short oligopeptide or polypeptide linker having a length of 2 to 10 amino acid residues that can form a bond between the transmembrane domain and the cytoplasmic region of the CAR. A non-limiting example of a preferred linker is a glycine-serine double chain. In some embodiments, the linker includes the amino acid sequence GGCKJSGGCKJS (SEQ ID NO: 69).
[0192] Intracellular signal transduction domains In some embodiments, the CARs of this disclosure include one or more cytoplasmic domains or regions. The cytoplasmic domains or regions of the CAR may include intracellular signaling domains. Intracellular signaling domains are typically involved in the activation of one or more effector functions of immune cells (e.g., T cells or NK cells) engineered to express the CARs of this disclosure. For example, the effector function of a T cell may be cytolytic activity or helper activity, such as cytokine secretion. Thus, in some embodiments, the term “intracellular signaling domain” refers to a portion of a protein that transmits effector function signals and instructs the cell to perform a specific function. Usually, the entire intracellular signaling domain may be used, but in many cases, it is not necessary to use the entire chain. In embodiments in which a cleaved portion of the intracellular signaling domain is used, such cleaved portion may be used in place of the corresponding intact chain, insofar as the cleaved portion transmits effector function signals.
[0193] Examples of suitable intracellular signaling domains that may be used in the CARs of this disclosure include, but are not limited to, cytoplasmic sequences of T cell receptors (TCRs), co-receptors that act cooperatively to initiate signaling after antigen receptor involvement, and any derivatives or variants of these sequences, and any recombinant sequences having the same functional capacity.
[0194] While we do not wish to be bound by theory, it is thought that the signal generated through the TCR alone is insufficient for complete T cell activation, and therefore, secondary and / or co-stimulatory signals are also required for complete activation. Thus, T cell activation may be mediated by two distinct classes of cytoplasmic signaling sequences: those that initiate antigen-dependent primary activation via the TCR (primary intracellular signaling domains), and those that act in an antigen-independent manner to provide secondary or co-stimulatory signals (secondary cytoplasmic domains, e.g., co-stimulatory domains).
[0195] In some embodiments, the primary signaling domain controls the primary activation of the TCR complex either stimulatingly or inhibitorily. Primary intracellular signaling domains acting stimulatingly may include known signaling motifs as immunoreceptor tyrosine-based activation motifs (ITAMs). Examples of suitable ITAM-containing primary intracellular signaling domains that may be used in the CARs of this disclosure include, but are not limited to, those of CD3-zeta, FcR-gamma, FcR-beta, CD3-gamma, CD3-delta, CD3-epsilon, CD5, CD22, CD79a, CD79b, CD278 (also known as "ICOS"), FcεRI, DAP10, DAP12, and CD66d.
[0196] In some embodiments, the CAR of the Disclosure includes an intracellular signaling domain, for example, the primary signaling domain of a CD3-zetapolypeptide. The CD3-zetapolypeptide of the Disclosure may have an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% homologous to the sequence or fragment thereof of NCBI reference number NP_932170 or NP_001106864.2. In some embodiments, the CD3-zetapolypeptide may contain one conservative amino acid substitution, up to two conservative amino acid substitutions, or up to three conservative amino acid substitutions. In some embodiments, the polypeptide may have an amino acid sequence that is a contiguous portion of NCBI reference number NP_932170 or NP_001106864.2, having an amino acid length of at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, or at least 160, at least 170, or at least 180 amino acids.
[0197] In other embodiments, the primary signaling domain includes a modified ITAM domain, such as a mutant ITAM domain, whose activity has been altered (e.g., increased or decreased) compared to a native ITAM domain. In one embodiment, the primary signaling domain includes a modified ITAM-containing primary intracellular signaling domain, such as an optimized and / or cleaved ITAM-containing primary intracellular signaling domain. In one embodiment, the primary signaling domain includes one, two, three, four, or more ITAM motifs.
[0198] In some embodiments, the intracellular signaling domain of the CAR of the Disclosure may comprise a CD3-zeta signaling domain by itself, or it may be combined with any other desired intracellular signaling domain useful in the context of the CAR of the Disclosure. For example, the intracellular signaling domain of the CAR may comprise a portion of the CD3 zeta chain and a costimulatory signaling domain. The costimulatory signaling domain may refer to a portion of the CAR comprising the intracellular domain of a costimulatory molecule. The costimulatory molecule of the Disclosure is a cell surface molecule other than an antigen receptor or its ligand that may be required for an efficient lymphocyte response to an antigen.Examples of suitable co-stimulatory molecules include ligands that specifically bind to CD97, CD2, ICOS, CD27, CD154, CD8, OX40, 4-1BB, CD28, ZAP40, CD30, GITR, HVEM, DAP10, DAP12, MyD88, 2B4, CD40, PD-1, lymphocyte function-associated antigen-1 (LFA-1), CD7, LIGHT, NKG2C, B7-H3, CD83, MHC class I molecules, TNF receptor proteins, and immunoglobulins. Phosphorus-like proteins, cytokine receptors, integrins, signaling lymphocyte activating molecules (SLAM proteins), activated NK cell receptors, BTLA, Toll ligand receptors, CDS, ICAM-1, (CD11a / CD18), BAFFR, KIRD3S1, KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, IL2R beta, IL2R gamma, IL7R alpha, I TGA4, VLAl, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, ITGAM, CD11b, I TGAX, CD11c, ITGB1, CD29, ITGB2, CD18, ITGB7, NKG2D, TNFR2, TRANCE / RANKL, DNAM1(CD226), SLAMF4(CD244, 2B4), CD84 This includes, but is not limited to, CD96 (tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, etc.
[0199] Table 8 provides non-exclusive examples of intracellular signaling domains (ICDs).
[0200] [Table 8]
[0201] In some embodiments, intracellular signaling sequences within the cytoplasmic portion of the CARs of this disclosure may be linked to one another in a random or specified order. In some embodiments, for example, short oligopeptides or polypeptide linkers of 2 to 10 amino acids in length (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids) may form links with the intracellular signaling sequences. In one embodiment, a glycine-serine double chain may be used as a suitable linker. In one embodiment, a single amino acid, such as alanine or glycine, may be used as a suitable linker.
[0202] In some embodiments, the intracellular signaling domain includes two or more co-stimulatory signaling domains, for example, two co-stimulatory signaling domains, three co-stimulatory signaling domains, four co-stimulatory signaling domains, five co-stimulatory signaling domains, six co-stimulatory signaling domains, seven co-stimulatory signaling domains, eight co-stimulatory signaling domains, nine co-stimulatory signaling domains, ten co-stimulatory signaling domains, or more co-stimulatory signaling domains. In one embodiment, the intracellular signaling domain includes two co-stimulatory signaling domains. In some embodiments, two or more co-stimulatory signaling domains are separated by a linker of the Disclosure. In one embodiment, the linker is a glycine residue. In another embodiment, the linker is an alanine residue.
[0203] In some embodiments, the CAR of the present disclosure further includes an epitope tag. The epitope tag is a polypeptide sequence included within the polypeptide as a label detectable, for example, by a monoclonal antibody. Examples of epitope tags include FLAG tags, strep tags, HA tags, V5 tags, and myc tags. An exemplary epitope tag is the myc tag of the amino acid sequence EQKLISEEDL (SEQ ID NO: 75).
[0204] In some embodiments, the cells of the Disclosure express a CAR comprising an antigen-binding domain that binds to the target antigen of the Disclosure, a transmembrane domain of the Disclosure, a primary signaling domain, and one or more costimulatory signaling domains.
[0205] Natural Killer Car (NK CAR) In some embodiments, the CARs of the present disclosure comprise one or more components of natural killer (NK) cells, thereby forming an NK CAR. The NK components include KIR2DL1, KIR2DL2 / L3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, DIR2DS5, KIR3DL1, KIR3DS1, KIR3DL2, KIR3DL3, KIR2DP1, and KIRS The transmembrane domain, hinge domain, or cytoplasmic domain may be from any suitable natural killer cell receptor, including, but not limited to, the following: killer cell immunoglobulin-like receptors (KIRs) such as DPI; innate cytotoxic receptors (NCRs) such as NKp30, NKp44, and NKp46; the signaling lymphocyte-activating molecule (SLAM) family of immune cell receptors such as CD48, CD229, 2B4, CD84, NTB-A, CRACC, BLAME, and CD2F-10; Fc receptors (FcRs) such as CD16 and CD64; and Ly49 receptors such as LY49A and LY49C. In some embodiments, the NK-CAR may interact with an adapter molecule or an intracellular signaling domain such as DAP12. The above-described structural components of the CAR can also be applied to the structure of the NK CAR.
[0206] Exemplary compositions and sequences of CARs containing NK receptor components are described in International Patent Publication WO2014 / 145252, published on September 18, 2014.
[0207] One advantage of CAR NK cell therapy compared to CAR T cell therapy is a significant reduction in the risk of inducing graft-versus-host disease (GvHD). Thus, since severe toxicity is not observed or expected to occur with CAR NK cells, treatment can be administered without hospitalization, significantly reducing the substantial indirect costs associated with CAR-T cell-based therapies due to post-treatment hospitalization (Oberschmidt et al. (2017), Front Immunol, 8:654).
[0208] Chimeric inhibitory receptor Certain aspects of the present disclosure relate to chimeric inhibitory receptors. Chimeric inhibitory receptors are useful, for example, as NOT logic gates for controlling cell activities such as immune cell activity. In some embodiments, the chimeric inhibitory receptors of the present disclosure specifically bind to one or more antigens that are expressed on normal cells but not on tumor cells.
[0209] In some embodiments, the chimeric inhibitory receptor comprises an antigen-binding domain, a transmembrane domain of the present disclosure (e.g., any suitable transmembrane domain used in conjunction with the chimeric receptors of the present disclosure), and an intracellular domain. In some embodiments, the chimeric inhibitory receptor can inhibit one or more activities of cells such as immune-responsive cells.
[0210] In some embodiments, the chimeric inhibitory receptor may include an enzyme inhibitory domain. When the chimeric inhibitory receptor is located proximal to a receptor such as an immune receptor within the cell membrane, binding to the antigen-binding domain of the cognate antigen activates the enzyme inhibitory domain to inhibit receptor activation. As used herein, the term "enzyme inhibitory domain" refers to a protein domain that inhibits an intracellular signaling cascade, such as the native T cell activation cascade. Thus, the disclosed chimeric inhibitory receptors can be engineered to include, for example, an appropriate antigen-binding domain that reduces the immune response in the presence of the cognate antigen. Use of the chimeric inhibitory receptors of the present disclosure includes, but is not limited to, reduction of the immune response, control of T cell activation, and control of CAR-NK or CAR-T responses.
[0211] In some embodiments, the enzyme inhibitory domain of the chimeric inhibitory receptor of the present disclosure includes at least a portion of an extracellular domain, a transmembrane domain, and / or an intracellular domain. In some embodiments, the enzyme inhibitory domain includes at least a portion of an enzyme. In some embodiments, the enzyme is selected from CSK, SHP-1, PTEN, CD45, CD148, PTP-MEG1, PTP-PEST, c-CBL, CBL-b, PTPN22, LAR, PTPH1, SHIP-1, and RasGAP (see, for example, Stanford et al., Regulation of TCR signaling by tyrosine phosphatases: from immune homeostasis to autoimmunity, Immunology, 2012 Sep;137(1):1-19). In some embodiments, a portion of the enzyme includes an enzyme domain, an enzyme fragment, or a variant thereof. In some embodiments, a portion of the enzyme is the catalytic domain of the enzyme. In some embodiments, the enzyme domain, enzyme fragment, or variant thereof is selected to maximize efficacy and minimize basal inhibition.
[0212] In some embodiments, the enzyme inhibitory domain includes one or more modifications that modulate basal inhibition. Examples of modifications include, but are not limited to, cleavage mutations, amino acid substitutions, introduction of sites for post-translational modification (examples of which are known to those skilled in the art), and addition of new functional groups. In some embodiments, the enzyme domain, enzyme fragment, or variant thereof is selected to maximize efficacy and minimize basal inhibition. In some embodiments, one or more modifications reduce basal inhibition. In other embodiments, one or more modifications increase basal inhibition.
[0213] In some embodiments, the enzyme inhibitory domain inhibits immune receptor activation, for example, upon recruitment of the chimeric inhibitory receptor of this disclosure adjacent to the immune receptor. In some embodiments, the immune receptor is a naturally occurring immune receptor. In some embodiments, the immune receptor is a naturally occurring antigen receptor. In some embodiments, the immune receptor is selected from T cell receptors, pattern recognition receptors (PRRs), NOD-like receptors (NLRs), Toll-like receptors (TLRs), killer-activating receptors (KARs), killer-inhibiting receptors (KIRs), complement receptors, Fc receptors, B cell receptors, and cytokine receptors. In some embodiments, the immune receptor is a T cell receptor. In some embodiments, the immune receptor is a chimeric immune receptor. In some embodiments, the chimeric immune receptor is a chimeric TCR or CAR.
[0214] In some embodiments, the chimeric inhibitory receptors of this disclosure may also comprise one or more intracellular inhibitory co-signaling domains. In some embodiments, the intracellular inhibitory co-signaling domain comprises an inhibitory domain. In some embodiments, the one or more intracellular inhibitory co-signaling domain comprises one or more ITIM-containing proteins or fragments thereof. ITIM is a conserved amino acid sequence found at the cytoplasmic terminals of many inhibitory immune receptors. In some embodiments, the one or more ITIM-containing proteins or fragments thereof are selected from PD-1, CTLA4, TIGIT, and LAIR1. In some embodiments, the one or more intracellular inhibitory co-signaling domain comprises one or more non-ITIM scaffolding proteins or fragments thereof. In some embodiments, the one or more non-ITIM scaffolding proteins or fragments thereof are selected from GRB-2, Dok-1, Dok-2, SLAP, LAG3, HAVR, BTLA, GITR, and PD-L1. Further examples of suitable intracellular inhibitory co-signaling domains include, but are not limited to, PD-L1, TIM3, LIR1, NKG2A, VISTA, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, KIR3DL1, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGF beta.
[0215] In some embodiments, inhibitory chimeric receptors bind to antigens expressed on non-tumor cells. Exemplary antigens for use with chimeric inhibitory receptors are listed in Table 9.
[0216] [Table 9]
[0217] In some embodiments, the chimeric inhibitory receptor binds to the VSIG2 antigen. In some embodiments, the chimeric inhibitory receptor binds to the CPM antigen. In some embodiments, the chimeric inhibitory receptor binds to the ITM2C antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC26A2 antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC4A4 antigen. In some embodiments, the chimeric inhibitory receptor binds to the GPA33 antigen. In some embodiments, the chimeric inhibitory receptor binds to the PLA2G2A antigen. In some embodiments, the chimeric inhibitory receptor binds to the ABCA8 antigen. In some embodiments, the chimeric inhibitory receptor binds to the ATP1A2 antigen. In some embodiments, the chimeric inhibitory receptor binds to the CHP2 antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC26A3 antigen.
[0218] In some embodiments, the chimeric inhibitory receptor is a multispecific receptor comprising two or more antigen-binding domains, and as a result, the chimeric inhibitory receptor can bind to two or more antigens. Alternatively, cells can be edited to express two or more chimeric inhibitory receptors that bind to different antigens. Exemplary antigen pairs of chimeric inhibitory receptors are found in Table 10. In some embodiments, the bicistronic chimeric receptor system comprises a CAR having two or more antigen-binding domains that target any antigen pair provided in Table 10, and the antigen pair comprises a CEA family member and an inhibitory antigen.
[0219] Immune-responsive cells Certain aspects of the present disclosure relate to cells genetically engineered to contain one or more chimeric receptors or one or more nucleic acids encoding such chimeric receptors, such as immune-responsive cells, and methods for using such cells to treat solid tumors.
[0220] In some embodiments, immune-responsive cells are genetically engineered to contain one or more CARs (or nucleic acids encoding them) that specifically bind to CEA family member tumor antigens, such as any of the CEA antigens in Table 1. In some embodiments, immune-responsive cells are genetically engineered to contain one or more CARs (or nucleic acids encoding them) that contain an antibody sequence of a representative anti-CEA antibody provided in Table 2 or its antigen-binding fragment. In some embodiments, immune-responsive cells are genetically engineered to contain one or more CARs (or nucleic acids encoding them) that contain an scFv derived from an antibody capable of binding to a solid tumor antigen, such as a representative anti-CEA scFv provided in Table 3. In some embodiments, a CAR that specifically binds to a CEA family member tumor antigen can be considered an activated CAR ("aCAR") as described herein.
[0221] In some embodiments, the cells are mammalian cells. In some embodiments, the mammalian cells are primary cells. In some embodiments, the mammalian cells are cell lines. In some embodiments, the mammalian cells are bone marrow cells, blood cells, skin cells, osteocytes, muscle cells, lung cells, gastrointestinal cells, brain cells, nerve cells, adipocytes, liver cells, or cardiac cells. In some embodiments, the cells are stem cells. Exemplary stem cells include, but are not limited to, embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), adult stem cells, and tissue-specific stem cells such as hematopoietic stem cells (blood stem cells), mesenchymal stem cells (MSCs), neural stem cells, epithelial stem cells, or skin stem cells. In some embodiments, the cells are cells derived from or differentiated from the stem cells of this disclosure. In some embodiments, the cells are immune cells. The immune cells of this disclosure may be isolated or differentiated from the stem cells of this disclosure (e.g., from ESCs or iPSCs). Exemplary immune cells include, but are not limited to, T cells (e.g., helper T cells, cytotoxic T cells, memory T cells, regulatory T cells, natural killer T cells, alpha-beta T cells, and gamma-delta T cells), B cells, natural killer (NK) cells, dendritic cells, myeloid cells, macrophages, and monocytes. In some embodiments, the cells are nerve cells. The nerve cells of this disclosure may be isolated or differentiated from the stem cells of this disclosure (e.g., from ESCs or iPSCs). Exemplary neuronal cells include, but are not limited to, neural progenitor cells, neurons (e.g., sensory neurons, motor neurons, cholinergic neurons, GABAergic neurons, glutamatergic neurons, dopaminergic neurons, or serotonergic neurons), astrocytes, oligodendrocytes, and microglia.
[0222] In some embodiments, the cells are immune-responsive cells. The immune-responsive cells of this disclosure may be isolated or differentiated from the stem cells of this disclosure (e.g., from ESCs or iPSCs). Exemplary immune-responsive cells of this disclosure include, but are not limited to, cells of lymphoid lineages. Lymphoid lineages, including B cells, T cells, and natural killer (NK) cells, provide functions such as antibody production, regulation of the cellular immune system, detection of foreign substances in the blood, and detection of foreign cells in the host. Examples of immune-responsive cells of lymphoid lineages include, but are not limited to, T cells, natural killer (NK) cells, embryonic stem cells, pluripotent stem cells, and induced pluripotent stem cells (e.g., those derived from or capable of differentiating from lymphocytes). T cells may be lymphocytes that mature in the thymus and are primarily responsible for cell-mediated immunity. T cells are involved in the adaptive immune system. In some embodiments, the T cells of this disclosure include T helper cells, cytotoxic T cells, memory T cells (central memory T cells, stem cell-like memory T cells (or stem-like memory T cells)), and two types of effector memory T cells, for example, T EM Cells and T EMRA These can be any type of T cell, including but not limited to regulatory T cells (also known as suppressor T cells), natural killer T cells, mucosa-associated invariant T cells, and γδ T cells. Cytotoxic T cells (CTLs or killer T cells) are a subset of T lymphocytes that can induce the death of infected somatic or tumor cells. A patient's own T cells can be genetically modified to target specific antigens through the introduction of one or more chimeric receptors, such as chimeric TCRs or CARs.
[0223] Natural killer (NK) cells are part of cell-mediated immunity and may be lymphocytes that act during the innate immune response. NK cells do not require prior activation to exert their cytotoxic effects on target cells.
[0224] In some embodiments, the immune-responsive cells of the Disclosure are T cells. The T cells of the Disclosure may be induced in vitro from autologous, allogeneic, or engineered progenitor or stem cells.
[0225] In some embodiments, the immune-responsive cells of this disclosure are universal T cells having a TCR-αβ defect. Methods for developing universal T cells are described in the Art, for example, Valton et al., Molecular Therapy (2015); 23 9, 1507-1518, and Torikai et al., Blood 2012 119: 5697-5705.
[0226] In some embodiments, the immune-responsive cells of the Disclosure are isolated immune-responsive cells comprising one or more chimeric receptors of the Disclosure. In some embodiments, the immune-responsive cells comprise one, two, three, four, five, six, seven, eight, nine, or ten or more chimeric receptors of the Disclosure.
[0227] In some embodiments, the immune-responsive cells are T cells. In some embodiments, the immune-responsive cells are natural killer (NK) cells.
[0228] Cells that express multiple chimeric receptors In some embodiments, the cells of the Disclosure (e.g., immune-responsive cells) comprise two or more chimeric receptors of the Disclosure. In some embodiments, the cells comprise two or more chimeric receptors, one of which is a chimeric inhibitory receptor. In some embodiments, the cells comprise three or more chimeric receptors, at least one of which is a chimeric inhibitory receptor. In some embodiments, the cells comprise four or more chimeric receptors, at least one of which is a chimeric inhibitory receptor. In some embodiments, the cells comprise five or more chimeric receptors, at least one of which is a chimeric inhibitory receptor.
[0229] In some embodiments, each of two or more chimeric receptors includes a different antigen-binding domain, e.g., an antigen-binding domain that binds to the same antigen or a different antigen. In some embodiments, each antigen bound by two or more chimeric receptors is expressed on the same cell type (e.g., the same solid tumor cell type). In one embodiment, a cell includes a first chimeric receptor that targets a first antigen and includes an intracellular signaling domain having a costimulatory signaling domain but not a primary signaling domain, and a second chimeric receptor that targets a second different antigen and includes an intracellular signaling domain having a primary signaling domain but not a costimulatory signaling domain. While we do not wish to be constrained by theory, it is thought that locating a costimulatory signaling domain (e.g., 4-1BB, CD28, or OX-40) on the first chimeric receptor and a primary signaling domain (e.g., CD3-zeta chain) on the second chimeric receptor may limit chimeric receptor activity to cells expressing both targets. Accordingly, in some embodiments, the cells of the Disclosure (e.g., immune-responsive cells) include (a) a first chimeric receptor comprising an antigen-binding domain, a transmembrane domain, and a costimulatory signaling domain for binding to a first antigen, and (b) a second chimeric receptor comprising an antigen-binding domain, a transmembrane domain, and a primary signaling domain for binding to a second antigen. In some embodiments, the cells of the present disclosure (e.g., immune-responsive cells) include (a) a first chimeric receptor comprising an antigen-binding domain, a transmembrane domain, a primary signaling domain, and a costimulatory domain for binding to a first antigen, and (b) a second chimeric receptor comprising an antigen-binding domain, a transmembrane domain, a primary signaling domain, and a costimulatory domain for binding to a second antigen.In embodiments where both the first chimeric receptor and the second chimeric receptor each include a co-stimulatory signaling domain, the co-stimulatory signaling domain of the first chimeric receptor and the co-stimulatory signaling domain of the second chimeric receptor can be derived from the same protein, such as 4-1BB, CD28, or OX40. Alternatively, the co-stimulatory signaling domain of the first chimeric receptor can be derived from a protein different from the co-stimulatory signaling domain of the second chimeric receptor.
[0230] In embodiments where the cells of the present disclosure (e.g., immune-responsive cells) express two or more distinct chimeric receptors, the antigen-binding domains of the different chimeric receptors can be designed such that the antigen-binding domains do not interact with each other. For example, the cells of the present disclosure (e.g., immune-responsive cells) expressing a first chimeric receptor and a second chimeric receptor can include a first chimeric receptor that includes an antigen-binding domain that does not form an association with the antigen-binding domain of the second chimeric receptor. For example, the antigen-binding domain of the first chimeric receptor can include an antibody fragment such as an scFv, while the antigen-binding domain of the second chimeric receptor can include a V H H.
[0231] Without wishing to be bound by theory, in cells having multiple chimeric membrane-embedded receptors each including an antigen-binding domain, an interaction between the antigen-binding domains of each receptor may undesirably have the potential to inhibit the ability of one or more of those antigen-binding domains to bind to their cognate antigen. Thus, in embodiments where the cells of the present disclosure (e.g., immune-responsive cells) express two or more chimeric receptors, the chimeric receptors include antigen-binding domains that minimize such inhibitory interactions. In one embodiment, the antigen-binding domain of one chimeric receptor includes an scFv and the antigen-binding domain of the second chimeric receptor includes a single VH domain, such as a camel, shark, or lamprey single VH domain, or a single VH domain derived from a human or mouse sequence.
[0232] In some embodiments, when present on the cell surface, the binding of the antigen-binding domain of the first chimeric receptor to its congener antigen is not substantially reduced by the presence of the second chimeric receptor. In some embodiments, the binding of the antigen-binding domain of the first chimeric receptor to its congener antigen in the presence of the second chimeric receptor is 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the binding of the antigen-binding domain of the first chimeric receptor to its congener antigen in the absence of the second chimeric receptor. In some embodiments, when present on the cell surface, the antigen-binding domains of the first and second chimeric receptors associate with each other less than when both are scFv antigen-binding domains. In some embodiments, the antigen-binding domains of the first and second chimeric receptors associate with each other 85%, 90%, 95%, 96%, 97%, 98%, or 99% less than when both are scFv antigen-binding domains.
[0233] In embodiments where the cells of the Disclosure (e.g., immune-responsive cells) include two or more distinct chimeric receptors of the Disclosure that bind to different antigens, the two or more chimeric receptors provide the cells with logical gating such as OR logical gating, AND logical gating, NOT logical gating, or any combination of such logical gating. Thus, in certain embodiments, the cells of the Disclosure (e.g., immune-responsive cells) include two or more chimeric receptors, and the binding of a first chimeric receptor to a first antigen can activate the cells. In some embodiments, the cells of the Disclosure (e.g., immune-responsive cells) include two or more chimeric receptors, and the binding of a second chimeric receptor to a second antigen can stimulate the cells. In some embodiments, the cells of the Disclosure (e.g., immune-responsive cells) include two or more chimeric receptors, and the binding of a first chimeric receptor to a first antigen and the binding of a second chimeric receptor to a second antigen are required to activate the cells. In some embodiments, the cells of the Disclosure (e.g., immune-responsive cells) comprise two or more chimeric receptors, and the binding of the first chimeric receptor to a first antigen and the binding of the second chimeric receptor to a second antigen are required to stimulate the cells. In some embodiments, the cells of the Disclosure (e.g., immune-responsive cells) comprise two or more chimeric receptors, and the cells exhibit a higher degree of cytolytic activity towards cells positive for both the first and second antigens compared to cytolytic activity towards cells positive for only the first antigen or only the second antigen. In some embodiments, the cells of the Disclosure (e.g., immune-responsive cells) comprise two or more chimeric receptors, and the binding of the first chimeric receptor to a first antigen or the binding of the second chimeric receptor to a second antigen can activate the immune-responsive cells.
[0234] In some embodiments, the cells of this disclosure (e.g., immune-responsive cells) include a mitotic chimeric receptor system, such as a mitotic CAR system. Exemplary mitotic chimeric receptor systems are described in WO2014 / 055442 and WO2014 / 055657. In some embodiments, the mitotic chimeric receptor system includes cells expressing a first chimeric receptor having a first antigen-binding domain and a costimulatory domain (e.g., 4-1BB), and a second chimeric receptor having a second antigen-binding domain and an intracellular signaling domain (e.g., CD3-zeta). In such embodiments, when the cell encounters the first antigen, the costimulatory domain is activated, and the cell proliferates. In addition, when the cell encounters the second antigen, the intracellular signaling domain is activated, and cell death activity is induced. Thus, in some embodiments, the cells of this disclosure (e.g., immune-responsive cells) are fully activated only in the presence of both antigens.
[0235] In certain embodiments, the cells of this disclosure (e.g., immune-responsive cells) exhibit a higher degree of cytolytic activity against cells positive for both the first and second antigens compared to cells positive for the first antigen alone. In certain embodiments, the first chimeric receptor binds to the first antigen with low binding affinity or low binding activity. In certain embodiments, the first chimeric receptor binds to the first antigen with a low contact epitope. In certain embodiments, the first chimeric receptor binds to the first antigen with a lower binding affinity compared to the binding affinity of the second chimeric receptor to the second antigen. In some embodiments, the first chimeric receptor binds to the first antigen with a binding affinity at least five times lower than the binding affinity of the second chimeric receptor to the second antigen. In some embodiments, the first chimeric receptor binds to the first antigen with a binding affinity at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 5000, 1000, 5000, or 10000 times lower than the binding affinity of the second chimeric receptor to the second antigen.
[0236] In some embodiments, pair selection should favor the redundant expression of two target antigens in the tumor to minimize the risk of antigen evasion. Therefore, in some embodiments, the cells of the Disclosure (e.g., immune-responsive cells) include (i) a first chimeric receptor that binds to a first antigen, and (ii) a second chimeric receptor that binds to a second antigen, and the combination of both chimeric receptors binding to those target antigens produces a therapeutic effect. In embodiments, binding to only one target antigen does not achieve a therapeutic effect.
[0237] In some embodiments, the cells of this disclosure (e.g., immune-responsive cells) comprise one or more chimeric receptors that bind to CEA family antigens, and optionally, the cells also comprise inhibitory chimeric receptors. In some embodiments, the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric receptor binds to the CEACAM6 antigen. In some embodiments, the chimeric receptor binds to CEA family antigens as described in Table 1. In some embodiments, the chimeric receptor that binds to CEA family antigens comprises an antigen-binding domain derived from an antibody selected from MRG1, rabetuzumab (i.e., hMN14), sibisatamab, tusamitamab, BW431 / 26, A5B7, MFE23, hMFE23, FM4 (also known as "MG7"), and tinuririmab. In some embodiments, the antigen-binding domain of the chimeric receptor that binds to the CEA family antigen includes an scFv containing the amino acid sequence provided in Table 3. In some embodiments, the chimeric receptor that binds to the CEA family antigen includes the amino acid sequence shown in Table 28 and / or is encoded by the polynucleotide sequence provided in Table 28. In some embodiments, the inhibitory chimeric receptor binds to the VSIG2 antigen. In some embodiments, the inhibitory chimeric receptor binds to the CPM antigen. In some embodiments, the inhibitory chimeric receptor binds to the ITM2C antigen. In some embodiments, the inhibitory chimeric receptor binds to the SLC26A2 antigen. In some embodiments, the inhibitory chimeric receptor binds to the SLC4A4 antigen. In some embodiments, the inhibitory chimeric receptor binds to the GPA33 antigen. In some embodiments, the inhibitory chimeric receptor binds to the PLA2G2A antigen. In some embodiments, the inhibitory chimeric receptor binds to the ABCA8 antigen. In some embodiments, the inhibitory chimeric receptor binds to the ATP1A2 antigen. In some embodiments, the inhibitory chimeric receptor binds to the CHP2 antigen. In some embodiments, the inhibitory chimeric receptor binds to the SLC26A3 antigen.In some embodiments, the chimeric receptor is a multispecific receptor comprising two or more antigen-binding domains, and as a result, the chimeric receptor can bind to two or more antigens.
[0238] In some embodiments, immune-responsive cells may comprise one or more tumor-targeted chimeric receptors and one or more inhibitory chimeric receptors that target antigens not expressed on tumors. Combinations of tumor-targeted and inhibitory chimeric receptors in the same immune-responsive cell can be used to reduce extratumor toxicity on the target. For example, if healthy cells express both antigens recognized by tumor-targeted chimeric receptors and antigens recognized by inhibitory chimeric receptors, immune-responsive cells expressing tumor antigens may bind to healthy cells. In such cases, the inhibitory chimeric antigen also binds to its homologous ligand on healthy cells, and the inhibitory function of the inhibitory chimeric receptor reduces, mitigates, prevents, or inhibits the activation of immune-responsive cells via tumor-targeted chimeric receptors.
[0239] In some embodiments, the inhibitory chimeric receptor binds to the VSIG2 antigen. In some embodiments, the inhibitory chimeric receptor binds to the CPM antigen. In some embodiments, the inhibitory chimeric receptor binds to the ITM2C antigen. In some embodiments, the inhibitory chimeric receptor binds to the SLC26A2 antigen. In some embodiments, the inhibitory chimeric receptor binds to the SLC4A4 antigen. In some embodiments, the inhibitory chimeric receptor binds to the GPA33 antigen. In some embodiments, the inhibitory chimeric receptor binds to the PLA2G2A antigen. In some embodiments, the inhibitory chimeric receptor binds to the ABCA8 antigen. In some embodiments, the inhibitory chimeric receptor binds to the ATP1A2 antigen. In some embodiments, the inhibitory chimeric receptor binds to the CHP2 antigen. In some embodiments, the inhibitory chimeric receptor binds to the SLC26A3 antigen.
[0240] Alternatively, cells can express two or more chimeric receptors that bind to different antigens. Exemplary antigen pairs are shown in Table 10.
[0241] [Table 10]
[0242] In some embodiments, the immune-responsive cells include a bisistronic chimeric antigen receptor system construct. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEA CAR and CEACAM1 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEA CAR and CEACAM5 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEA CAR and CEACAM6 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM1 CAR and CEACAM5 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM1 CAR and CEACAM6 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM5 CAR and CEACAM6 CAR.
[0243] In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEA CAR and VSIG2 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEA CAR and CPM CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEA CAR and ITM2C CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEA CAR and SLC26A2 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEA CAR and SLC4A4 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEA CAR and GPA33 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEA CAR and PLA2G2A CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEA CAR and ABCA8 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes a CEA CAR and an ATP1A2 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes a CEA CAR and a CHP2 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes a CEA CAR and an SLC26A3 CAR.
[0244] In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM1 CAR and VSIG2 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM1 CAR and CPM CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM1 CAR and ITM2C CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM1 CAR and SLC26A2 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM1 CAR and SLC4A4 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM1 CAR and GPA33 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM1 CAR and PLA2G2A CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM1 CAR and ABCA8 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM1 CAR and ATP1A2 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM1 CAR and CHP2 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM1 CAR and SLC26A3 CAR.
[0245] In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM5 CAR and VSIG2 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM5 CAR and CPM CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM5 CAR and ITM2C CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM5 CAR and SLC26A2 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM5 CAR and SLC4A4 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM5 CAR and GPA33 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM5 CAR and PLA2G2A CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM5 CAR and ABCA8 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM5 CAR and ATP1A2 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM5 CAR and CHP2 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM5 CAR and SLC26A3 CAR.
[0246] In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM6 CAR and VSIG2 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM6 CAR and CPM CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM6 CAR and ITM2C CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM6 CAR and SLC26A2 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM6 CAR and SLC4A4 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM6 CAR and GPA33 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM6 CAR and PLA2G2A CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM6 CAR and ABCA8 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM6 CAR and ATP1A2 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM6 CAR and CHP2 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM6 CAR and CHP2 CAR. In some embodiments, the bisistronic chimeric antigen receptor system construct includes CEACAM6 CAR and SLC26A3 CAR.
[0247] In some embodiments, the bicistronic chimeric antigen receptor system construct includes any pair of antigens provided in Table 10.
[0248] Cells expressing chimeric inhibitory receptors In some embodiments, the cells of the Disclosure (e.g., immune-responsive cells) include one or more chimeric inhibitory receptors of the Disclosure. In some embodiments, each of the one or more chimeric inhibitory receptors includes an antigen-binding domain that binds to an antigen expressed on normal cells but not on tumor cells such as solid tumor cells. In some embodiments, the one or more chimeric inhibitory receptors bind to an antigen expressed on non-tumor cells derived from tissues selected from the group consisting of brain, nerve tissue, endocrine, bone, bone marrow, immune system, endothelial tissue, muscle, lung, liver, gallbladder, pancreas, gastrointestinal tract, kidney, bladder, male genitalia, female genitalia, fat, soft tissue, and skin.
[0249] In some embodiments, the chimeric inhibitory receptor may be used as a NOT logic gate to control, modulate, or inhibit the activity of one or more chimeric receptors (e.g., chimeric TCRs or CARs) expressed on, for example, the cells of the Disclosure (e.g., immune-responsive cells). In some embodiments, the chimeric receptors of the Disclosure may inhibit the activity of one or more cells of the Disclosure (e.g., immune-responsive cells). In some embodiments, the chimeric inhibitory receptor may be combined with one or more chimeric receptors of the Disclosure to combine OR logic gating with NOT logic gating, and / or AND logic gating with NOT logic gating.
[0250] In some embodiments, the chimeric inhibitory receptor binds to one or more antigens selected from VSIG2, CPM, ITM2C, SLC26A2, SLC4A4, GPA33, PLA2G2A, ABCA8, ATP1A2, CHP2, and SLC26A3.
[0251] In some embodiments, the chimeric receptor binds to the CEA antigen, and the chimeric inhibitory receptor binds to the VSIG2, CPM, ITM2C, SLC26A2, SLC4A4, GPA33, PLA2G2A, ABCA8, ATP1A2, CHP2, or SLC26A3 antigen.
[0252] In some embodiments, the chimeric receptor binds to the CEACAM1 antigen, and the chimeric inhibitory receptor binds to the VSIG2, CPM, ITM2C, SLC26A2, SLC4A4, GPA33, PLA2G2A, ABCA8, ATP1A2, CHP2, or SLC26A3 antigen.
[0253] In some embodiments, the chimeric receptor binds to the CEACAM5 antigen, and the chimeric inhibitory receptor binds to the VSIG2, CPM, ITM2C, SLC26A2, SLC4A4, GPA33, PLA2G2A, ABCA8, ATP1A2, CHP2, or SLC26A3 antigen.
[0254] In some embodiments, the chimeric receptor binds to the CEACAM6 antigen, and the chimeric inhibitory receptor binds to the VSIG2, CPM, ITM2C, SLC26A2, SLC4A4, GPA33, PLA2G2A, ABCA8, ATP1A2, CHP2, or SLC26A3 antigen.
[0255] In some embodiments, the chimeric inhibitory receptor binds to the VSIG2 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the VSIG2 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the VSIG2 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the VSIG2 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0256] In some embodiments, the chimeric inhibitory receptor binds to the CPM antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the CPM antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the CPM antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the CPM antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0257] In some embodiments, the chimeric inhibitory receptor binds to the ITM2C antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the ITM2C antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the ITM2C antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the ITM2C antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0258] In some embodiments, the chimeric inhibitory receptor binds to the SLC26A2 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC26A2 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC26A2 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC26A2 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0259] In some embodiments, the chimeric inhibitory receptor binds to the SLC4A4 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC4A4 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC4A4 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC4A4 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0260] In some embodiments, the chimeric inhibitory receptor binds to the GPA33 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the GPA33 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the GPA33 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the GPA33 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0261] In some embodiments, the chimeric inhibitory receptor binds to the PLA2G2A antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the PLA2G2A antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the PLA2G2A antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the PLA2G2A antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0262] In some embodiments, the chimeric inhibitory receptor binds to the ABCA8 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the ABCA8 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the ABCA8 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the ABCA8 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0263] In some embodiments, the chimeric inhibitory receptor binds to the ATP1A2 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the ATP1A2 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the ATP1A2 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the ATP1A2 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0264] In some embodiments, the chimeric inhibitory receptor binds to the CHP2 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the CHP2 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the CHP2 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the CHP2 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0265] In some embodiments, the chimeric inhibitory receptor binds to the SLC26A3 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC26A3 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC26A3 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC26A3 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0266] In some embodiments, the inhibitory chimeric receptor includes an antigen-binding domain derived from an anti-VSIG2 antibody. The VSIG2 antibody may be any suitable VSIG2 antibody known in the art.
[0267] In some embodiments, the inhibitory chimeric receptor comprises an antigen-binding domain derived from an anti-CPM antibody. The CPM antibody may be any suitable CPM antibody known in the art.
[0268] In some embodiments, the inhibitory chimeric receptor comprises an antigen-binding domain derived from an anti-ITM2C antibody. The ITM2C antibody may be any suitable ITM2C antibody known in the art.
[0269] In some embodiments, the inhibitory chimeric receptor comprises an antigen-binding domain derived from an anti-SLC26A2 antibody. The SLC26A2 antibody may be any suitable SLC26A2 antibody known in the art.
[0270] In some embodiments, the inhibitory chimeric receptor comprises an antigen-binding domain derived from an anti-SLC4A4 antibody. The SLC4A4 antibody may be any suitable SLC4A4 antibody known in the art.
[0271] In some embodiments, the inhibitory chimeric receptor comprises an antigen-binding domain derived from an anti-GPA33 antibody. The GPA33 antibody may be any suitable GPA33 antibody known in the art.
[0272] In some embodiments, the inhibitory chimeric receptor comprises an antigen-binding domain derived from an anti-PLA2G2A antibody. The PLA2G2A antibody may be any suitable PLA2G2A antibody known in the art.
[0273] In some embodiments, the inhibitory chimeric receptor comprises an antigen-binding domain derived from an anti-ABCA8 antibody. The ABCA8 antibody may be any suitable ABCA8 antibody known in the art.
[0274] In some embodiments, the inhibitory chimeric receptor comprises an antigen-binding domain derived from an anti-ATP1A2 antibody. The ATP1A2 antibody may be any suitable ATP1A2 antibody known in the art.
[0275] In some embodiments, the inhibitory chimeric receptor comprises an antigen-binding domain derived from an anti-CHP2 antibody. The CHP2 antibody may be any suitable CHP2 antibody known in the art.
[0276] In some embodiments, the inhibitory chimeric receptor comprises an antigen-binding domain derived from an anti-SLC26A3 antibody. The SLC26A3 antibody may be any suitable SLC26A3 antibody known in the art.
[0277] Co-stimulatory ligand In some embodiments, the cells of the Disclosure (e.g., immune-responsive cells, e.g., NK cells) may further comprise one or more recombinant or exogenous costimulatory ligands. For example, cells may be further transduced with one or more costimulatory ligands so that they co-express or are induced to co-express one or more chimeric receptors and one or more costimulatory ligands of the Disclosure. While we do not wish to be constrained by theory, it is thought that the interaction between one or more chimeric receptors and one or more costimulatory ligands may provide non-antigen-specific signals important for the complete activation of cells. Examples of suitable costimulatory ligands include, but are not limited to, members of the tumor necrosis factor (TNF) superfamily and immunoglobulin (Ig) superfamily ligands. TNF is a cytokine involved in systemic inflammation and stimulates acute-phase responses. Its primary role is the regulation of immune cells. Members of the TNF superfamily share several common characteristics. The majority of TNF superfamily members are synthesized as type II transmembrane proteins (extracellular C-terminus) containing a short cytoplasmic segment and a relatively long extracellular region. Suitable examples of TNF superfamily members include, but are not limited to, nerve growth factor (NGF), CD40L (CD40L) / CD154, CD137L / 4-1BBL, TNF-α, CD134L / OX40L / CD252, CD27L / CD70, Fas ligand (FasL), CD30L / CD153, tumor necrosis factor beta (TNFP) / lymphotoxin-alpha (LTa), lymphotoxin-beta (LTP), CD257 / B cell activator (B AFF) / Bly s / THANK / Tall-1, glucocorticoid-inducible TNF receptor ligand (GITRL), and TNF-related apoptosis-inducible ligand (TRAIL), LIGHT (TNFSF14). The immunoglobulin (Ig) superfamily is a large group of cell surface and soluble proteins involved in cell recognition, binding, or adhesion processes. These proteins share structural features with immunoglobulins and possess an immunoglobulin domain (folding).Examples of suitable immunoglobulin superfamily ligands include, but are not limited to, CD80 and CD86, ligands for both CD28, and PD-L1 / (B7-H1), which is a ligand for PD-1. In certain embodiments, one or more co-stimulatory ligands are selected from 4-1BBL, CD80, CD86, CD70, OX40L, CD48, TNFRSF14, PD-L1, and combinations thereof.
[0278] Effector molecules In some embodiments, the cells of the Disclosure (e.g., immune-responsive cells, e.g., NK cells) may comprise one or more chimeric receptors and further comprise one or more immunomodulatory effector molecules. Non-limiting examples of effector molecules encompassed by the Disclosure include cytokines, antibodies, chemokines, nucleotides, peptides, enzymes, and oncolytic viruses. For example, cells can be engineered to express and secrete at least one, two, three, or more of the following immunomodulatory effector molecules in a controlled manner: IL-12, IL-16, IFN-β, IFN-γ, IL-2, IL-15, IL-7, IL-36γ, IL-18, IL-1β, IL-21, OX40 ligand, CD40L, anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, anti-TGFβ antibody, anti-TNFR2, MIP1α(CCL3), MIP1β(CCL5), CCL21, CpG oligodeoxynucleotide, and antitumor peptides (e.g., antimicrobial peptides with antitumor activity, e.g., Gaspar, D. et al. Front Microbiol. 2013; 4:294; Chu, H. et al. PLoS). See One.2015;10(5):e0126390 and the website:aps.unmc.edu / AP / main.php.
[0279] In some embodiments, the effector molecule comprises an effector molecule that stimulates T cell signaling, activity, and / or recruitment; antigen presentation and / or processing; natural killer cell-mediated cytotoxic signaling, activity, and / or recruitment; dendritic cell differentiation and / or maturation; immune cell recruitment; macrophage signaling; stromal degradation; immunostimulatory metabolite production; or type I interferon signaling; and at least one protein It is an immunomodulatory effector molecule that inhibits negative co-stimulatory signaling, inhibits pro-apoptotic signaling of anti-tumor immune cells, inhibits regulatory T (Treg) cell signaling, activity, and / or recruitment, inhibits tumor checkpoint molecules, activates interferon gene stimulator (STING) signaling, inhibits bone marrow-derived suppressor cell signaling, activity, and / or recruitment, degrades immunosuppressive factors / metabolites, inhibits vascular endothelial growth factor signaling, or directly kills tumor cells.
[0280] In some embodiments, one or more effector molecules include cytokines selected from IL-15, IL-12 (e.g., IL-12p70 fusion protein), IL-18, and IL-21.
[0281] Chemokine receptors In some embodiments, the cells of this disclosure (e.g., immune-responsive cells, e.g., NK cells) may comprise one or more chimeric receptors, and may further comprise one or more chemokine receptors. For example, transgenic expression of the chemokine receptor CCR2b or CXCR2 in cells such as T cells enhances transport to CCL2-secreting or CXCL1-secreting solid tumors (Craddock et al, J Immunother. 2010 Oct;33(8):780-8 and Kershaw et al. Hum Gene Ther. 2002 Nov 1;13(16):1971-80). While we do not wish to be bound by theory, it is conceivable that chemokine receptors expressed on chimeric receptor-expressing cells of this disclosure may recognize chemokines secreted by tumors and improve the targeting of cells to tumors, thereby promoting cell invasion into tumors and enhancing the antitumor effect of cells. The chemokine receptors of this disclosure may include naturally occurring chemokine receptors, recombinant chemokine receptors, or chemokine-binding fragments thereof. Preferred chemokine receptors that can be expressed on cells of this disclosure include, but are not limited to, CXC chemokine receptors such as CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, or CXCR7; CC chemokine receptors such as CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, or CCR11; CX3C chemokine receptors such as CX3CR1; XC chemokine receptors such as XCR1; and chemokine-binding fragments thereof. In some embodiments, the chemokine receptors expressed on cells are selected based on chemokines secreted by tumors.
[0282] Chimeric receptor regulation Some embodiments of this disclosure relate to controlling the activity of one or more chimeric receptors in chimeric receptor-expressing cells of this disclosure. Several methods exist for controlling chimeric receptor activity. In some embodiments, controllable chimeric receptors capable of controlling the activity of one or more chimeric receptors may be desirable to optimize the safety and / or efficacy of chimeric receptor therapy. For example, inducing apoptosis using a caspase fused to a dimerizing domain (see, e.g., Di et al., N Engl. J. Med. 2011 Nov. 3;365(18):1673-1683) can be used as a safety switch in chimeric receptor therapy. In some embodiments, the chimeric receptor-expressing cells of the present disclosure can also express inducible caspase-9 (i-caspase-9), which induces caspase-9 activation and leads to cellular apoptosis upon administration of a dimerizing agent such as limiducide (IUPAC name: [(1R)-3-(3,4-dimethoxyphenyl)-1-[3-[2-[2-[[2-[3-[(1R)-3-(3,4-dimethoxyphenyl)-1-[(2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetyl]amino]ethylamino]-2-oxoethoxy]phenyl]propyl](2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carboxylate). In some embodiments, i-caspase-9 includes a binding domain containing a chemical inducer of dimerization (CID) that mediates dimerization in the presence of CID, resulting in inducible and selective depletion of chimeric receptor-expressing cells.
[0283] Alternatively, in some embodiments, the chimeric receptors of the Disclosure may be controlled by utilizing small molecules or antibodies that inactivate or inhibit chimeric receptor activity. For example, an antibody may cause deletion of chimeric receptor-expressing cells by inducing antibody-dependent cell-mediated cytotoxicity (ADCC). In some embodiments, the chimeric receptor-expressing cells of the Disclosure may further express antigens recognized by molecules that can induce ADCC-mediated or complement-induced cell death. For example, the chimeric receptor-expressing cells of the Disclosure may further express receptors that can be targeted by antibodies or antibody fragments. Examples of suitable receptors that can be targeted by antibodies or antibody fragments include EpCAM, VEGFR, and integrins (e.g., ανβ3, α4, αI). 3 CD11, CD11a / LFA-1, CD15, CD18 / I This includes, but is not limited to, TGB2, CD19, CD20, CD22, CD23 / IgE receptors, CD25, CD28, CD30, CD33, CD38, CD40, CD41, CD44, CD51, CD52, CD62L, CD74, CD80, CD125, CD147 / basidine, CD152 / CTLA-4, CD154 / CD40L, CD195 / CCR5, CD319 / SLAMF7, and EGFR, as well as their cleaved versions.
[0284] In some embodiments, the chimeric receptor-expressing cells of this disclosure may also express cleaved epidermal growth factor receptor (EGFR) that lacks signaling ability but retains an epitope recognized by a molecule capable of inducing ADCC (e.g., WO2011 / 056894).
[0285] In some embodiments, the chimeric receptor-expressing cells of this disclosure further include a highly expressed small marker / suicide gene that combines target epitopes from both CD32 and CD20 antigens in the chimeric receptor-expressing cells, which binds to an anti-CD20 antibody (e.g., rituximab) and results in selective depletion of the chimeric receptor-expressing cells by ADCC. Other methods for depleting the chimeric receptor-expressing cells of this disclosure include, but are not limited to, the administration of a monoclonal anti-CD52 antibody that selectively binds to and targets the chimeric receptor-expressing cells for destruction by inducing ADCC. In some embodiments, the chimeric receptor-expressing cells may be selectively targeted using a chimeric receptor ligand, such as an anti-idiotype antibody. In some embodiments, the anti-idiotype antibody can induce effector cell activity, such as ADCC or ADC activity. In some embodiments, the chimeric receptor ligand can further bind to a cell death-inducing agent, such as a toxin. In some embodiments, the chimeric receptor-expressing cells of this disclosure may further express a target protein recognized by the cell depletion agent of this disclosure. In some embodiments, the target protein is CD20, and the cell depletion agent is an anti-CD20 antibody. In such embodiments, the cell depletion agent is administered when it is desirable to reduce or eliminate chimeric receptor-expressing cells. In some embodiments, the cell depletion agent is an anti-CD52 antibody.
[0286] In some embodiments, a controlled chimeric receptor comprises a set of polypeptides in which the components of the chimeric receptor of this disclosure are distributed onto separate polypeptides or members. For example, the set of polypeptides may include a dimerization switch that, in the presence of a dimerizing molecule, can conjugate the polypeptides together to form a functional chimeric receptor.
[0287] Nucleic acid constructs encoding chimeric receptors Certain aspects of this disclosure relate to nucleic acids (e.g., isolated nucleic acids) encoding one or more chimeric receptors of this disclosure. In some embodiments, the nucleic acid is an RNA construct, such as a messenger RNA (mRNA) transcript or modified RNA. In some embodiments, the nucleic acid is a DNA construct.
[0288] In some embodiments, the nucleic acids of this disclosure encode a chimeric receptor comprising one or more antigen-binding domains, each domain binding to a target antigen (e.g., a solid tumor antigen), a transmembrane domain, and one or more intracellular signaling domains. In some embodiments, the nucleic acids encode a chimeric receptor comprising an antigen-binding domain, a transmembrane domain, a primary signaling domain (e.g., a CD3-zeta domain), and one or more costimulatory signaling domains. In some embodiments, the nucleic acids further comprise a nucleotide sequence encoding a spacer region. In some embodiments, the antigen-binding domain is connected to the transmembrane domain by the spacer region. In some embodiments, the spacer region comprises a nucleic acid sequence selected from any of the nucleic acid sequences listed in Table 9. In some embodiments, the nucleic acids further comprise a nucleotide sequence encoding a leader sequence.
[0289] The nucleic acids of this disclosure can be obtained by any suitable recombinant method known in the art, including, but not limited to, screening a library from cells expressing the gene of interest, inducing the gene of interest from a vector known to contain the gene, or directly isolating the gene of interest from cells and tissues containing the gene using standard techniques. Alternatively, the gene of interest may be produced synthetically.
[0290] In some embodiments, the nucleic acids of the Disclosure are contained within a vector. In some embodiments, the nucleic acids of the Disclosure are expressed intracellularly via transposons, CRISPR / Cas9 systems, TALENs, or zinc finger nucleases.
[0291] In some embodiments, the expression of nucleic acids encoding the chimeric receptors of this disclosure can be achieved by operably ligating the nucleic acid with a promoter and incorporating the construct into an expression vector. Suitable vectors can be replicated and incorporated in eukaryotic cells. Typical cloning vectors include transcriptional and translational terminators, start sequences, and promoters useful for controlling the expression of the desired nucleic acid.
[0292] In some embodiments, the expression constructs of the Disclosure may also be used for nucleic acid immunization and gene therapy using standard gene delivery protocols (e.g., US5399346, US5580859, and US5589466). In some embodiments, the vectors of the Disclosure are gene therapy vectors.
[0293] The nucleic acids of this disclosure may be cloned into several types of vectors. For example, the nucleic acids may be cloned into vectors including, but not limited to, plasmids, phagemids, phage derivatives, animal viruses, or cosmids. In some embodiments, the vector may be an expression vector, a replication vector, a probe generation vector, or a sequencing vector.
[0294] In some embodiments, the plasmid vector includes a transposon / transposase system for incorporating the nucleic acid of this disclosure into the host cell genome. Methods for expressing proteins in immune cells using transposon and transposase plasmid systems are generally described in Chicaybam L, Hum Gene Ther. 2019 Apr;30(4):511-522.doi:10.1089 / hum.2018.218; and Ptackova P, Cytotherapy. 2018 Apr;20(4):507-520.doi:10.1016 / j.jcyt.2017.10.001, each of which is incorporated herein by reference in its entirety. In some embodiments, the transposon system is a Sleeping Beauty transposon / transposase or a piggyBac transposon / transposase.
[0295] In some embodiments, the expression vectors of the Disclosure may be delivered to cells in the form of viral vectors. Suitable viral vector systems are well known in the Art. For example, viral vectors may be derived from retroviruses (e.g., gamma retroviruses and lentiviruses), adenoviruses, adeno-associated viruses, and herpesviruses. In some embodiments, the vectors of the Disclosure are retroviral vectors. Types of retroviral vectors include lentiviral vectors and gamma retroviral vectors. In some embodiments, the vectors of the Disclosure are lentiviral vectors. Lentiviral vectors are derived from lentiviruses such as human immunodeficiency virus (HIV) and are generally suitable for long-term gene transfer because they allow for long-term and stable integration of the transgene and its proliferation in daughter cells. Lentiviral vectors can typically transduce non-proliferating cells and may therefore be advantageous over other retroviral vectors for transducing specific cell types (e.g., mouse leukemia virus). In some embodiments, the vectors of the Disclosure are gamma retroviral vectors. Gamma retrovirus vectors are derived from viruses of the genus Gamma Retrovirus, including mouse leukemia virus (MLV) and feline leukemia virus.
[0296] Viral particles produced using retroviral vectors (e.g., lentiviral vectors and gamma-retroviral vectors) are typically pseudotyped to include an envelope protein that is exogenous in retroviruses. A common envelope protein used for pseudotyping is vesicular stomatitis virus (VSV) G glycoprotein. In some embodiments, retroviral vectors (e.g., lentiviral vectors or gamma-retroviral vectors) are pseudotyped using baboon endogenous retrovirus (BaEV) envelope protein. The BaEV envelope protein may be a wild-type BaEV envelope, or a variant BaEV envelope, such as a chimeric BaEV in which the cytoplasmic tail is replaced with that of the MLV-A virus, or a version cleaved to remove the R peptide at the C-terminus (e.g., Anais Girard-Gagnepain, et al. Blood 2014;124(8):1221-1231.doi:https: / / doi.org / 10.1182 / blood-2014-02-558163).
[0297] In some embodiments, the vectors of the Disclosure are adenovirus vectors (A5 / 35). In some embodiments, the vectors of the Disclosure include a functional origin of replication in at least one organism, a promoter sequence, a convenient restriction endonuclease site, and one or more selectable markers (e.g., WO01 / 96584, WO01 / 29058, and US6326193). Numerous virus-based systems have been developed for gene delivery into mammalian cells. Selected genes can be inserted into vectors and packaged into retroviral particles using techniques known in the art. Recombinant viruses can then be isolated and delivered to mammalian cells either in vivo or ex vivo. Several retroviral systems are known in the art.
[0298] In some embodiments, the vectors of this disclosure include additional promoter elements, such as enhancers, which control the frequency of transcription initiation. Enhancers are typically located 30 bp to 110 bp upstream of the initiation site, although some promoters have been shown to also include functional elements downstream of the initiation site. The spacing between promoter elements may be flexible so that promoter function is maintained when elements are inverted or moved relative to one another. For example, in the thymidine kinase (tk) promoter, the spacing between promoter elements can be increased to 50 bp before activity begins to decrease. Depending on the promoter, individual elements may function cooperatively or independently to activate transcription. Exemplary promoters may include, but are not limited to, the SFFV gene promoter, the EFS gene promoter, the CMV IE gene promoter, the EF1a promoter, the ubiquitin C promoter, and the phosphoglycerokinase (PGK) promoter.
[0299] In some embodiments, the promoter capable of expressing the nucleic acids of the Disclosure in mammalian cells such as the immune-responsive cells of the Disclosure is the EF1a promoter. The native EF1a promoter drives the expression of the alpha subunit of the elongation factor-1 complex, which is responsible for the enzymatic delivery of aminoacyl-tRNA to ribosomes. The EF1a promoter is widely used in mammalian expression plasmids and has been shown to be effective in promoting chimeric receptor expression from nucleic acids cloned into lentiviral vectors.
[0300] In some embodiments, the promoter capable of expressing the nucleic acids of the Disclosure in mammalian cells such as immune-responsive cells of the Disclosure is a constitutive promoter. For example, a preferred constitutive promoter is the pre-early cytomegalovirus (CMV) promoter. The CMV promoter is a potent constitutive promoter capable of driving high levels of expression of any polynucleotide sequence operably linked to the promoter. Other preferred constitutive promoters include, but are not limited to, the ubiquitin C (UbiC) promoter, the Simian virus 40 (SV40) early promoter, the mouse mammary cancer virus (MMTV) promoter, the human immunodeficiency virus (HIV) terminal repeat (LTR) promoter, the MoMuLV promoter, the avian leukemia virus promoter, the Epstein-Barr virus pre-early promoter, the Roussarcoma virus promoter, the actin promoter, the myosin promoter, the elongation factor 1a promoter, the hemoglobin promoter, and the creatine kinase promoter.
[0301] In some embodiments, the promoter capable of expressing the nucleic acids of the Disclosure in mammalian cells, such as immune-responsive cells of the Disclosure, is an inducible promoter. The use of an inducible promoter may provide a molecular switch that can induce or suppress the expression of the nucleic acids of the Disclosure when the promoter is operably linked to the nucleic acid. Examples of inducible promoters include, but are not limited to, the metallothionein promoter, the glucocorticoid promoter, the progesterone promoter, and the tetracycline promoter.
[0302] In some embodiments, the vectors of the present disclosure may further include signal sequences for promoting secretion, polyadenylation signals and transcription terminators, factors enabling episome replication, and / or factors enabling selection. Exemplary signal sequences are provided in Table 11.
[0303] [Table 11]
[0304] In some embodiments, the vectors of this disclosure may further include selectable marker genes and / or reporter genes to facilitate the identification and selection of chimeric receptor-expressing cells from a population of cells transduced with the vector. In some embodiments, the selectable markers may be encoded by nucleic acids that are isolated from the vector and used in a simultaneous translocation procedure. Either the selectable marker or reporter gene may be flanked by appropriate regulatory sequences to enable expression in host cells. Examples of selectable markers include, but are not limited to, antibiotic resistance genes such as neo.
[0305] In some embodiments, a reporter gene may be used to identify transduced cells and to evaluate the functionality of a regulatory sequence. As disclosed herein, a reporter gene is a gene that encodes a polypeptide that is not present or expressed in the recipient organism or tissue, and whose expression imparts readily detectable properties such as enzymatic activity. The expression of the reporter gene can be assayed at a suitable time after the nucleic acid has been introduced into the recipient cells. Examples of reporter genes include, but are not limited to, genes encoding luciferase, beta-galactosidase, chloranphenicol acetyltransferase, secreted alkaline phosphatase, and green fluorescent protein. Suitable expression systems are well known in the art and can be prepared using known techniques or are commercially available. In some embodiments, a construct having the smallest 5' adjacent region exhibiting the highest level of expression of the reporter gene is identified as a promoter. Such a promoter region may be ligated to the reporter gene and used to evaluate a drug for its ability to regulate promoter-driven transcription.
[0306] In some embodiments, a vector comprising a nucleic acid sequence encoding the chimeric receptor of the present disclosure further comprises a second nucleic acid encoding a polypeptide that increases the activity of the chimeric receptor.
[0307] In embodiments where chimeric receptor-expressing cells include two or more chimeric receptors, a single nucleic acid may encode two or more chimeric receptors under a single regulatory element (e.g., a promoter) or under separate regulatory elements for each nucleotide sequence encoding a chimeric receptor contained in the nucleic acid. In some embodiments where chimeric receptor-expressing cells include two or more chimeric receptors, each chimeric receptor may be encoded by a separate nucleic acid. In some embodiments, each separate nucleic acid includes its own regulatory element (e.g., a promoter). In some embodiments, a single nucleic acid encodes two or more chimeric receptors, and the nucleotide sequences encoding the chimeric receptors are in the same reading frame and expressed as a single polypeptide chain. In such embodiments, two or more chimeric receptors may be separated by one or more peptide cleavage sites, e.g., autocleavage sites of intracellular proteases or substrates. Preferred peptide cleavage sites may include, but are not limited to, T2A peptide cleavage sites, P2A peptide cleavage sites, E2A peptide cleavage sites, and F2A peptide cleavage sites. In some embodiments, two or more chimeric receptors include a T2A peptide cleavage site. In some embodiments, two or more chimeric receptors include an E2A peptide cleavage site. In some embodiments, two or more chimeric receptors include a T2A and an E2A peptide cleavage site.
[0308] Methods for introducing and expressing genes in cells are well known in the art. For example, in some embodiments, expression vectors can be transferred to host cells by physical, chemical, or biological means. Examples of physical means for introducing nucleic acids into host cells include, but are not limited to, calcium phosphate precipitation, lipofection, particle guns, microinjection, and electroporation. Examples of chemical means for introducing nucleic acids into host cells include, but are not limited to, colloidal dispersions, macromolecular complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. Examples of biological means for introducing nucleic acids into host cells include, but are not limited to, the use of DNA and RNA vectors.
[0309] In some embodiments, liposomes may be used as a nonviral delivery system for introducing nucleic acids or vectors of the Disclosure into host cells in vitro, ex vivo, or in vivo. In some embodiments, nucleic acids may associate with lipids by, for example, being encapsulated within an aqueous liposome, being dispersed within the lipid bilayer of a liposome, being attached to a liposome via a linking molecule that associates with both the liposome and the nucleic acid, being confined within a liposome, being complexed with a liposome, being dispersed in a lipid-containing solution, being mixed with lipids, being combined with lipids, being contained as a suspension in lipids, being contained in or complexed in micelles, or being associated with lipids in other ways. As disclosed herein, lipid-associated nucleic acid or vector compositions are not limited to any particular structure in solution. In some embodiments, such compositions may exist as micelles or in bilayer structures having a “broken-down” structure. Such compositions may also be dispersed in solution to form aggregates that are not uniform in size or shape. As disclosed herein, lipids are fatty substances that are naturally occurring or can be synthesized. In some embodiments, lipids may include naturally occurring lipid droplets in the cytoplasm, or a class of compounds containing long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, amino alcohols, and aldehydes. Suitable lipids may be obtained from commercial sources and include, but are not limited to, dimyristylphosphatidylcholine ("DMPC"), dicetyl phosphate ("DCP"), cholesterol, and dimyristylphosphatidylglycerol ("DMPG"). Storage solutions of lipids in chloroform or chloroform / methanol can be stored at about -20°C. Chloroform is used as the solvent because it evaporates more readily than methanol. As used herein, "liposomes" may encompass a variety of single and multilayer lipid vehicles formed by the formation of encapsulated lipid bilayers or aggregates. In some embodiments, liposomes may be characterized as having a vesicular structure with a phospholipid bilayer membrane and an internal aqueous medium.In some embodiments, multilayer liposomes may have multiple lipid layers separated by an aqueous medium. Multilayer liposomes can spontaneously form when phospholipids are suspended in an excess aqueous solution. In some embodiments, the lipid components may undergo self-rearrangement before the formation of a closed structure, allowing water and dissolved solutes to be trapped between the lipid bilayers. In some embodiments, the lipids may exist in micelle structures or only as heterogeneous aggregates of lipid molecules.
[0310] In some embodiments, the nucleic acids or vectors of the Disclosure are introduced into mammalian host cells, such as immune-responsive cells of the Disclosure. In some embodiments, the presence of the nucleic acids or vectors of the Disclosure in host cells can be confirmed by any suitable assay known in the Art, including but not limited to Southern blot assays, Northern blot assays, RT-PCR, PCR, ELISA assays, and Western blot assays.
[0311] In some embodiments, the nucleic acids or vectors of the Disclosure are stably transduced into immune-responsive cells of the Disclosure. In some embodiments, cells exhibiting stable expression of the nucleic acids or vectors express the encoded chimeric receptor for at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, at least 3 months, at least 6 months, at least 9 months, or at least 12 months after transduction.
[0312] In embodiments in which the chimeric receptor of the Disclosure is transiently expressed in cells, the nucleic acid or vector encoding the chimeric receptor of the Disclosure is transfected into immune-responsive cells of the Disclosure. In some embodiments, the immune-responsive cells express the chimeric receptor for about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 days after transfection.
[0313] In some embodiments, the nucleic acid construct encodes a bicistronic chimeric antigen receptor, comprising a chimeric receptor and a chimeric inhibitory receptor. In some embodiments, the nucleic acid construct comprises a multicistronic chimeric antigen receptor, comprising two or more chimeric receptors and a chimeric inhibitory receptor. In some embodiments, multiple nucleic acid constructs are used, one construct encoding a chimeric receptor and another construct encoding a chimeric inhibitory receptor.
[0314] In some embodiments, the chimeric receptor binds to the CEACAM6 antigen, and the chimeric inhibitory receptor binds to the VSIG2, CPM, ITM2C, SLC26A2, SLC4A4, GPA33, PLA2G2A, ABCA8, ATP1A2, CHP2, or SLC26A3 antigen.
[0315] In some embodiments, the chimeric inhibitory receptor binds to the VSIG2 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the VSIG2 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the VSIG2 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the VSIG2 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0316] In some embodiments, the chimeric inhibitory receptor binds to the CPM antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the CPM antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the CPM antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the CPM antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0317] In some embodiments, the chimeric inhibitory receptor binds to the ITM2C antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the ITM2C antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the ITM2C antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the ITM2C antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0318] In some embodiments, the chimeric inhibitory receptor binds to the SLC26A2 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC26A2 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC26A2 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC26A2 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0319] In some embodiments, the chimeric inhibitory receptor binds to the SLC4A4 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC4A4 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC4A4 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC4A4 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0320] In some embodiments, the chimeric inhibitory receptor binds to the GPA33 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the GPA33 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the GPA33 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the GPA33 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0321] In some embodiments, the chimeric inhibitory receptor binds to the PLA2G2A antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the PLA2G2A antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the PLA2G2A antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the PLA2G2A antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0322] In some embodiments, the chimeric inhibitory receptor binds to the ABCA8 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the ABCA8 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the ABCA8 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the ABCA8 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0323] In some embodiments, the chimeric inhibitory receptor binds to the ATP1A2 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the ATP1A2 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the ATP1A2 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the ATP1A2 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0324] In some embodiments, the chimeric inhibitory receptor binds to the CHP2 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the CHP2 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the CHP2 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the CHP2 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0325] In some embodiments, the chimeric inhibitory receptor binds to the SLC26A3 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC26A3 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC26A3 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC26A3 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0326] In some embodiments, the encoded bicistronic chimeric antigen receptor system includes a CAR having an antigen-binding domain that targets any of the antigens provided in Table 1. In some embodiments, the encoded bicistronic chimeric antigen receptor system includes a CAR having an antigen-binding domain derived from an antibody provided in Table 2. In some embodiments, the encoded bicistronic chimeric antigen receptor system includes a CAR having an antigen-binding domain containing an scFv provided in Table 3. In some embodiments, the encoded bicistronic chimeric antigen receptor includes a CAR having two or more antigen-binding domains that target any of the antigen pairs provided in Table 10.
[0327] In some embodiments, the nucleic acid construct encodes a bivalent chimeric antigen receptor, including a chimeric receptor and a chimeric inhibitory receptor. In some embodiments, the chimeric receptor binds to the CEACAM6 antigen, and the chimeric inhibitory receptor binds to the VSIG2, CPM, ITM2C, SLC26A2, SLC4A4, GPA33, PLA2G2A, ABCA8, ATP1A2, CHP2, or SLC26A3 antigen.
[0328] In some embodiments, the chimeric inhibitory receptor binds to the VSIG2 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the VSIG2 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the VSIG2 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the VSIG2 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0329] In some embodiments, the chimeric inhibitory receptor binds to the CPM antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the CPM antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the CPM antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the CPM antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0330] In some embodiments, the chimeric inhibitory receptor binds to the ITM2C antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the ITM2C antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the ITM2C antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the ITM2C antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0331] In some embodiments, the chimeric inhibitory receptor binds to the SLC26A2 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC26A2 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC26A2 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC26A2 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0332] In some embodiments, the chimeric inhibitory receptor binds to the SLC4A4 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC4A4 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC4A4 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC4A4 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0333] In some embodiments, the chimeric inhibitory receptor binds to the GPA33 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the GPA33 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the GPA33 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the GPA33 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0334] In some embodiments, the chimeric inhibitory receptor binds to the PLA2G2A antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the PLA2G2A antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the PLA2G2A antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the PLA2G2A antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0335] In some embodiments, the chimeric inhibitory receptor binds to the ABCA8 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the ABCA8 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the ABCA8 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the ABCA8 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0336] In some embodiments, the chimeric inhibitory receptor binds to the ATP1A2 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the ATP1A2 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the ATP1A2 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the ATP1A2 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0337] In some embodiments, the chimeric inhibitory receptor binds to the CHP2 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the CHP2 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the CHP2 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the CHP2 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0338] In some embodiments, the chimeric inhibitory receptor binds to the SLC26A3 antigen, and the chimeric receptor binds to the CEA antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC26A3 antigen, and the chimeric receptor binds to the CEACAM1 antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC26A3 antigen, and the chimeric receptor binds to the CEACAM5 antigen. In some embodiments, the chimeric inhibitory receptor binds to the SLC26A3 antigen, and the chimeric receptor binds to the CEACAM6 antigen.
[0339] In some embodiments, the encoded bivalent chimeric antigen receptor includes a CAR having an antigen-binding domain that targets any of the antigens provided in Table 1. In some embodiments, the encoded bivalent chimeric antigen receptor includes a CAR having an antigen-binding domain derived from an antibody provided in Table 2. In some embodiments, the encoded bivalent chimeric antigen receptor system includes a CAR having an antigen-binding domain containing an scFv provided in Table 3. In some embodiments, the encoded bivalent chimeric antigen receptor includes a CAR having two or more antigen-binding domains that target any of the antigen pairs provided in Table 10.
[0340] Pharmaceutical composition and administration Certain aspects of the present disclosure relate to compositions (e.g., pharmaceutical compositions) comprising one or more chimeric receptors of the present disclosure or immune-responsive cells of the present disclosure expressing such one or more chimeric receptors. In some embodiments, compositions comprising such chimeric receptors or recombinant immune-responsive cells expressing such chimeric receptors can be provided systemically or directly to a target for the treatment of proliferative disorders such as solid tumors.
[0341] Compositions comprising the gene-modified cells of this disclosure may be administered intravascularly via any physiologically acceptable vehicle, for example, but they may also be introduced into bone or other convenient sites where the gene-modified cells can find a suitable site for regeneration and differentiation (e.g., the thymus). Compositions comprising the gene-modified cells of this disclosure may include purified cell populations. Methods for determining the proportion of gene-modified cells in a cell population are well known in the art and include, but are not limited to, fluorescence-activated cell sorting (FACS). In some embodiments, the purity of gene-modified cells in a cell population may be about 50%, about 55%, about 60%, or about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 97%, about 98%, about 99%, or higher. Dosage can be readily adjusted by those skilled in the art (e.g., decreased purity may require increased dosage).
[0342] In certain embodiments, the composition is a pharmaceutical composition comprising genetically modified cells, such as immune-responsive cells or their progenitor cells, and a pharmaceutically acceptable carrier. Administration may be autologous or heterologous.
[0343] Treatment method Certain aspects of this disclosure relate to methods for using chimeric receptors and genetically modified cells expressing such chimeric receptors (e.g., immune-responsive cells, e.g., NK cells) to treat subjects requiring such treatment. In some embodiments, the methods of this disclosure are useful for treating cancer in subjects where the cancer expresses CEA (i.e., CEA+). In some embodiments, the methods of this disclosure are useful for treating cancer in subjects where the cancer expresses CEACAM1 (i.e., CEACAM1+). In some embodiments, the methods of this disclosure are useful for treating cancer in subjects where the cancer expresses CEACAM5 (i.e., CEACAM5+). In some embodiments, the methods of this disclosure are useful for treating cancer in subjects where the cancer expresses CEACAM6 (i.e., CEACAM6+). In some embodiments, the methods of this disclosure are useful for treating cancer in subjects such as solid tumors.
[0344] In some embodiments, the solid tumor is cancer of the lung, pancreas, gastrointestinal tract, and colon. In some embodiments, the solid tumor is lung adenocarcinoma. In some embodiments, the solid tumor is pancreatic cancer. In some embodiments, the solid tumor is gastrointestinal cancer (including, but not limited to, cancer of the esophagus, stomach, small intestine, colon, or rectum). In some embodiments, the solid tumor is colon cancer. In some embodiments, the solid tumor is colorectal cancer.
[0345] In some embodiments, the methods of the Disclosure may include administering the gene-modified cells of the Disclosure in an amount effective to achieve a desired effect, including but not limited to mitigating an existing condition, preventing a condition, treating an existing condition, managing an existing condition, or preventing recurrence or relapse of a condition. In some embodiments, the effective amount may be provided by a single or series of administrations of the gene-modified cells of the Disclosure (e.g., immune-responsive cells, e.g., NK cells). In some embodiments, the effective amount may be provided by a bolus or continuous perfusion.
[0346] As disclosed herein, an “effective dose” or “therapeutic effective dose” is an amount sufficient to produce a beneficial or desired clinical outcome at the time of treatment. An effective dose may be administered to a subject in one or more doses. With respect to treatment, an effective dose is an amount sufficient to mitigate, improve, stabilize, reverse, or delay the progression of a disease, or to reduce the pathological outcomes of the disease. The effective dose is generally determined on a case-by-case basis by a physician and is within the scope of the skill of those skilled in the art. Several factors are typically considered when determining the appropriate dosage to achieve an effective dose. These factors include the subject’s age, sex, and weight, the condition being treated, the severity of the condition, and the morphology and effective concentration of the immune-responsive cells being administered.
[0347] In some embodiments, the method reduces the number of tumor cells. In some embodiments, the method reduces tumor size. In some embodiments, the method reduces tumor volume. In some embodiments, the method increases progression-free survival in the subject. In some embodiments, the method increases survival in the subject.
[0348] Treatment In some embodiments, the methods of the present disclosure increase the immune response in subjects requiring it. In some embodiments, the methods of the present disclosure include methods for treating and / or preventing solid tumors in subjects. In some embodiments, the subjects are human. In some embodiments, human subjects suitable for treatment may include two therapeutic groups that can be distinguished by clinical criteria. Subjects having “progressive disease” or “high tumor burden” are subjects having clinically measurable tumors. Clinically measurable tumors are tumors that can be detected based on tumor mass (e.g., based on the percentage of tumor cells by palpation, CAT scan, ultrasound, mammography, or X-ray; positive biochemical or histopathological markers are insufficient in themselves to identify this population). In some embodiments, the pharmaceutical compositions of the present disclosure are administered to these subjects to induce an antitumor response for the purpose of alleviating their condition. In some embodiments, a reduction in tumor burden occurs as a result of administration of the pharmaceutical composition, but any clinical improvement would constitute a benefit. In some embodiments, clinical improvement includes a reduction in the risk of pathological consequences of the tumor or a reduction in the rate of progression. In some embodiments, a second group of preferred human subjects is the “adjuvant group” subjects. These subjects are individuals with a history of solid tumors but who have responded to other treatments. Previous treatments may include, but are not limited to, surgical resection, radiotherapy, and / or conventional chemotherapy. As a result, these individuals do not have clinically measurable tumors. However, they are suspected to be at risk of disease progression near the original tumor site or due to metastasis. In some embodiments, this group can be further subdivided into high-risk and low-risk individuals. Subdivision can be made based on features observed before or after initial treatment. These features are known in clinical practice and are preferably defined for each different solid tumor. Typical features of the high-risk subgroup include tumor infiltration into adjacent tissue or lymph node involvement.
[0349] In any and all embodiments of the increase in the immune response described herein, any increase, decrease, or change in any aspect of the characteristic or function is compared to cells that have not been in contact with the immune-responsive cells described herein.
[0350] An increase in the immune response can be either an enhancement or an induction of the immune response. For example, increasing the immune response encompasses both initiating or starting an immune response, or increasing or amplifying an ongoing or existing immune response. In some embodiments, a treatment induces an immune response. In some embodiments, the induced immune response is an adaptive immune response. In some embodiments, the induced immune response is an innate immune response. In some embodiments, a treatment enhances the immune response. In some embodiments, the enhanced immune response is an adaptive immune response. In some embodiments, the enhanced immune response is an innate immune response. In some embodiments, a treatment increases the immune response. In some embodiments, the increased immune response is an adaptive immune response. In some embodiments, the increased immune response is an innate immune response.
[0351] In some embodiments, a further group of subjects may be those who have a genetic predisposition to solid tumor disease but have not yet demonstrated clinical signs of solid tumor disease. For example, a woman who has tested positive for a gene mutation associated with cancer of the female genitalia (e.g., breast cancer, ovarian cancer) but is still of childbearing age may benefit from receiving one or more cells of this disclosure (e.g., immune-responsive cells, e.g., NK cells) in prophylactic treatment to prevent the development of such cancer of the female genitalia until she is suitable to undergo prophylactic surgery. In some embodiments, subjects may have a disease progression morphology, in which case the treatment objectives may include mitigating or reversing disease progression and / or improving side effects. In some embodiments, subjects may have a history of a condition for which they have already been treated, in which case the treatment objectives may typically include reducing or delaying the risk of recurrence.
[0352] In some embodiments, the activity of CEA CARs (e.g., CEACAM1 CAR, CEACAM5 CAR, or CEACAM6 CAR) is inhibited. In some embodiments, the activity of immune cells expressing CEA CARs (e.g., CEACAM1 CAR, CEACAM5 CAR, or CEACAM6 CAR) is inhibited. In certain embodiments, the activity of CEA CARs is inhibited using an inhibitory chimeric receptor. In certain embodiments, the activity of immune cells expressing CEA CARs is inhibited using an inhibitory chimeric receptor. In some embodiments, the inhibitory chimeric receptor binds to the VSIG2 antigen. In some embodiments, the inhibitory chimeric receptor binds to the CPM antigen. In some embodiments, the inhibitory chimeric receptor binds to the ITM2C antigen. In some embodiments, the inhibitory chimeric receptor binds to the SLC26A2 antigen. In some embodiments, the inhibitory chimeric receptor binds to the SLC4A4 antigen. In some embodiments, the inhibitory chimeric receptor binds to the GPA33 antigen. In some embodiments, the inhibitory chimeric receptor binds to the PLA2G2A antigen. In some embodiments, the inhibitory chimeric receptor binds to the ABCA8 antigen. In some embodiments, the inhibitory chimeric receptor binds to the ATP1A2 antigen. In some embodiments, the inhibitory chimeric receptor binds to the CHP2 antigen. In some embodiments, the inhibitory chimeric receptor binds to the SLC26A3 antigen. In some embodiments, the chimeric receptor is a multispecific receptor containing two or more antigen-binding domains, and as a result, the chimeric receptor can bind to two or more antigens.
[0353] Combination therapy In some embodiments, genetically modified cells of the Disclosure expressing one or more chimeric receptors of the Disclosure (e.g., immune-responsive cells, e.g., NK cells) may be used in combination with other known agents and therapies. In some embodiments, the combination therapy of the Disclosure includes genetically modified cells of the Disclosure, which may be administered in combination with one or more additional therapeutic agents. In some embodiments, the recombinant cells and one or more additional therapeutic agents may be administered simultaneously, in the same or separate compositions, or sequentially. For sequential administration, the genetically modified cells may be administered first, followed by one or more additional agents, or the order of administration may be reversed. In some embodiments, the genetically modified cells are further modified to express one or more additional therapeutic agents.
[0354] kit Certain aspects of the present disclosure relate to kits for the treatment and / or prevention of solid tumors. In certain embodiments, the kit comprises a therapeutic or preventive composition comprising an effective amount of one or more chimeric receptors of the present disclosure, isolated nucleic acids of the present disclosure, vectors of the present disclosure, and / or cells of the present disclosure (e.g., immune-responsive cells). In some embodiments, the kit comprises a sterile container. In some embodiments, such a container may be a box, ampoule, bottle, vial, tube, bag, pouch, blister pack, or other suitable container form known in the art. The container may be made of plastic, glass, laminated paper, metal foil, or other material suitable for holding drugs.
[0355] In some embodiments, the therapeutic or preventive composition is provided with instructions for administering the therapeutic or preventive composition to subjects having or at risk of developing solid tumors, for example, colorectal cancer, pancreatic cancer, lung adenocarcinoma, and / or gastric cancer. In some embodiments, the instructions may include information regarding the use of the composition for the treatment and / or prevention of a disorder. In some embodiments, the instructions may include, but are not limited to, a description of the therapeutic or preventive composition, a dosing schedule, a dosing schedule for the treatment or prevention of the disease or its symptoms, precautions, warnings, indications, contraindications, overdose information, adverse reactions, animal pharmacology, clinical trials, and / or references. In some embodiments, the instructions may be printed directly on the container (if any), or as a label affixed to the container, or as a separate sheet, brochure, card, or folder provided inside or with the container.
[0356] Embodiment 1. An inhibitory chimeric receptor comprising an extracellular antigen-binding domain that binds to an antigen selected from the group consisting of VSIG2, CPM, ITM2C, SLC26A2, SLC4A4, GPA33, PLA2G2A, ABCA8, ATP1A2, CHP2, and SLC26A3. 2. The inhibitory chimeric receptor according to Embodiment 1, wherein the antigen is VSIG2. 3. The inhibitory chimeric receptor according to Embodiment 1, wherein the antigen is CPM. 4. The inhibitory chimeric receptor according to Embodiment 1, wherein the antigen is ITM2C. 5. The inhibitory chimeric receptor according to Embodiment 1, wherein the antigen is SLC26A2. 6. The inhibitory chimeric receptor according to Embodiment 1, wherein the antigen is SLC4A4. 7. The inhibitory chimeric receptor according to Embodiment 1, wherein the antigen is GPA33. 8. The inhibitory chimeric receptor according to Embodiment 1, wherein the antigen is PLA2G2A. 9. The inhibitory chimeric receptor according to Embodiment 1, wherein the antigen is ABCA8. 10. The inhibitory chimeric receptor according to Embodiment 1, wherein the antigen is ATP1A2. 11. The inhibitory chimeric receptor according to Embodiment 1, wherein the antigen is CHP2. 12. The inhibitory chimeric receptor according to Embodiment 1, wherein the antigen is SLC26A3. 13. An inhibitory chimeric receptor according to any one of Embodiments 1 to 12, wherein when expressed on a cell, the inhibitory chimeric receptor inhibits one or more activities of the cell. 14. An inhibitory chimeric receptor according to any one of Embodiments 1 to 13, wherein the antigen is not expressed on tumor cells, or the antigen is expressed on tumor cells at a lower level than it is expressed on non-tumor cells. 15. An inhibitory chimeric receptor according to any one of Embodiments 1 to 14, wherein the antigen is expressed on non-tumor cells, or the antigen is expressed on non-tumor cells at a higher level than it is expressed on corresponding tumor cells. 16. The inhibitory chimeric receptor according to Embodiment 15, wherein the antigen is expressed on non-tumor cells derived from tissues selected from the group consisting of lung, pancreas, gastrointestinal tract, colon, brain, nerve tissue, endocrine system, bone, bone marrow, immune system, muscle, liver, gallbladder, kidney, bladder, male genitalia, female genitalia, fat, soft tissue, and skin. 17. The inhibitory chimeric receptor according to any one of Embodiments 1 to 16, wherein the inhibitory chimeric receptor comprises one or more intracellular inhibitory domains selected from the group consisting of PD-1, CTLA4, TIGIT, LAIR1, GRB-2, Dok-1, Dok-2, SLAP, LAG3, HAVR, BTLA, LIR1, NKG2A, KIR3DL1, GITR, PD-L1, CSK, SHP-1, PTEN, CD45, CD148, PTP-MEG1, PTP-PEST, c-CBL, CBL-b, PTPN22, LAR, PTPH1, SHIP-1, RasGAP, CD94, and CD161. 18. An inhibitory chimeric receptor according to any one of Embodiments 1 to 17, wherein the antigen-binding domain comprises one or more antibodies, antigen-binding fragments of antibodies, F(ab) fragments, F(ab') fragments, single-chain variable fragments (scFv), or single-domain antibodies (sdAb). 19. An inhibitory chimeric receptor according to any one of Embodiments 1 to 18, wherein the antigen-binding domain comprises one or more single-chain variable fragments (scFv). 20. An inhibitory chimeric receptor according to Embodiment 19, wherein each of the one or more scFvs comprises a heavy chain variable domain (VH) and a light chain variable domain (VL). 21. The inhibitory chimeric receptor according to Embodiment 20, wherein VH and VL are separated by a peptide linker. 22. The inhibitory chimeric receptor according to Embodiment 21, wherein the peptide linker comprises the amino acid sequence of SEQ ID NO: 39 or SEQ ID NO: 77. 23. An inhibitory chimeric receptor according to any one of Embodiments 20 to 22, wherein each of one or more scFv comprises the structure VH-L-VL or VL-L-VH, where VH is a heavy chain variable domain, L is a peptide linker, and VL is a light chain variable domain. 24. Isolated cells containing the inhibitory chimeric receptor described in any one of Embodiments 1 to 23. 25. Isolated cells according to Embodiment 24, wherein an inhibitory chimeric receptor is expressed by recombination. 26. Isolated cells according to Embodiment 24 or Embodiment 25, wherein the inhibitory chimeric receptor is expressed from a locus selected from the vector or the cell's genome. 27. Isolated cells according to any one of embodiments 24 to 26, wherein the cells further comprise a chimeric receptor comprising one or more extracellular antigen-binding domains, and one or more extracellular antigen-binding domains bind to one or more antigens selected from the group consisting of CEA, CEACAM1, CEACAM5, and CEACAM6. 28. Isolated cells, (a) An inhibitory chimeric receptor comprising an extracellular antigen-binding domain that binds to an antigen, wherein the antigen is selected from the group consisting of VSIG2, CPM, ITM2C, SLC26A2, SLC4A4, GPA33, PLA2G2A, ABCA8, ATP1A2, CHP2, and SLC26A3, (b) Isolated cells comprising a chimeric receptor having one or more extracellular antigen-binding domains, wherein one or more extracellular antigen-binding domains bind to one or more additional antigens selected from the group consisting of CEA, CEACAM1, CEACAM5, and CEACAM6. 29. Isolated cells according to Embodiment 27 or Embodiment 28, wherein the chimeric receptor is a chimeric T cell receptor or a chimeric antigen receptor (CAR). 30. Isolated cells according to Embodiment 29, wherein the chimeric receptor is a CAR. 31. The isolated cell according to Embodiment 30, wherein the CAR comprises one or more intracellular signaling domains, and one or more intracellular signaling domains are selected from the group consisting of a CD3 zeta chain intracellular signaling domain, a CD3 epsilon chain intracellular signaling domain, a CD97 intracellular signaling domain, a CD11a-CD18 intracellular signaling domain, a CD2 intracellular signaling domain, an ICOS intracellular signaling domain, a CD27 intracellular signaling domain, a CD154 intracellular signaling domain, a CD8 intracellular signaling domain, an OX40 intracellular signaling domain, a 4-1BB intracellular signaling domain, a CD28 intracellular signaling domain, a ZAP40 intracellular signaling domain, a CD30 intracellular signaling domain, a GITR intracellular signaling domain, a HVEM intracellular signaling domain, a DAP10 intracellular signaling domain, a DAP12 intracellular signaling domain, a MyD88 intracellular signaling domain, a 2B4 intracellular signaling domain, an NKp46 intracellular signaling domain, an NKp30 intracellular signaling domain, an NKp44 intracellular signaling domain, an NKG2D intracellular signaling domain, a CD226 intracellular signaling domain, and a CD160 intracellular signaling domain. 32. Isolated cells according to Embodiment 30 or Embodiment 31, wherein CAR includes a transmembrane domain, and the transmembrane domain is selected from the group consisting of CD8 transmembrane domain, CD28 transmembrane domain, CD25 transmembrane domain, CD7 transmembrane domain, CD3 zeta chain transmembrane domain, CD4 transmembrane domain, 4-1BB transmembrane domain, OX40 transmembrane domain, ICOS transmembrane domain, CTLA-4 transmembrane domain, LAX transmembrane domain, LAT transmembrane domain, PD-1 transmembrane domain, LAG-3 transmembrane domain, TIM3 transmembrane domain, KIR3DS1 transmembrane domain, KIR3DL1 transmembrane domain, NKG2D transmembrane domain, NKG2A transmembrane domain, TIGIT transmembrane domain, 2B4 transmembrane domain, and BTLA transmembrane domain. 33. An isolated cell according to any one of embodiments 30 to 32, wherein the CAR includes a spacer region between an antigen-binding domain and a transmembrane domain, and the spacer region has an amino acid sequence selected from the group consisting of SEQ ID NOs: 49 to 58. 34. Isolated cells according to any one of Embodiments 27 to 33, wherein the inhibitory chimeric receptor and / or the antigen-binding domain of the chimeric receptor comprises one or more antibodies, antigen-binding fragments of antibodies, F(ab) fragments, F(ab') fragments, single-chain variable fragments (scFv), or single-domain antibodies (sdAb). 35. Isolated cells according to any one of embodiments 27 to 33, wherein the inhibitory chimeric receptor and / or the antigen-binding domain of the chimeric receptor comprises one or more single-chain variable fragments (scFv). 36. Isolated cells according to Embodiment 35, wherein each of the one or more scFvs comprises a heavy chain variable domain (VH) and a light chain variable domain (VL). 37. Isolated cells according to Embodiment 36, wherein VH and VL are separated by a peptide linker. 38. Isolated cells according to Embodiment 37, wherein the peptide linker comprises the amino acid sequence of SEQ ID NO: 39 or SEQ ID NO: 77. 39. Isolated cells according to any one of embodiments 36 to 38, wherein each of one or more scFv comprises the structure VH-L-VL or VL-L-VH, where VH is a heavy chain variable domain, L is a peptide linker, and VL is a light chain variable domain. 40. Isolated cells according to any one of embodiments 28 to 39, wherein one or more additional antigens is CECAM1. 41. Isolated cells according to Embodiment 40, wherein the antigen-binding domain that binds to CEACAM1 comprises a heavy chain variable domain (VH) containing the amino acid sequence of SEQ ID NO: 1 and a light chain variable domain (VL) containing the amino acid sequence of SEQ ID NO: 2. 42. Isolated cells according to any one of embodiments 28 to 39, wherein one or more additional antigens are CECAM5. 43. The antigen-binding domain that binds to CEACAM5 is (a) VH containing the amino acid sequence of SEQ ID NO: 3 and VL containing the amino acid sequence of SEQ ID NO: 4 (b) VH containing the amino acid sequence of SEQ ID NO: 9 and VL containing the amino acid sequence of SEQ ID NO: 10 (c) VH containing the amino acid sequence of SEQ ID NO: 11 and VL containing the amino acid sequence of SEQ ID NO: 12, (d) VH containing the amino acid sequence of SEQ ID NO: 13 and VL containing the amino acid sequence of SEQ ID NO: 14, (e) VH containing the amino acid sequence of SEQ ID NO: 78 and VL containing the amino acid sequence of SEQ ID NO: 79, (f) Isolated cells according to Embodiment 42, comprising a heavy chain variable domain (VH) and a light chain variable domain (VL) selected from the group consisting of VH containing the amino acid sequence of SEQ ID NO: 15 and VL containing the amino acid sequence of SEQ ID NO: 16. 44. The antigen-binding domain that binds to CEACAM5 is (a) HC containing the amino acid sequence of SEQ ID NO: 5 and LC containing the amino acid sequence of SEQ ID NO: 6, (b) Isolated cells according to Embodiment 42, comprising a heavy chain (HC) and a light chain (LC) selected from the group consisting of an HC containing the amino acid sequence of SEQ ID NO: 7 and an LC containing the amino acid sequence of SEQ ID NO: 8. 45. Isolated cells according to any one of embodiments 28 to 39, wherein one or more additional antigens is CECAM6. 46. Isolated cells according to Embodiment 45, wherein the antigen-binding domain that binds to CEACAM6 comprises a heavy chain variable domain (VH) containing the amino acid sequence of SEQ ID NO: 17 and a light chain variable domain (VL) containing the amino acid sequence of SEQ ID NO: 18. 47. Isolated cells according to any one of embodiments 28 to 39, wherein the cells are immune-responsive cells. 48. Isolated cells according to any one of embodiments 28 to 47, wherein the binding of an inhibitory chimeric receptor to an antigen can inhibit immune-responsive cells. 49. Isolated cells according to any one of embodiments 28 to 48, wherein the binding of a chimeric receptor with one or more additional antigens can activate immune-responsive cells. 50. Isolated cells according to any one of embodiments 28 to 49, wherein the chimeric receptor binds to one or more additional antigens with low binding affinity. 51. Isolated cells according to any one of embodiments 28 to 50, wherein the chimeric receptor binds to one or more additional antigens at a binding affinity lower than the binding affinity of the inhibitory chimeric receptor to the antigen. 52. Isolated cells according to any one of embodiments 28 to 51, wherein the inhibitory chimeric receptor binds to the antigen with low binding affinity. 53. Isolated cells according to any one of embodiments 27 to 52, wherein the chimeric receptor is expressed by recombination. 54. An isolated cell according to any one of embodiments 27 to 53, wherein the chimeric receptor is expressed from a locus selected from the vector or the cell's genome. 55. Isolated cells according to any one of embodiments 27 to 54, wherein the cells are selected from the group consisting of T cells, natural killer (NK) cells, cytotoxic T lymphocytes (CTLs), regulatory T cells, natural killer T (NKT) cells, myeloid cells, macrophages, human embryonic stem cells (ESCs), ESC-derived cells, pluripotent stem cells, and induced pluripotent stem cells (iPSCs), as well as iPSC-derived cells. 56. Isolated cells according to any one of embodiments 24 to 55, wherein the cells are autologous. 57. Isolated cells according to any one of embodiments 24 to 55, wherein the cells are allogeneic. 58. An isolated nucleic acid encoding an inhibitory chimeric receptor as described in any one of Embodiments 1 to 23. 59. A vector comprising the nucleic acid described in Embodiment 58. 60. Genetically modified cells comprising the nucleic acid described in Embodiment 58 or the vector described in Embodiment 59. 61. A method for administering treatment to a subject requiring treatment, the method comprising administering isolated cells described in any one of embodiments 24 to 57. 62. A method for stimulating a cellular immune response against tumor cells in a subject, the method comprising administering isolated cells described in any one of embodiments 24 to 57 to a subject having a tumor. 63. A method for providing antitumor immunity in a subject, the method comprising administering isolated cells described in any one of embodiments 24 to 57 to a subject in need thereof. 64. A method for reducing tumor volume in a subject, comprising administering to the subject an isolated cell described in any one of embodiments 24 to 57. 65. The method according to embodiment 64, wherein the method reduces the number of tumor cells. 66. The method according to embodiment 64, wherein the method reduces tumor size. 67. The method according to embodiment 64, wherein the method reduces tumor volume. 68. The method according to embodiment 64, wherein the method eradicates a tumor in the subject. 69. A method for treating a subject having a tumor, the method comprising administering isolated cells described in any one of embodiments 24 to 57. 70. A method for treating or preventing colorectal cancer in a subject, comprising administering isolated cells described in any one of embodiments 24 to 57 to the subject. 71. A method for treating or preventing pancreatic cancer in a subject, comprising administering isolated cells described in any one of embodiments 24 to 57 to the subject. 72. A method for treating or preventing lung adenocarcinoma in a subject, comprising administering isolated cells described in any one of embodiments 24 to 57 to the subject. 73. A method for treating or preventing gastric cancer in a subject, comprising administering isolated cells described in any one of embodiments 24 to 57 to the subject. 74. The method according to any one of embodiments 61 to 73, wherein isolated cells are administered in an effective dose. 75. A method according to any one of embodiments 69 to 74, wherein the method increases progression-free survival in the subject. 76. A method according to any one of embodiments 69 to 75, wherein the method increases survival in a subject. 77. A pharmaceutical composition comprising an effective amount of isolated cells according to any one of embodiments 24 to 57, and a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, or a combination thereof. 78. The pharmaceutical composition according to Embodiment 77, wherein the pharmaceutical composition is for treating and / or preventing colorectal cancer, pancreatic cancer, lung adenocarcinoma, and / or gastric cancer. 79. A kit for treating and / or preventing colorectal cancer, pancreatic cancer, lung adenocarcinoma, and / or gastric cancer, comprising isolated cells according to any one of embodiments 24 to 57, or a pharmaceutical composition according to embodiment 77. 80. The kit according to Embodiment 79, further comprising written instructions for using isolated cells to treat and / or prevent colorectal cancer, pancreatic cancer, lung adenocarcinoma, and / or gastric cancer in a subject. 81. A kit for treating and / or preventing colorectal cancer, pancreatic cancer, lung adenocarcinoma, and / or gastric cancer, comprising the isolated nucleic acid described in Embodiment 58 or the vector described in Embodiment 59. 82. The kit according to Embodiment 81, further comprising instructions for using nucleic acids to produce one or more antigen-specific cells for treating and / or preventing colorectal cancer, pancreatic cancer, lung adenocarcinoma, and / or gastric cancer in a subject. [Examples]
[0357] The following are examples of methods and compositions of this disclosure. It will be understood that various other embodiments may be implemented in light of the general descriptions provided herein.
[0358] The following are examples of specific embodiments for carrying out the subject matter claimed in this disclosure. The embodiments are provided for illustrative purposes only and are not intended to limit the scope of this disclosure in any way. Efforts have been made to ensure accuracy with respect to the numbers used (e.g., examples, quantities, temperatures), however, some experimental errors and deviations should of course be acceptable.
[0359] Example 1: Bioinformatics screening for solid tumor antigens CEA was selected for further research because, in addition to its established role as a tumor antigen, its therapeutic efficacy is limited due to extra-tissue toxicity. Microarray data, RNA-seq data, and proteomics data from selected solid tumor and normal tissue samples, as well as data from off-target tissues, were analyzed for the expression levels of CEACAM1, CEACAM5, and CEACAM6. A comparative analysis of CEA family members is shown in Figure 1. Analysis of data from the Cancer Genome Atlas (TCGA) showed that CEACAM5 and CEACAM6 expression was high in both colorectal cancer (CRC) and normal tissue (Figure 2). The analysis allowed for comparisons between different cohorts. The y-axis on a log2 scale allowed for the determination of relative differences in expression between different tumors and normal tissues. These findings were confirmed by bioinformatics analysis of patients using RNA datasets provided by single-cell RNA sequencing of colon cancer and healthy colon, as published in Lee et al. (2020) Nat Genetics, 52(1):56-73. CEACAM5 expression was shown in Figure 3A and CEACAM6 expression in Figure 3B, revealing comparable expression between cancer cells and normal cells. Protein analysis in normal and cancerous tissues was evaluated by immunohistochemical staining of tissue microarrays, and CEA family protein expression was confirmed at the protein level (Figure 4). Although high expression was found in normal tissues as well, the high levels of CEACAM family members across solid tissue types highlighted that CEACAM1, CEACAM5, and CEACAM6 are favorable targets for solid tumor therapy. To further validate the system, a panel of human colon cancer cell lines was purchased from ATCC, and the expression of different CEACAM isoforms (CEA family members: CEACAM1, 5, and 6) was determined using flow cytometry (Figure 5).
[0360] Example 2: Bioinformatics screening for inhibitory antigen targets ("NOT" targets) Next, the CEACAM1, CEACAM5, and CEACAM6 antigens identified in Example 1 were paired for NOT gating. NOT targets were determined using scRNA sequencing data, employing the following criteria: NOT targets exhibited low expression in solid tumor tissue and high expression in the desired tissue. Potential NOT antigens were identified by performing differential gene expression (DEG) analysis on scRNAseq data. Targets were first filtered by Log factor change (LFC) > 1 (healthy tissue:tumor tissue). Targets were then filtered to consider only putative membrane or cell surface proteins. These were then manually prioritized and validated based on literature searches, etc. Similarly, suitable NOT targets were identified by investigating their expression compared to the solid tumor antigens CEACAM1, CEACAM5, or CEACAM6. Selected NOT targets exhibited low expression in tumor cells and high expression in healthy epithelial cells when solid tumor antigen expression was high.
[0361] The "NOT" gating targets determined by this strategy include VSIG2, CPM, ITM2C, SLC26A2, SLC4A4, GPA33, PLA2G2A, ABCA8, and ATP1A2. The "NOT" targets are also listed in Table 9.
[0362] RNA analysis from the TCGA dataset is shown for ABCA8 (Figure 6A) and ATP1A2 (Figure 6B). The results of single-cell RNA sequencing (scRNAseq) for ABCA8 are shown in Figures 7A and 7B.
[0363] VSIG2 expression was analyzed across tumor cells and various normal cells using the following RNA datasets provided by Li et al. (2017) Nat. Genetics, 11(23):6861-6873 (GSE81861), Lee et al. (2020) Nat. Genetics, 52(1):56-73 (GSE132465), and GSE144735, along with the analysis described in Example 1 above. As shown in Figure 8, VSIG2 expression was not detected in tumor cells. In contrast, normal tissues showed detectable VSIG2 expression in four normal cell subsets examined, indicating that VSIG2 met the criteria as a NOT target. VSIG2 expression was further analyzed for specific expression in the epithelial compartments of tissues using independent scRNAseq datasets. Using major component analysis (PCA), scRNAseq expression of VSIG2 was identified by overlay to specify particular subpopulations of cells. As shown in Figures 9A and 9B, VSIG2 expression was high in the normal epithelial compartment subpopulation (outline region of Figure 9A, left panel), low in the tumor cell epithelial compartment subpopulation (outline region of Figure 9A, right panel), and low throughout the tumor tissue, again indicating that VSIG2 met the criteria as a NOT target.
[0364] Comparative gene expression studies of VSIG2 and CEACAM5 were also conducted across normal and tumor tissues. As shown in Figures 10A–10E, the analysis showed an inverse correlation of expression across a range of tissue types. A similar expression pattern was observed for VSIG2 when compared to CEACAM6. A series of scRNAseq analyses across cell types and tissues were also performed for VSIG2, and the analysis was consistent with the above results (Figure 11). Consistent with the comparative expression analysis in Figures 10A–10E, as shown in Figure 12A, VSIG2 correlated with CEACAM5 and CEACAM6 expression in healthy lung tissue.
[0365] Presumptive VSIG2 protein expression was determined using tissue microarrays containing multiple gastrointestinal tumor and healthy tissue samples (Figure 13A). VSIG2 protein expression was determined by immunohistochemistry (IHC) using two different commercially available antibodies (monoclonal antibody OTI2D8 and polyclonal antibody ab252969). Representative images of healthy intestinal mucosa show positive VSIG2 immunoreactivity in epithelial cells (Figures 13B-C). Co-localization of aCAR-targeted CEACAM5 and iCAR-targeted VSIG2 in healthy epithelial cells of the digestive tract was observed using multiplexed IHC (Figures 14A-14B). Importantly, co-localization of aCAR-targeted CEACAM5 and iCAR-targeted VSIG2 was not observed in grade 3, stage IIB colon cancer samples, and the majority of VSIG2 signals were observed to be low or nuclear signals, suggesting that the iCAR NOT gate technology does not provide protection to cancerous tissue, but rather would protect healthy tissue in particular (Figure 15). The co-expression of aCAR target (CEACAM5) and iCAR target (VSIG2) in the stromal compartment and immune cells of colon samples was determined by analyzing scRNAseq data from two datasets (Figures 16A-16C).
[0366] Another potential NOT target, CPM, was similarly analyzed for gene expression. Expression analyses were performed in colon cancer and normal tissue (Figure 17A) and normal lung tissue (Figure 17B). Comparative gene expression studies of CPM, CEACAM5, and CEACAM6 across normal and tumor tissues showed inverse correlations in expression, as shown in Figure 17C.
[0367] Further putative gene expression analyses were performed on NOT candidate antigens to determine their expression in normal and tumor tissues: GPA33 (Figures 18A-18B), PLA2G2A (Figures 19A-19B), ITM2C (Figures 20A-20B), CHP2 (Figures 21A-21B), SLC26A2 (Figures 22A-22B), SLC4A4 (Figures 23A-23B), and SLC26A3 (Figures 24A-24B).
[0368] Example 3: CEA aCAR-expressing T cells show increased cytokine / chemokine induction and target cell killing. T cells transduced with lentiviruses to constructs encoding CEA-activated CARs ("aCAR") were evaluated for CAR expression, cytokine expression, and target cell killing. Primary donor T cells from two different donors were transduced with CEA CAR constructs containing a CD28 costimulatory domain and a CD3 zeta intracellular domain, and various anti-CEA scFv (derived from hMN14, hMFE23, MG7, and MRG1) were tested. Each CAR construct encoded a CD8 signal sequence (SEQ ID NO: 76), an scFv domain (i.e., a "binding factor"), a Myc epitope tag (SEQ ID NO: 75), a CD8 hinge (SEQ ID NO: 50), a transmembrane domain derived from either CD28 (SEQ ID NO: 46) or OX40 (SEQ ID NO: 47), a costimulatory domain derived from either CD28 (SEQ ID NO: 71) or OX40 (SEQ ID NO: 72), and a CD3 zeta-activating domain (SEQ ID NO: 73) in the N-terminal to C-terminal direction. Table 12 provides a description of each binding factor, transmembrane domain, and co-stimulatory domain used in each construct. T cells were transduced with a lentivirus MOI of 0.6 or 0.3 picograms per T cell (measured by p24 assay). Primary T cells were obtained from two different donors (referred to as "Donor 1" and "Donor 2") and used to evaluate the transduction efficiency of the constructs. CAR expression was assessed via flow cytometry by staining for the presence of the epitope tag (Myc). Cells were stained on days 4 and 7 after transduction to determine the stability of construct expression. A gate for determining Myc% expression was drawn using a non-transduced control (virus-free) so that <1% of Myc+ cells were within the positive gate. The median fluorescence intensity (MFI) was determined to quantify and evaluate CAR expression levels. Table 13 shows the expression levels of each CAR in Donor 1 and Donor 2 T cells on day 4. Table 14 shows the expression levels in T cells from donor 1 and donor 2 of each CAR on day 8.
[0369] [Table 12]
[0370] [Table 13]
[0371] [Table 14]
[0372] The killing activity of CEA aCAR-transduced T cells was evaluated. CEA aCAR-transduced T cells were incubated overnight (16-18 hours) with target cells of the colon cancer cell line (LS174t) at a 2:1 E:T ratio. The Ls174t target cell line included "parental" LS174t cells (left panel) and "mKate" cells (right panel) transduced to express the fluorescent reporter mKate. Potential CAR activity was evaluated using two T cell donors (Donor 1 and Donor 2). Cell culture supernatants were collected and tested for killing activity. LDH levels in the cell culture supernatant were measured to assess cell death due to killing activity. Increased LDH release indicates killing of target cells. LDH activity was determined according to the manufacturer's instructions (CyQUANT LDH cytotoxicity assay, Thermo Fisher). Maximum killing activity was determined from chemically lysed target cells, while spontaneous LDH release was determined from target cells only. The LDH release percentage (as a percentage of maximum LDH release) was calculated for parental target cells co-cultured with donor 1 T cells transduced with the construct (Figure 25A), mKate target cells co-cultured with donor 1 T cells transduced with the construct (Figure 25B), parental target cells co-cultured with donor 2 T cells transduced with the construct (Figure 26A), and mKate target cells co-cultured with donor 2 T cells transduced with the construct (Figure 26B). All CEA aCARs showed significantly greater killing activity than the non-transduced control (no virus), indicating CAR-mediated killing of congeneral target cells. Killing activity was comparable across both target lines tested.
[0373] Cytokine activity of CEA aCAR-transduced T cells was evaluated. Measurement was performed by LDH release, and the same cell culture supernatant was used to evaluate T cell cytokine activity in the killing assays shown in Figures 25A, 25B, 26A, and 26B. Cell culture supernatant collected from the killing assay performed on donor 2 was evaluated using Luminex. In the LDH assay, since the difference between parental target cells and target cell lines expressing mkate was minimal, the two target lines were evaluated in the same group as technical replicates. T cell activity was further evaluated by measuring the levels of IL-2 (Figure 27A), IFNγ (Figure 27B), TNFα (Figure 27C), caspase-3 (Figure 27D), perforin (Figure 27E), and granzyme B (Figure 27F) using multiplex immunoassays (ProcartaPlex, Thermo Fisher). As shown in Figures 27A-27F, T cells expressing CEA aCAR showed significantly higher cytokine and chemokine activity than non-transduced control T cells (without virus), indicating CAR-mediated activation of T cells after recognition of congenital target cells.
[0374] Example 4: Lentiviral transducer CEA aCAR NK cells show increased target cell killing. In this example, lentiviral vectors encoding various CEA aCAR constructs and off-target control constructs expressing CARs containing Axl-binding domains were transduced into primary donor-derived NK cells, and CAR expression and CAR-mediated killing were evaluated. Each CEA aCAR construct encoded a CD8 signal sequence (SEQ ID NO: 76), an scFv domain (i.e., a "binding factor"), a Myc epitope tag (SEQ ID NO: 75), a CD8 hinge (SEQ ID NO: 50), a transmembrane domain derived from either CD28 (SEQ ID NO: 46) or OX40 (SEQ ID NO: 46), a costimulatory domain derived from either CD28 (SEQ ID NO: 70) or OX40 (SEQ ID NO: 72), and a CD3 zeta-activating domain (SEQ ID NO: 74) from the N-terminus to the C-terminus. CEA aCAR expression in transduced NK cells was evaluated on day 5 after transduction. Constructs containing various antigen-binding domains, either CD28 or OX40 costimulatory domains, and CD3 zeta-intracellular domains were tested with various scFvs. The antigen-binding and costimulatory domains of each construct are provided in Table 15. An off-target "control" CAR (SB02716) was also tested as a negative control. NK cells were transduced with an MOI of 30 IU per NK cell. CAR expression was assessed via flow cytometry by staining for the presence of an epitope tag (Myc). Cells were stained on day 5 after transduction to determine the stability of construct expression. A gate for determining Myc% expression was drawn using a non-transduced control (virus-free) so that <1% of Myc+ cells were within the positive gate. The median fluorescence intensity (MFI) was determined to quantify and evaluate CAR expression levels. The expression levels of each CAR on day 4 are shown in Table 15.
[0375] [Table 15]
[0376] Killing activity of CEA aCAR lentiviral transducer NK cells in flow assays. On day 5 after transduction, CEA aCAR transducer NK cells were incubated overnight (16-18 hours) with a colorectal cancer target cell (LS174t) at a 1:1 E:T ratio. Cells were co-cultured in ultra-low binding U-bottom plates to promote cell-cell interactions and reduce plate adhesion. Cells were harvested and stained for flow cytometry to determine cell phenotype and death. Target cells were distinguished from CD56+ NK cells using mKate-expressing Ls174t target cells. Live cells were distinguished from dead cells using Zombie UV (Biolegend) dye. The percentage of dead cells was calculated and is shown in Figure 28. As shown in Figure 28, six of the tested CEA aCAR constructs showed significantly higher killing activity than non-transduced (virus-free) NK controls. Statistical significance was determined using a standard one-way ANOVA with Dunnett's multiple comparison correction, with p<0.0001. These results indicate significant CAR-mediated lethality.
[0377] Example 5: Expression and killing activity of NK cells transduced with lentiviruses and gamma-retroviruses expressing various CEA aCAR constructs CEA aCAR expression in lentiviral and gamma-retroviral transduced NK cells was evaluated. Lentiviral constructs with various hinges, transmembrane domains, and intracellular domains were tested using two CEACAM5-specific scFv (A5B7 and Tus) in either VH-VL or VL-VH orientation. Each CAR construct encoded a CD8 signal sequence (SEQ ID NO: 76), an scFv domain (i.e., a "binding factor"), a Myc epitope tag (SEQ ID NO: 75), a CD8 hinge (SEQ ID NO: 50) or CD28 hinge (SEQ ID NO: 49), a transmembrane domain derived from either CD28 (SEQ ID NO: 46) or CD8 (SEQ ID NO: 45), a co-stimulatory domain derived from either CD28 (SEQ ID NO: 71) or 4-1BB (SEQ ID NO: 70), and a CD3 zeta-activating domain (SEQ ID NO: 74) from the N-terminus to the C-terminus. In parallel, γ-retroviral constructs were tested with various scFvs (three CEACAM5-specific scFvs: hMN14, hMFE23, and tusamitamab, as well as one CEACAM1-specific scFv: MRG1), transmembrane domains, and costimulatory domains. Each gamma-retroviral construct also included a CD8 signaling sequence (SEQ ID NO: 76), a myc epitope tag (SEQ ID NO: 75), and the C-terminus of the CD3 zeta-activating domain (SEQ ID NO: 74) for the costimulatory domain. An off-target "control" CAR (SB02716) was also tested as a negative control. CAR expression was assessed via flow cytometry by staining for the presence of the epitope tag (Myc). Cells were stained on days 4 and 7 after transduction to determine the stability of construct expression. A gate for determining Myc% expression was drawn using a non-transduced control (no virus) so that <1% of Myc+ cells were within the positive gate. The median fluorescence intensity (MFI) was determined, and the CAR expression level was quantified and evaluated. Table 16 shows the CAR expression levels on day 4 for lentiviral transdermal NK cells. Table 17 shows the CAR expression levels on day 4 for gamma retrovirus transdermal NK cells. Table 18 shows the CAR expression levels on day 7 for lentiviral transdermal NK cells. Table 19 shows the CAR expression levels on day 7 for gamma retrovirus transdermal NK cells.
[0378] Table 16
[0379] Table 17
[0380] Table 18
[0381] Table 19
[0382] The killing activity of NK cells transduced with subsets of constructs shown in Tables 16-19 was evaluated using flow assays. aCAR-transduced NK cells were incubated overnight (16-18 hours) with the colorectal cancer target strain LS174t in a 1:1 "E:T" ratio of effector cells (i.e., NK cells, "E") to target cells (in this case, LS174t cells, "T"). Cells were co-cultured in ultra-low binding U-bottom plates to promote cell-cell interactions and reduce plate adhesion. Cells were harvested and stained for flow cytometry to determine cell phenotype and death. Target cells were distinguished from CD56+ NK cells using mKate expression in Ls174t target cells. Live cells were distinguished from dead cells using Zombie UV (Biolegend) dye. The percentage of dead cells was calculated and is shown in Figure 29. As shown in Figure 29, many CEA aCAR constructs (SB03089, SB03097, SB03098, SB03174, SB03176, and SB03180) showed higher killing activity than untransduced (virus-free) NK controls with a 1:1 E-to-T ratio. Statistical significance was determined using standard one-way ANOVA with Dunnett's multiple comparison correction, with p<0.05, **p<0.005, and ****p<0.0001. In summary, these results demonstrate significant killing activity of CEA aCAR-expressing NK cells produced using both lentiviral and gamma-retroviral vectors.
[0383] Example 6: Killing activity of lentiviral transducer NK cells expressing various CEA aCAR constructs at various effector cell-to-target cell ratios. CEA aCAR expression in lentivirally transduced NK cells was evaluated on day 5 post-transduction using various CEA aCAR constructs. Lentiviral constructs containing a CD28 or 4-1BB costimulatory domain and a CD3 zeta intracellular domain were tested using CEACAM5-specific scFv (A5B7, tusamitamab, or "Tus" and hMN14). For A5B7 and tusamitamab-derived scFv, both orientations, VH-VL, and VL-VH were tested. An off-target "control" CAR (SB02716) was also tested as a negative control. A description of each construct is provided in Table 20. CAR expression was evaluated via flow cytometry by staining for the presence of an epitope tag (Myc). Cells were stained on day 5 post-transduction to determine the stability of construct expression. Lentiviruses SB03089–SB03100 were added to transduce cells at a p24 MOI of 2 pg per NK cell. Viruses SB02463 and SB02779 were titrated to ensure CAR expression matched for both constructs. A gate for determining Myc% expression was drawn using a non-transduction control (no virus) so that <1% of Myc+ cells were within the positive gate. Median fluorescence intensity (MFI) was determined to quantify and evaluate CAR expression levels. The expression of each construct as determined by Myc-tagged expression is shown in Table 20.
[0384] [Table 20]
[0385] The killing activity of NK cells transduced with subsets of constructs shown in Table 20 was evaluated using flow assays at different E:T ratios. NK cells transduced with two CEA aCAR constructs (SB02463 and SB02779) shown in Table 16 were incubated overnight (16-18 hours) with the colorectal cancer target cell line LS174t at E:T ratios of 1:1, 1:2, and 1:4. To promote cell-cell interactions and reduce plate adhesion, cells were co-cultured in ultra-low binding U-bottom plates. Further co-culture was performed using untransduced NK cells (virus-free) and NK cells transduced with an off-target CAR (SB02716 targeting Axl) as negative controls. Cells were harvested and stained for flow cytometry to determine cell phenotype and death. Target cells were distinguished from CD56+ NK cells using mKate-expressing Ls174t target cells. Live cells were distinguished from dead cells using Zombie UV (Biolegend) dye. The percentage of dead cells was calculated and is shown in Figure 30. As shown in Figure 30, both CEA aCAR constructs showed higher killing activity than the non-transduced (virus-free) NK control at a lower E:T ratio, demonstrating CAR-mediated killing of congeneral target cells. Statistical significance was determined using standard two-way ANOVA with Dunnett's multiple comparison correction, with *p<0.05 and **p<0.005.
[0386] Example 7: Expression of CEA aCAR with various binding and signaling domains after gamma retroviral gene transfer in NK cells CEA aCAR expression on gamma retrovirus-transduced NK cells was evaluated. Multiple gamma retrovirus constructs were tested with four different scFvs (Tus, hMN14, hMFE23, and MG7), four different transmembrane domains: CD8 (SEQ ID NO: 45), CD28 (SEQ ID NO: 46), OX40 (SEQ ID NO: 47), and 2B4 (SEQ ID NO: 48), and four different costimulatory domains: CD28 (SEQ ID NO: 71), OX40 (SEQ ID NO: 72), 2B4 (SEQ ID NO: 73), and 4-1BB (SEQ ID NO: 70). Each construct also contained a myc epitope tag, a CD8 hinge domain (SEQ ID NO: 50), and a CD3 zeta-activating domain (SEQ ID NO: 74). A description of each construct is provided in Table 21. CAR expression was assessed via flow cytometry by staining for the presence of the epitope tag (Myc). Cells were stained on days 3 and 7 after transduction to determine the stability of construct expression. A gate for determining myc% expression was drawn using a non-transduction control (virus-free) so that <1% of Myc+ cells were within the positive gate. Median fluorescence intensity (MFI) was determined to quantify and evaluate CAR expression levels. Table 22 shows the CAR expression levels on days 3 and 7 for gamma retrovirus-transduced NK cells.
[0387] [Table 21]
[0388] [Table 22]
[0389] Surface marker activation of transduced CEA aCAR NK cells cultured with target cells. CEA aCAR transduced NK cells were incubated overnight (16-18 hours) with a colorectal cancer target cell line (LS174t) at a 1:1 E:T ratio. Cells were co-cultured in ultra-low binding U-bottom plates to promote cell-cell interactions and reduce plate adhesion. Cells were harvested and stained for flow cytometry to determine cell phenotype and death. Target cells were distinguished from CD56+ NK cells using mKate-expressing Ls174t target cells. CAR NK activity in the presence of target cells was evaluated by staining for NK activation markers NKp46, CD16, and CD107A. MFI was calculated for each and is shown in Figure 31A (NKp46), Figure 31B (CD16), and Figure 31C (CD107a). Significant differences were determined using standard one-way ANOVA with Dunnett's multiple comparison correction, with p<0.05, **p<0.005, ***p<0.0005, and ****p<0.0001. As shown in Figures 31A, 31B, and 31C, surface marker activity increased in some of the tested CEA aCAR NK cell populations, indicating NK cell activation after recognition of congenital target cells.
[0390] Example 8: Killing activity of transduced CEA aCAR NK cells evaluated by real-time fluorescence assay. A population of colorectal cancer cells expressing CEA (Ls174t cell line) was stably transduced with the fluorescent reporter mKate, and the proliferation and abundance of target cells in culture were tracked. Transduced Ls174t cells are referred to herein as the “target line.” Transduced NK cells with CEA aCAR (construct SB03180) and untransduced control ("virus-free" or "NV") NK cells were then incubated with LS174t at an E:T ratio of 2:1. Cells were seeded in six technical replications for each condition: target line only, untransduced ("NV") NK cells and target line, and CEA aCAR NK cells (transduced with construct SB03180; see Table 21) and target line. During culture, reporter signals from target cells were imaged every 3 hours via a real-time fluorescence assay, and mkate was measured. The abundance of target cells for each state was determined from the total red integral intensity per well. The percentage of dead cells was calculated and is shown in Figure 32. All data were normalized to values from target cells only and plotted with + / - SEM. As shown in Figure 32, CEA CAR NK cells inhibited the proliferation of target cells in vitro at a faster rate than non-transduced controls (NV NK), demonstrating CAR-mediated killing of congeneral target cells.
[0391] Example 9: In vivo transduction of CEA aCAR and its killing activity in NK cells The killing activity of NK cells transduced with CEA aCAR was evaluated in vivo. To track tumor progression in vivo, colorectal cancer Ls174t target cells expressing CEA were transduced to express firefly luciferase (fLuc). Mice were intraperitoneally inoculated with 1e6 L1S174t target cells per mouse 5 days prior to NK cell treatment (-5 days, indicated by black arrows in the right panel). Each group was treated with 30e6 NK cells (NK cells transduced with CEA aCAR construct SB03180 or untransduced NK cells) via intraperitoneal (IP) delivery or vehicle control (PBS). Each group started with 8 mice, and 3 mice were sacrificed for intermediate analysis at an intermediate point (day 6, indicated by purple arrows) (n=8 initially, n=5 after dissection). After inoculation with cancer cells, fLuc signaling was evaluated twice weekly using whole-body bioluminescence imaging (BLI). As shown in Figure 33A, changes in BLI were normalized to the initial baseline value at treatment (day 0). Representative images taken on day 16 post-treatment are shown in Figure 33B. As shown in Figures 33A and 33B, at day 16 post-treatment, mice treated with CEA aCAR NK cells showed significantly lower tumor load than mice treated with non-transduction, which demonstrates CAR-mediated killing of tumor cells in vivo, rather than non-viral (NV) control NK cells (*p<0.05, two-way ANOVA with Sidak's multiple comparison test).
[0392] Example 10: CAR expression and CAR-NK killing in tumor cells after transduction with baboon-envelope-pseudotyped gamma-retrovirus Primary NK cells were obtained from a first donor ("NK Donor 1") and a second donor ("NK Donor 2"). Gamma retroviruses encoding various CEA aCARs were produced using self-inactivated gamma retrovirus vectors, and baboon endogenous virus (BaEV) envelopes were used for pseudotyping. Gamma retroviruses were transduced into NK cells from both donors, and CEA aCAR expression on the transduced NK cells was evaluated. Retroviral constructs using the first and second gamma retrovirus construct skeletons ("Retrovirus 1" and "Retrovirus 2") encoding CARs with CD28 and CD3 zeta intracellular domains or OX40 and CD3 zeta intracellular domains were tested for two CEACAM5-specific scFvs (hMN-14 and tusamitamab, "Tus"). CAR expression was assessed via flow cytometry by staining for the presence of an epitope tag (Myc). Cells were stained 11 days after transduction to determine the stability of construct expression. A gate for determining Myc% expression was drawn using a non-transduction control (virus-free) so that <1% of Myc+ cells were within the positive gate. The median fluorescence intensity (MFI) was determined to quantify and evaluate CAR expression levels. Table 23 shows CAR expression in NK donor 1 cells transduced with BaEV pseudotyped gamma retrovirus. Table 24 shows CAR expression in NK donor 2 cells transduced with the same BaEV pseudotyped gamma retrovirus. Table 25 shows the mean expression percentage (transduction) between the two donors.
[0393] [Table 23]
[0394] [Table 24]
[0395] [Table 25]
[0396] A population of colorectal cancer cells expressing CEA (Ls174t cell line) was stably transduced with the fluorescent reporter mKate, and the proliferation and abundance of target cells in culture were tracked. Transduced Ls174t cells are referred to herein as the “target line.” Transduced NK cells with CEA aCAR (construct SB03180) and untransduced control ("virus-free" or "NV") NK cells were then incubated with LS174t at an E:T ratio of 2:1. Cells were seeded in six technical replications for each condition: target line only, untransduced ("NV") NK cells and target line, and CEA aCAR NK cells (construct SB03180) and target line. During culture, reporter signals from target cells were imaged every 3 hours via a real-time fluorescence assay, and mkate was measured. The abundance of the target line for each condition was determined from the total red integrated intensity per well. The percentage of target cells killed was calculated for the constructs included in the first killing assay (SB03173, SB04293, SB04444, and SB04445, Figure 34). A separate second killing assay was performed on SB04443, SB04444, and SB04445, and the percentage of target cells killed in this second assay is shown in Figure 35. As shown in Figure 34, NK cells transduced with CEA aCAR constructs SB03173, SB04293, SB04443, and SB04445 showed higher killing than untransduced NK cells, and killing was confirmed in the second assay for constructs SB04443 and SB04445, both of which contained the OX40 intracellular domain, as shown in Figure 35. All data were normalized to values from target lines only and plotted using + / - SEM. The killing activity shown in Figure 35, compared to killing by unmanipulated NK cells, and also as shown in Figure 34, supports the higher killing ability of NK cells transduced with CEA aCAR constructs SB04443 and SB04445.
[0397] Example 11: In vivo antitumor activity of CAR-NK cells transduced with baboon-enveloped pseudotyped gamma-retrovirus. CEA aCAR NK cells were generated and their in vivo antitumor activity was evaluated. Primary NK cells were transduced with various CEA aCAR constructs (constructs SBSB03173, SB03174, SB03180, SB03290, and SB03176) or were kept as untransduced ("virus-free" or "NV") NK cells. CAR expression was assessed via flow cytometry by staining for the presence of the epitope tag (Myc). Cells were stained 11 days post-transduction to determine the stability of construct expression. A gate for determining Myc% expression was drawn using untransduced controls (virus-free) so that <1% of Myc+ cells were within the positive gate. Median fluorescence intensity (MFI) was determined to quantify and evaluate CAR expression levels. The respective expression percentages at 8 and 16 days post-transduction are shown in Table 26.
[0398] [Table 26]
[0399] As shown in Table 26, CAR expression remained stable over time, reaching at least 20% and a maximum of approximately 40% on day 16 after transduction.
[0400] To track tumor progression in vivo, colorectal cancer Ls174t target cells expressing CEA were transduced to express firefly luciferase (fLuc). Mice were intraperitoneally inoculated with 1e6 L1S174t target cells per mouse 5 days prior to NK cell treatment. Each group was treated with a population of 30e6 NK cells via intraperitoneal (IP) delivery or vehicle control (PBS). Each group started with 9 mice. After cancer cell inoculation, fLuc signaling was evaluated 2 days after NK cell treatment using whole-body bioluminescence imaging (BLI), and images of 9 mice from each group are shown in Figure 36. fLuc signaling was also evaluated 13 days after NK cell treatment using ...
Claims
1. (a) a chimeric inhibitory receptor comprising an extracellular antigen-binding domain that binds to an antigen, the antigen being selected from the group consisting of VSIG2, CPM, ITM2C, SLC26A2, SLC4A4, GPA33, PLA2G2A, ABCA8, ATP1A2, CHP2, and SLC26A3; (b) a chimeric receptor comprising one or more extracellular antigen binding domains, wherein the one or more extracellular antigen binding domains bind to one or more additional antigens selected from the group consisting of CEA, CEACAM1, CEACAM5, and CEACAM6; 1. An isolated cell comprising:
2. (a) the antigen-binding domain of said inhibitory chimeric receptor comprises one or more single chain variable fragments (scFv), optionally each of said one or more scFvs comprises a heavy chain variable domain (VH) and a light chain variable domain (VL), optionally said VH and VL are separated by a peptide linker, optionally said peptide linker comprises the amino acid sequence of SEQ ID NO: 39 or SEQ ID NO: 77, and / or optionally each of said one or more scFvs comprises the structure VH-L-VL or VL-L-VH, where VH is a heavy chain variable domain, L is a peptide linker, and VL is a light chain variable domain; (b) the chimeric inhibitory receptor comprises a transmembrane domain, the transmembrane domain being selected from the group consisting of CD8 transmembrane domain, CD28 transmembrane domain, CD25 transmembrane domain, CD7 transmembrane domain, CD3 zeta chain transmembrane domain, CD4 transmembrane domain, 4-1BB transmembrane domain, OX40 transmembrane domain, ICOS transmembrane domain, CTLA-4 transmembrane domain, LAX transmembrane domain, LAT transmembrane domain, PD-1 transmembrane domain, LAG-3 transmembrane domain, TIM3 transmembrane domain, KIR3DS1 transmembrane domain, KIR3DL1 transmembrane domain, NKG2D transmembrane domain, NKG2A transmembrane domain, TIGIT transmembrane domain, 2B4 transmembrane domain, and BTLA transmembrane domain; (c) the inhibitory chimeric receptor comprises a spacer region between the antigen-binding domain and the transmembrane domain, optionally wherein the spacer region has an amino acid sequence selected from the group consisting of SEQ ID NOs: 49-58; and / or (d) the inhibitory chimeric receptor comprises one or more intracellular inhibitory domains selected from the group consisting of PD-1, CTLA4, TIGIT, LAIR1, GRB-2, Dok-1, Dok-2, SLAP, LAG3, HAVR, BTLA, LIR1, NKG2A, KIR3DL1, GITR, PD-L1, CSK, SHP-1, PTEN, CD45, CD148, PTP-MEG1, PTP-PEST, c-CBL, CBL-b, PTPN22, LAR, PTPH1, SHIP-1, RasGAP, CD94, and CD161; The isolated cell of claim 1.
3. the chimeric receptor is a CAR, Optionally, the CAR comprises one or more intracellular signaling domains, wherein the one or more intracellular signaling domains are selected from the group consisting of: CD3 zeta chain intracellular signaling domain, CD3 epsilon chain intracellular signaling domain, CD97 intracellular signaling domain, CD11a-CD18 intracellular signaling domain, CD2 intracellular signaling domain, ICOS intracellular signaling domain, CD27 intracellular signaling domain, CD154 intracellular signaling domain, CD8 intracellular signaling domain, OX40 intracellular signaling domain, 4-1BB intracellular signaling domain, CD28 intracellular signaling domain, ZAP40 intracellular signaling domain, CD30 intracellular signaling domain, GITR intracellular signaling domain, HVEM intracellular signaling domain, DAP10 intracellular signaling domain, DAP12 intracellular signaling domain, MyD88 intracellular signaling domain, 2B4 intracellular signaling domain, NKp46 intracellular signaling domain, NKp30 intracellular signaling domain, NKp44 intracellular signaling domain, NKG2D intracellular signaling domain, CD226 intracellular signaling domain, and CD160 intracellular signaling domain; Optionally, the CAR comprises a transmembrane domain, wherein the transmembrane domain is selected from the group consisting of CD8 transmembrane domain, CD28 transmembrane domain, CD25 transmembrane domain, CD7 transmembrane domain, CD3 zeta chain transmembrane domain, CD4 transmembrane domain, 4-1BB transmembrane domain, OX40 transmembrane domain, ICOS transmembrane domain, CTLA-4 transmembrane domain, LAX transmembrane domain, LAT transmembrane domain, PD-1 transmembrane domain, LAG-3 transmembrane domain, TIM3 transmembrane domain, KIR3DS1 transmembrane domain, KIR3DL1 transmembrane domain, NKG2D transmembrane domain, NKG2A transmembrane domain, TIGIT transmembrane domain, 2B4 transmembrane domain, and BTLA transmembrane domain; Optionally, the CAR comprises a spacer region between the antigen binding domain and the transmembrane domain, wherein the spacer region has an amino acid sequence selected from the group consisting of SEQ ID NOs: 49-58; Optionally, the inhibitory chimeric receptor and / or the antigen-binding domain of the chimeric receptor comprises one or more single chain variable fragments (scFv), optionally each of the one or more scFvs comprises a heavy chain variable domain (VH) and a light chain variable domain (VL), optionally the VH and VL are separated by a peptide linker, optionally the peptide linker comprises the amino acid sequence of SEQ ID NO: 39 or SEQ ID NO: 77; Optionally, each of the one or more scFvs comprises the structure VH-L-VL or VL-L-VH, wherein the VH is a heavy chain variable domain, L is a peptide linker, and VL is a light chain variable domain.
3. An isolated cell according to claim 1 or 2.
4. (a) the one or more additional antigens is CECAM1, and optionally the antigen-binding domain that binds to CEACAM1 comprises a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO:1 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO:2; (b) the one or more additional antigens is CECAM5, and optionally the antigen-binding domain that binds to CEACAM5 comprises: (i) a VH comprising the amino acid sequence of SEQ ID NO: 3 and a VL comprising the amino acid sequence of SEQ ID NO: 4; (ii) VH comprising the amino acid sequence of SEQ ID NO: 9 and VL comprising the amino acid sequence of SEQ ID NO: 10; (iii) a VH comprising the amino acid sequence of SEQ ID NO: 11 and a VL comprising the amino acid sequence of SEQ ID NO: 12; (iv) VH comprising the amino acid sequence of SEQ ID NO: 13 and VL comprising the amino acid sequence of SEQ ID NO: 14; (v) a VH comprising the amino acid sequence of SEQ ID NO: 78 and a VL comprising the amino acid sequence of SEQ ID NO: 79; and (vi) a VH comprising the amino acid sequence of SEQ ID NO: 15 and a VL comprising the amino acid sequence of SEQ ID NO: 16 or The antigen-binding domain that binds to CEACAM5 is (i) a HC comprising the amino acid sequence of SEQ ID NO:5 and a LC comprising the amino acid sequence of SEQ ID NO:6; and (ii) a HC comprising the amino acid sequence of SEQ ID NO: 7 and a LC comprising the amino acid sequence of SEQ ID NO: 8 or comprising a heavy chain (HC) and a light chain (LC) selected from the group consisting of: (c) the one or more additional antigens are CECAM6, and optionally the antigen-binding domain that binds to CECAM6 comprises a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 17 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 18; An isolated cell according to any one of claims 1 to 3.
5. the cell is an immunoresponsive cell; Optionally, binding of the inhibitory chimeric receptor to the antigen can inhibit the immunoresponsive cell, and / or binding of the chimeric receptor to the one or more additional antigens can activate the immunoresponsive cell. An isolated cell according to any one of claims 1 to 4.
6. (a) the chimeric receptor binds the one or more additional antigens with low binding affinity; (b) the chimeric receptor binds the one or more additional antigens with a binding affinity that is lower than the binding affinity with which the inhibitory chimeric receptor binds the antigen; and / or (c) the inhibitory chimeric receptor binds the antigen with low avidity; An isolated cell according to any one of claims 1 to 5.
7. 7. The isolated cell of any one of claims 1 to 6, wherein the chimeric receptor is recombinantly expressed, optionally wherein the chimeric receptor is expressed from a vector or from a selected locus in the genome of the cell.
8. the cell is selected from the group consisting of T cells, natural killer (NK) cells, cytotoxic T lymphocytes (CTLs), regulatory T cells, natural killer T (NKT) cells, bone marrow cells, macrophages, human embryonic stem cells (ESCs), ESC-derived cells, pluripotent stem cells, and induced pluripotent stem cells (iPSCs), and iPSC-derived cells; Optionally, the cells are autologous or the cells are allogeneic. An isolated cell according to any one of claims 1 to 7.
9. An isolated nucleic acid encoding an inhibitory chimeric receptor according to any one of claims 1 to 8.
10. A vector comprising the nucleic acid of claim 9.
11. A genetically modified cell comprising the nucleic acid of claim 9 or the vector of claim 10.
12. 13. A pharmaceutical composition comprising an effective amount of the isolated cell of any one of claims 1 to 8 and 11, the isolated nucleic acid of claim 9, or the vector of claim 10, together with a pharma- ceutically acceptable carrier, a pharma-ceutically acceptable excipient, or a combination thereof.
13. A pharmaceutical composition comprising the isolated cell of any one of claims 1 to 8 and 11 for treating a subject in need thereof.
14. A pharmaceutical composition comprising the isolated cells according to any one of claims 1 to 8 and 11 for stimulating a cellular immune response against tumor cells in a subject.
15. A pharmaceutical composition comprising the isolated cell of any one of claims 1 to 8 and 11 for providing anti-tumor immunity in a subject.
16. A pharmaceutical composition for reducing tumor burden in a subject comprising the isolated cell of any one of claims 1 to 8 and 11, optionally comprising (a) the cells reduce the number of tumor cells; (b) the cells reduce tumor size; (c) the cells reduce tumor volume; and / or (d) the cells eradicate the tumor in the subject. The pharmaceutical composition.
17. A pharmaceutical composition comprising the isolated cell according to any one of claims 1 to 8 and 11 for treating a subject having a tumor.
18. 12. A pharmaceutical composition comprising the isolated cell of any one of claims 1 to 8 and 11 for treating or preventing cancer in a subject, wherein the cancer is selected from the group consisting of colorectal cancer, pancreatic cancer, lung adenocarcinoma, and gastric cancer.
19. (a) the cells increase progression-free survival in the subject; and / or (b) the cells increase survival in the subject.
19. A pharmaceutical composition according to claim 17 or 18.
20. A pharmaceutical composition comprising the nucleic acid of claim 9 for treating a subject in need thereof.
21. A pharmaceutical composition comprising the nucleic acid described in claim 9 for stimulating a cellular immune response against tumor cells in a subject.
22. A pharmaceutical composition comprising the nucleic acid of claim 9 for providing anti-tumor immunity in a subject.
23. A pharmaceutical composition comprising the nucleic acid of claim 9 for reducing tumor burden in a subject.
24. A pharmaceutical composition comprising the nucleic acid of claim 9 for treating a subject having a tumor.
25. A pharmaceutical composition comprising the nucleic acid of claim 9 for treating or preventing cancer in a subject, wherein the cancer is selected from the group consisting of colorectal cancer, pancreatic cancer, lung adenocarcinoma, and gastric cancer.
26. 1. A kit for treating and / or preventing colorectal cancer, pancreatic cancer, lung adenocarcinoma, and / or gastric cancer, comprising: The kit comprises an isolated cell according to any one of claims 1 to 8 and 11, an isolated nucleic acid according to claim 9, a vector according to claim 10, or a pharmaceutical composition according to claim 12, Optionally, the kit further comprises written instructions for using the isolated cells or pharmaceutical composition to treat and / or prevent colorectal cancer, pancreatic cancer, lung adenocarcinoma, and / or gastric cancer in a subject, or the kit further comprises instructions for using the nucleic acid or vector to generate one or more antigen-specific cells to treat and / or prevent colorectal cancer, pancreatic cancer, lung adenocarcinoma, and / or gastric cancer in a subject. The kit.
